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Abstract 
Objectives 
To evaluate the role of stress perfusion cardiovascular magnetic resonance 
(CMR) in the investigation of stable coronary artery disease (CAD).  
Background 
Coronary artery disease remains the biggest cause of morbidity and 
mortality. The multi-parametric CMR examination is established as an 
investigative strategy for the investigation of CAD.  
Methods 
Study 1 & 2: Patients with stable coronary artery disease underwent a multi-
parametric CMR protocol assessing 4 components: i) left ventricular 
function; ii) myocardial perfusion; iii) viability (late gadolinium enhancement 
(LGE)) and iv) coronary magnetic resonance angiography (MRA). The 
diagnostic accuracy of the individual components were assessed. The 
ischaemic burden of stress CMR Vs. Single Photon Emission Computed 
Tomography (SPECT) was determined.  
Study 3: Volunteers and patients were scanned with perfusion sequence 
which adapts the spatial resolution to the available scanning time and field-
of-view. 
Study 4: A multi-centre pragmatic randomised controlled trial of patients with 
stable angina comparing CMR guided-care Vs. SPECT guided-care Vs. 
National Institute of Health and Care Excellence guided-care. 
Results 
Study 1 demonstrated the stress perfusion component of the multi-
parametric CMR exam was the single most important component for overall 
diagnostic accuracy. However, the full combined multi-parametric protocol 
- ix - 
  
was the optimal approach for disease rule-out, and the LGE component best 
for rule-in. Study 2 showed that there was reasonable agreement of the 
summed stress scores between CMR and SPECT (a well established 
investigation with significant amounts of prognostic data). 
In study 3, a perfusion pulse sequence which automatically adapts the 
acquisition sequence to the available scanning time results in spatial 
resolution improvement and reduction in dark rim artefact. 
Finally in study 4 in patients with suspected angina using CMR as an initial 
investigative strategy produced a significantly lower probability of 
unnecessary angiography compared to NICE guidance. There were similar 
rates of CAD detection were comparable suggesting no penalty for using 
functional imaging as a gatekeeper for angiography. 
 
Conclusion 
CMR has high diagnostic accuracy for the detection of coronary artery 
disease; with similar detection of ischaemic burden to established tests and 
can be used safely and effectively as a gate keeper to invasive coronary 
angiography. 
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Chapter 1 
Background 
 
1.1 Coronary Heart Disease 
Coronary heart disease (CHD) is a leading cause of death and disability 
worldwide. In the United States (US) 15.4 million people have CHD costing 
the US economy $108.9 billion/yr[1] and each year 715,000 have a 
myocardial infarction[2]; whilst in the United Kingdom (UK) there are an 
estimated 2 million people with angina costing £9.0 billion/yr[3]. In a typical 
hospital setting a variety of investigations may be used to diagnose CHD, as 
well as risk stratify the individual and determine the need for coronary 
revascularization. These may involve anatomical imaging of the coronary 
arterial tree with computed tomography coronary angiography (CTCA) or 
invasive X-ray coronary angiography; or assessment for functionally 
significant coronary artery stenosis with single-photon emission computed 
tomography (SPECT), stress echocardiography, cardiovascular magnetic 
resonance (CMR) or positron emission tomography (PET). 
 
1.2 Cardiovascular Magnetic Resonance 
Cardiovascular magnetic resonance (CMR) is an established advanced 
cross-sectional imaging modality for the functional and anatomical 
assessment of a wide range of cardiovascular disease. CMR produces high 
resolution images which can be acquired in any plane and allows the 
assessment of global and regional cardiac function, myocardial perfusion, 
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myocardial viability, tissue characterisation and proximal coronary anatomy - 
all within a single study and without the use of ionising radiation. This unique 
multi-parametric approach leads to a high diagnostic accuracy for the 
detection of CHD and an important role in the management of both the 
stable and acute patient. In patients with stable CHD, CMR can detect and 
localise ischemia, quantify ischemic burden and determine myocardial 
viability, all of which can be used to risk-stratify patients and guide 
revascularization (Figure 1.1). In patients presenting with acute coronary 
syndromes, CMR can accurately determine ischemia and infarction and 
provide prognostic information such as the size and location of myocardial 
infarction, the area at risk (myocardial oedema) and the presence or 
absence of microvascular obstruction (MO), intramyocardial haemorrhage 
(IMH) or sequelae such as left ventricular thrombus (Figure 1.2). There is an 
extensive and growing evidence base for CMR and for many cardiovascular 
conditions it is the reference standard imaging test.  
 
1.3 CMR in National & International Guidelines 
CMR is therefore firmly established in both national and international 
guidelines, which recommend a variety of investigative strategies for the 
diagnosis of CHD[4-6] with recognised international training syllabi and 
accreditation/certification processes[7-9]. The 2013 European Society of 
Cardiology (ESC) guidelines on the management of stable CHD [5] give a 
Class I recommendation for non-invasive stress testing and recommend 
CMR as an imaging option for the initial diagnostic assessment of angina. 
The American College of Cardiology Foundation/American Heart Association 
- 4 - 
  
(ACCF/AHA) guidelines give CMR a class IIa recommendation for the 
investigation of those with intermediate to high pre-test probability of 
obstructive CHD in those physically able to exercise but with an ECG which 
would be un-interpretable during an exercise test; and class IIb in those 
intermediate to high risk unable to exercise[4]. There is also a role for 
ischemia and viability testing with CMR in those with known CHD and after 
myocardial infarction (MI), particularly in those with multi-vessel disease.[10] 
The ACCF/AHA gives CMR a Class I recommendation in those with known 
CHD of unclear physiological significance considered for revascularization 
and the ESC guidelines give non-invasive stress imaging IIa classification for 
this indication[5]. 
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Figure 1.1  CMR in Stable Coronary Artery Disease 
Top Panel) Short axis cine stack used for demonstration of global and 
regional ventricular function. Middle Panel) Adenosine stress (top row) and 
rest (bottom row) first pass perfusion demonstrating inducible inferior and 
infero-lateral hypoperfusion (ischaemia) (arrows) consistent with severe 
stenosis of the right coronary artery (Video 1). Bottom Panel) Late 
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gadolinium enhancement image demonstrating no evidence of myocardial 
infarction. 
 
Figure 1.2  CMR in Acute Myocardial Infarction  
A) T2w image with high signal (oedema) of the inferior LV and RV wall 
(arrow) with an area of hypointense core representing intra-myocardial 
haemorrhage (star). B) Early gadolinium enhancement (EGE) image with 
dark central core of the inferior wall representing an area of microvascular 
obstruction (MO). C) Late gadolinium enhancement (LGE) image with full 
thickness myocardial infarction demonstrated by hyperintense (white) areas 
of the inferior wall and inferior septum extending into the RV. The central 
dark area (arrow) is MO. D&E) LV apical thrombus on EGE image (arrows). 
F) Short axis LGE image with ventricular septal defect (star). G&H) Inferior 
aneurysm (arrows) with thrombus. I) Contained apical LV rupture with 
thrombus (arrow). 
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1.4 CMR Physics, Methodology & Safety  
1.4.1 Basic CMR Physics 
CMR imaging uses a strong superconducting magnet (cooled in liquid 
helium) to construct images with high spatial resolution and excellent soft 
tissue contrast[11]. This magnet operates at a field strength measured in 
units of Tesla (T), with 1T ≈ 20,000 times the earth’s magnetic field. Three 
types of magnetic fields are used to produce images: a strong, static 
magnetic field (B0), a gradient magnetic field (which can be rapidly switched 
on and off) and a radiofrequency (RF) field. 
 
CMR uses the signal generated from magnetising hydrogen nuclei (single 
protons) as they are in abundance. When a patient is placed into the 
scanner the protons within free water and lipid molecules align themselves 
either parallel or anti-parallel to the static field B0. For imaging purposes a 
RF pulse is applied, delivering energy to the protons, which tilt them away 
from their alignment with B0. When this extrinsic RF pulse is removed, 
protons return to their resting state, releasing this energy in the form of a 
radio signal, a process that is used to generate the image. 
 
The relaxation of protons back to their equilibrium state after withdrawal of 
the RF pulse is defined by two important parameters known as T1 and 
T2[12]. The T1 relaxation time (ms) is defined as the duration for longitudinal 
magnetization of excited tissues to recover to approximately 63% of their 
original value. This increases with increasing magnetic field strength. T2 
relaxation (ms) is the time when 63% of the transverse magnetisation of 
excited tissues has recovered and this is essentially unaffected by 
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increasing magnetic field strengths. In biological tissues, T2 values are 
substantially shorter than T1. Fat has short T1 and T2 relaxation; fluids have 
long T1 and T2 relaxation. 
 
Both the delay between successive RF applications (Repetition Time, TR) 
and between each RF application and subsequent signal readout (Echo 
Time, TE) can be specified by the operator[12]. This is exploited for 
purposes of tissue characterisation by permitting imaging sequences 
preferentially weighted to T1 (T1w: short TE and TR,) or T2 (T2w: long TE 
and TR).  
 
The two most commonly used pulse sequence types in CMR are Spin Echo 
(SE) and Gradient Echo (GE). SE sequences are generally used for static 
anatomical definition. SE produces high quality T1w and T2w images and is 
termed black-blood imaging (as blood is usually black and fat white).[13] On 
T1w SE images, fluid typically appears dark and fat bright, whereas both are 
bright on T2w images. 
 
GE sequences permit fast cine acquisition (motion) with high temporal 
resolution and generally generate bright-blood images (both blood and fat 
are bright)[14]. In addition to standard cine imaging, it is also possible to 
assess intra-myocardial motion by “tagging” the myocardium with a grid 
pattern and then track its deformation through the cardiac cycle[15]. The 
displacement of tagging features permits measurement of myocardial strain, 
strain rate and torsion[16].  
 
- 9 - 
  
Phase-encoded GE sequences (also called phase-contrast or velocity 
encoded sequences) are a technique whereby the net direction of the 
moving blood is displayed as a phase map. Pixels travelling in different 
directions and at different velocities are displayed as either black (moving 
away from the phase encoding direction), white (moving towards the phase 
encoding direction) or grey (stationary). Phase-contrast velocity mapping is 
typically used to measure blood flow e.g. aortic or pulmonary valvular 
regurgitation[17] and total flow volumes per cardiac cycle with both forward 
and reverse flow components measurable. CMR allows precise alignment of 
the imaging plane (in-plane or through-plane)  with the direction of flow but is 
limited by temporal resolution (typically 25-45ms, 10-fold lower than Doppler 
echocardiography) and thus may underestimate peak values in high velocity 
jets (e.g. severe aortic stenosis). 
 
The duration of a CMR scan typically ranges from 30 minutes to an hour 
depending on the complexity of the referral question. Patients are breath-
held for the acquisition of most images, which with modern fast scanners 
can be just a few seconds in duration, and can be adjusted according to 
patient ability. Vector-cardiogram (equivalent to ECG) triggering and gating 
are used to prevent image distortion due to cardiac motion[18]; with cine 
images acquired during the entire cardiac cycle (prospective or retrospective 
gating[19]) and static images preferentially acquired during diastole 
(prospective triggering). Arrhythmias and poor breath holding can thus 
degrade image quality[20], although in most cases diagnostic quality 
information can still be obtained by using arrhythmia rejection algorithms and 
non-breath holding (free breathing) techniques.  
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1.4.2 Image Quality and Artefacts 
CMR image acquisition can be associated with a number of classical 
artefacts[21], although in the vast majority of cases an experienced 
technologist can minimise these to produce diagnostic quality images. The 
most common include:  
- Image aliasing: indicative of too small a field a view with signal from 
peripheral parts of the body wrapping centrally into the main image. 
- Ghosting artefact from respiratory motion: caused by movement of 
tissue between each TR with subsequent misplacement of signal in 
the image. 
- Arrhythmia artefact: Poor quality ECG triggering generates cardiac 
motion artefacts during cine acquisition due to jumps in TR and 
variation in R-R intervals.  
- Chemical shift artefact: typically a signal void at the interface between 
fat layers and surrounding water-based tissue. It is important to 
recognise in order to avoid misinterpretation e.g. the false impression 
of aortic wall dissection “flap”. 
- Metallic artefact: can significantly degrade images, appearing as a 
large signal void; particularly affecting GE based pulse sequences. 
- Dark–rim artefact: refers to a band of transient low signal in the 
endocardium during first-pass perfusion when contrast first enters the 
LV cavity. It does not indicate hypo-perfusion and subsequently 
resolves within a few heartbeats as myocardial enhancement occurs. 
- Complex flow signal loss: Turbulent blood flow commonly associated 
with valvular pathology can cause phase shift dispersion and appear 
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as signal loss artefact. Caution is required as the area of signal void 
may not be directly related to the severity of the valve lesion. 
 
1.4.3 CMR Safety and the Safety of Implanted Medical Devices  
The magnetic field of the MR scanner is always on and although the 
magnetic field is strongest within the bore of the magnet, the surrounding 
fringe field can also adversely affect pacemakers and other implants. 
Importantly, any ferromagnetic objects will accelerate towards the magnet 
core, posing a projectile hazard with potentially fatal consequences. For 
these reasons, health and safety regulations dictate a controlled area must 
be defined enclosing the 0.5mTesla fringe field (the “pacemaker” line)[22]. 
Access to this area is restricted to trained staff, and patients who have been 
screened in particular for pacemakers, cerebral aneurysm clips and ocular 
foreign bodies. Items of hospital equipment and medical devices should all 
be classified using the American Society for Testing Materials (ASTM) 
guidance as MR Safe, MR conditional or MR unsafe[23]. 
 
1.4.3.1 Safety of Implanted Medical Devices  
Both mechanical and bioprosthetic heart valves, including transcatheter 
aortic valve implants, and intracoronary and aortic stents are all generally 
considered safe to scan shortly after implantation. The online resource 
www.MRISafety.com provides an extensive list of tested medical 
devices/implants. MR conditional pacemakers and defibrillators are now 
increasingly being implanted. However, MR imaging remains conditional on 
meeting stringent manufacturer safety criteria and requires prior 
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reprogramming and also immediate post-imaging parameter checks to 
ensure safe device operation before the patient leaves the department.  
 
1.4.4 CMR Contrast Agents: Indications and Safety 
Intravenously administered gadolinium chelate-based contrast agents (0.1-
0.2mmol/Kg), are typically extracellular and highly paramagnetic[24], 
shortening T1 relaxation times and increasing signal intensity of adjacent 
water molecules on T1w images.  
 
The reported incidence of allergic reactions to gadolinium is very low 
(~1:10,000); at least one order of magnitude lower than that of iodinated 
contrast agents[25]. No harm has been reported during pregnancy, although 
scanning during 1st trimester is generally avoided. The use of several 
gadolinium-based contrast agents in patient with advanced renal failure has 
been associated with Nephrogenic Systemic Fibrosis[26]. Several cyclic 
contrast agents appear not to cause this condition and it has never been 
reported in those with an eGFR>30ml/min/1.73m2. The FDA advises 
avoiding gadolinium based contrast agents when the eGFR is below 30 
ml/min/1.73m2, unless diagnostic information is essential and otherwise 
unattainable.   
 
1.5 Cardiovascular Magnetic Resonance for the Investigation 
of Stable Coronary Heart Disease. 
CMR is an established method for demonstrating myocardial ischemia and 
in some UK and European centres has become the preferred investigation 
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for patients with suspected stable angina. A CMR study for this purpose 
takes between 30 and 60 minutes and typically includes cine images in 
multiple planes for assessment of left ventricular (LV) volumes and function, 
stress and rest perfusion for myocardial ischemia and late gadolinium 
enhancement (LGE) for delineation of scar and assessment of viability. The 
combination of the above techniques in a single multi-parametric exam 
allows the quantification of ischemic burden and determines myocardial 
viability, which can be used to risk-stratify patients and guide 
revascularisation. 
 
1.5.1 Global and Regional LV Volumetric Assessment 
CMR is the reference standard in terms of accuracy and reproducibility of 
quantitation of LV volumes, mass and for the assessment of regional and 
global systolic function[27]; the latter remains the most powerful predictor of 
mortality in cardiovascular disease. LV volumes are performed with a 
contiguous stack of cine images parallel to the mitral valve annulus covering 
the whole of the left ventricle, providing a full three dimensional (3D) dataset. 
Full acquisition typically takes only a couple of minutes using breath hold 
techniques, and free breathing approaches are also possible. 
 
1.5.2  Stress Cardiovascular Magnetic Resonance 
Stress assessment with CMR for myocardial ischemia can be performed 
with vasodilatory or inotropic stress agents. Vasodilatory stress with 
adenosine, regadenoson (and less commonly dipyridamole or nicorandil) 
uses gadolinium based contrast agents to demonstrate myocardial 
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hypoperfusion. Dobutamine stress CMR, like stress echocardiography, 
induces wall motion abnormalities in the presence of functionally significant 
coronary stenoses without the need for a gadolinium based contrast agent 
(although first pass perfusion can be performed at peak stress for additional 
value). Typical multi-parametric CMR protocols can be seen in Figure 1.3.  
 
1.5.2.1  Vasodilatory Stress CMR 
Vasodilatory stress CMR has high diagnostic accuracy for the detection of 
CHD and a recent meta-analysis of 37 studies demonstrated a combined 
sensitivity of 89% (95%CI: 88%-91%) and specificity of 76% (95%CI: 73%-
78%)[28]. The largest prospective randomized controlled trial, the CE-MARC 
study, which was not included in the meta-analysis, demonstrated similar 
results and comprehensively established superiority over SPECT with a 
higher sensitivity (87% vs. 67%, p<0.0001) and negative predictive value 
(91% vs. 79%, p<0.0001) but similar specificity (83% vs. 83% p=0.916) and 
positive predictive values (77% vs. 71%, p=0.061)[29, 30]. A recent pre-
specified CE-MARC gender sub-analysis has shown that in terms of 
sensitivity, CMR outperformed SPECT in both males and females, whereas 
the sensitivity of SPECT in females was significantly worse than in 
males[31]. 
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Figure 1.3  Multi Parametric CMR Protocols in Coronary Artery Disease 
Panel A – Typical multi-parametric CMR protocol for the assessment of 
acute coronary syndromes involving T2w imaging demonstrating oedema, 
stress and rest perfusion for hypoperfusion (ischaemia), cine imaging for 
regional and global ventricular function, EGE for thrombus and MO and LGE 
for viability assessment and demonstration of scar. Panel B&C – Typical 
multi-parametric CMR protocols for the assessment of stable coronary artery 
disease with adenosine stress perfusion (B) or high dose dobutamine stress 
(C). EGE – early gadolinium enhancement; LGE – late gadolinium 
enhancement; MO – microvascular obstruction; T2w – T2 weighted 
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Like CE-MARC, the subsequently published multi-centre MR-IMPACT II trial 
also showed a greater sensitivity of CMR compared to SPECT (67% vs. 
59%, p=0.024) but a lower specificity (61% vs. 72%, p=0.038)[32]. However 
in this trial only the perfusion components of the CMR examination were 
analysed and as a result, diagnostic accuracy was comparatively lower. This 
may also be explained by the multicenter, multivendor, non-standardized 
pulse sequence trial design of MR-IMPACT II with reporting performed by an 
independent core laboratory without clinical details, and emphasizes the 
incremental value of reporting imaging studies in their clinical context and 
with experience and knowledge of the techniques used.  
 
Whilst both CE-MARC and MR-IMPACT II assessed the ability for CMR and 
SPECT to detect inducible myocardial perfusion deficits with adenosine 
stress, CE-MARC also evaluated the incremental value of the addition of 
infarction detection with late gadolinium enhancement (LGE), cine imaging 
for regional ventricular function and magnetic resonance angiography (MRA) 
for coronary artery anatomy. The value of combining such components in 
one single multi-parametric CMR examination added to the increased 
specificity in the CE-MARC trial. Indeed this issue has been examined in 
small scale studies with ventricular function and LGE improving the 
specificity and diagnostic accuracy above the stress perfusion examination 
alone. The clinical utility of imaging coronary artery anatomy by MRA within 
already lengthy protocols however still remains to be established[33].  In CE-
MARC the overall diagnostic accuracy did not alter whether or not the results 
of the MRA were included in the analysis. Other investigators have 
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evaluated the effect of adding coronary MRA to stress perfusion CMR on 
diagnostic performance; when compared to invasive pressure-wire derived 
fractional flow reserve (FFR) at 1.5T there was no significant improvement in 
diagnostic accuracy[34].  
 
Whilst the CE-MARC study proved the superiority of CMR over SPECT in 
terms of diagnostic accuracy of CHD detection, questions were raised over 
the availability and cost benefit of the technology[35]. Subsequent health 
economic analysis demonstrated that a diagnostic strategy which includes 
CMR is cost effective falling between the lower and upper limits thresholds 
(£20-30,000) per quality adjusted life year (QALY) as defined by National 
Institute for Health and Care Excellence (NICE)[36]. Furthermore the cost 
effectiveness of CMR has been corroborated in other international models 
against both direct to invasive coronary angiography and SPECT, although 
direct referral to invasive coronary angiography may be more cost effective 
in those with a high pre-test probability of having underlying CHD[37, 38]. 
 
1.5.2.2  Inotropic Stress CMR 
Inotropic stress CMR with dobutamine for the detection of significant CHD 
relies on the induction of wall motion abnormalities and therefore evaluating 
a later stage of the ischemic cascade than perfusion imaging. Nevertheless 
dobutamine stress CMR also has a high diagnostic accuracy for the 
detection of CHD with one meta-analysis of 14 studies showing a pooled 
sensitivity of 0.83 (95%CI: 0.79-0.88) and specificity of 0.86 (95%CI: 0.81-
0.91)[39]. One single centre study demonstrated dobutamine stress CMR to 
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be superior to dobutamine stress echocardiography (DSE) with sensitivity of 
86% vs. 74%, p<0.05 and specificity 86% vs. 70%, p<0.05, although this 
benefit of dobumtamine stress CMR above DSE was limited to those with 
suboptimal echocardiographic images[40]. In terms of prognostic value, 
those with a negative DSCMR have an excellent prognosis with an event 
rate of only 1.2% in the first year after the test, [41-43] which is similar to that 
published annual event rate of 1.3% of a negative DSE[44]. Dobutamine 
stress CMR has been demonstrated to be extremely safe with a comparable 
safety profile to DSE[45, 46]. 
 
1.5.2.3 Pushing the boundaries: improving stress technology 
Since the inception of the CE-MARC and MR-IMPACT II studies, which used 
perfusion sequences with an in-plane spatial resolution of 2-3mm, there 
have been major advances in CMR technology. Notably, there have been 
improvements in acquisition techniques such as highly accelerated pulse 
sequences based on spatio-temporal undersampling (for example k-t 
sensitivity encoding (SENSE) and highly constrained back projection 
(HYPR)) and improvements in hardware, such as higher field strengths and 
improved cardiac phase-array coils for higher signal-to-noise[47]. Perfusion 
CMR at 1.5 Tesla (T) using  k-t SENSE acceleration to achieve an in-plane 
spatial resolution of 1.6mm has been demonstrated to have a greater overall 
diagnostic accuracy than standard resolution (2.5mm) for identifying both 
single (p<0.001) and multi vessel disease (p=0.002), with an area under the 
curve (AUC) of 0.93 vs. 0.83; p<0.001[47]. Similarly, diagnostic performance 
at 3.0T exceeds that at 1.5T for both single-vessel disease (AUC: 0.89 vs 
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0.70; p<0.05) and multivessel disease (AUC: 0.95 vs. 0.82; p<0.05)[48]. 
Using similar high resolution techniques at 3.0T can regularly achieve an in-
plane spatial resolution of <1.5mm, which is the basis for improved detection 
of subendocardial ischemia, and this advance is now beginning to make the 
transition into clinical practice[49]. 
Conventional stress perfusion CMR images are typically acquired in 3 short 
axis slices to assess 16 of the 17 segments in the AHA/ACC model 
(excluding the apical cap). Faster image acquisition also allows 3-
dimensional (3D) whole heart myocardial perfusion imaging with full left 
ventricular coverage and therefore overcomes assumptions made about the 
myocardium between slices seen with the conventional approach [47]. An 
additional advantage of 3D perfusion CMR is that all the data are acquired in 
one shot and thus in the same cardiac phase. Two recent studies have 
validated 3D perfusion CMR against FFR and shown high diagnostic 
accuracy[50, 51]. Manka et al demonstrated 3D perfusion CMR at 1.5T was 
found to have a sensitivity, specificity and diagnostic accuracy of 90%, 82% 
and 87% respectively[50]. Jogiya et al found similar figures of 91%, 90% and 
91% respectively at 3.0T[51]. Both of these studies also verified the 
feasibility and reproducibility of myocardial ischemic burden quantification 
from 3D data using volumetry of myocardial hypo-enhancement expressed 
as a percentage of total myocardium. 3D myocardial stress perfusion CMR 
is therefore a highly promising development with high diagnostic accuracy, 
with a potential additional role in the assessment and follow-up of total 
myocardial ischemic burden.  
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1.5.3 Coronary Artery Imaging 
Unlike cardiac CT coronary angiography which produces exquisite 
anatomical images of the coronary arteries, the clinical utility of detection 
coronary artery stenosis by magnetic resonance angiography (MRA) 
remains to be established. This is due to the required long imaging times, 
more limited spatial resolution, and the impact of cardiac and respiratory 
motion on MRA image quality. One question unanswered from the CE-
MARC multi parametric protocol is the valve of the addition of the MRA on 
the diagnostic accuracy. Other data has suggested that there is no 
incremental value on including the MRA[33]. Coronary MRA, however, is 
useful for detecting the location of coronary aneurysms (such as those seen 
in Kawasaki disease), and the presence of anomalous coronary arteries with 
accurate delineation of their anatomical course[52]; the principal advantage 
of MRA being the lack of ionising radiation in children and younger adults.  
 
1.6 Cardiovascular Magnetic Resonance after Acute 
Coronary Syndromes  
The pathophysiology and prognosis of both acute and chronic MI are highly 
variable. Multi-parametric imaging with CMR has high diagnostic accuracy 
for the detection of CAD in the assessment of both ST-segment and non-ST-
segment elevation acute coronary syndromes [53, 54]. CMR can uniquely 
determine the likelihood of functional recovery after revascularization, 
assess the area of myocardium at risk (and myocardial salvage), 
differentiate acute from chronic infarction, demonstrate microvascular 
obstruction (MO) and intramyocardial haemorrhage (IMH), as well as being 
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able to detect several sequelae of MI. These individual features may be 
more powerful surrogate markers of outcome than the traditionally used left 
ventricular ejection fraction. 
 
1.6.1 Acute Myocardial Infarction  
After an acute coronary syndrome, LGE imaging confirms the presence of 
myocardial infarction (MI), which is seen as hyperenhancement, and can 
determine its size and location. In acute MI, the distribution volume of 
extracellular gadolinium-based contrast agents is increased within 
myocardium due to the destruction of sarcolemmal membranes and 
abnormal washout kinetics. Similarly, in chronic MI, the presence of 
replacement fibrotic tissue increases the contrast distribution volume. The 
resulting differences in contrast distribution between normal and injured 
myocardium can therefore be used to delineate MI (whether it be acute or 
chronic) using a T1-sensitive inversion-recovery sequence performed 10-
15mins after contrast injection – i.e. LGE imaging (Figures 1.1, 1.2 & 1.4). 
 
1.6.1.1 Myocardial Oedema 
Following acute MI T2-weighted imaging can be used in acute coronary 
syndromes to identify myocardial oedema (inflammation), which occurs in 
reversibly ischemic injured myocardium[55]. Contrast agents are not 
required as the myocardial free water content affects paramagnetic 
properties of the tissue providing intrinsic image contrast, although with 
relatively low signal-to-noise ratio (SNR) and requires experience to 
interpret. T2-weighted oedema imaging is both sensitive [56] and specific 
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[57] to the timing of an event, thereby differentiating acute from chronic 
infarction (Figures 1.2 & 1.4). It therefore also allows delineation of the ‘area-
at-risk’ (AAR) in acute infarction and the area of ‘myocardial salvage’ 
calculated by subtraction of the infarcted area determined by LGE[56]. The 
high signal on oedema imaging is persistent for up to 2 weeks after the 
reversible ischemic insult, the AAR can therefore be measured hours or 
days after a primary PCI, which makes it an ideal research tool for studies 
assessing novel antithrombotics and adjuvant techniques for mechanical 
revascularization. 
 
1.6.1.2 Microvascular obstruction 
In acute MI, despite successful revascularization therapy, perfusion is not 
completely restored in up to 30% of patients due to MO. This is seen 
angiographically as the ‘no-reflow’ phenomenon and is the consequence of 
capillary necrosis, clogging of small myocardial arterioles with embolic 
debris, acute inflammation, platelet aggregation and vasospasm. 
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Figure 1.4  CMR in Acute Myocardial Infarction 
The top row shows mid-ventricular short-axis images from a patient on day 3 
following an acute septal STEMI. Myocardial oedema i.e. the ‘area-at risk’  is 
seen as high-signal intensity on T2 weighted imaging (arrow, 1a) and a 
central core of reperfusion haemorrhage is seen as low signal intensity on 
T2* imaging (arrow, 1b). The middle row shows mid-ventricular short-axis 
images images from another patient with an occlusion of the proximal left 
anterior descending artery. Both EGE and LGE imaging show a core of non-
contrast uptake i.e. microvascular obstruction (large arrows, 2a and 2b) 
within a transmural septal wall MI which is outlined by hyperenhancement on 
LGE imaging (small arrows, 2b). The bottom row shows 4-chamber images 
from a 55-year-old man with a recent LAD territory MI. EGE and LGE 
imaging show a non-enhancing (and therefore avascular) mass typical of LV 
thrombus. LGE imaging demonstrates that the thrombus overlies mid to 
apical antero-septum infarction seen as hyperenhancement (small arrows, 
3b). 
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Contrast enhanced CMR allows accurate depiction of areas of microvascular 
damage within the core of the infarcted myocardium the extent of which 
correlates with biochemical markers of infarction[58]. In MO gadolinium 
penetration is impaired and limited to diffusion[59, 60] and results in contrast 
devoid low-signal intensity regions within the high-intensity infarcted areas 
(Figures 1.2 & 1.4). This may be imaged with several imaging techniques: 
first-pass perfusion, early gadolinium enhancement (EGE) imaging at 1 to 2 
minutes after contrast injection (Figures 1.2 & 1.4) and LGE (10-15 mins 
after injection)[61]. Studies have shown that the presence and extent of MO 
(on EGE or LGE imaging) after acute MI is a strong predictor of adverse 
ventricular remodelling and clinical outcome, independent of infarct size or 
LV ejection fraction (LVEF) [62-66]. Notably, the presence and extent of MO 
imaged with LGE imaging (so called ‘persistent’ MO) is the strongest 
predictor of worse outcomes[67]. After acute MI, MO slowly shrinks over the 
following weeks (rarely persisting beyond 1 month) and is therefore not a 
feature of chronic infarction. 
 
1.6.1.3 Intramyocardial haemorrhage 
Reperfusion of severely ischemic myocardium can lead to IMH within the 
infarct core caused by extravasation of red blood cells through large gaps in 
damaged endothelial walls. Deoxyhemoglobin is oxidised to methemoglobin, 
which causes shortening of the T2 relaxation time due to its paramagnetic 
properties and magnetic susceptibility effect and therefore, haemorrhage 
can be detected as areas of dark hypointense signal surrounded by oedema 
(bright signal) on T2-weighted imaging. Several studies have validated the 
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use of T2-weighted CMR imaging to identify IMH in acute MI against 
histopathological findings[68, 69].  Furthermore, T2* CMR has also shown 
potential to detect IMH in the setting of acute MI, with the advantage of 
better distinction from MO (which is also seen as hypointensity on standard 
T2-weighted imaging)[70](Figure 1.4). 
 
1.6.1.4 Other sequelae of myocardial infarction 
CMR is superior to echocardiography for the identification of ventricular 
thrombi, which appear as dark filling defects on EGE or LGE imaging, 
typically on the endocardial surface of infarcts[71, 72](Figures 1.2 & 1.4). 
CMR is also able to detect other complications of MI including ventricular 
aneurysm, pseudoaneurysms, ventricular septal perforation and mitral 
regurgitation. Furthermore the high spatial resolution of CMR allows 
assessment of right ventricular involvement in acute myocardial infarction.  
  
1.6.2 Assessment of Myocardial Viability after Myocadial 
Infarction 
Ischemic myocardial injury is characterised by the presence of scar in 
predominantly a subendocardial distribution extending towards the 
epicardium reflecting the transmural gradient in the vulnerability of the 
myocardium. The transmural extent of hyperenhancement forms the basis 
upon which LGE can be used to assess tissue viability. The value of LGE 
CMR imaging for viability assessment in patients with a chronic CAD or a 
remote history of MI was established in the landmark study by Kim et al 
which demonstrated the relationship between transmural extent of hyper-
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enhancement and the likelihood of functional recovery after 
revascularization[73]. They established that hyper-enhancement <25% of 
transmural extent was most likely to confer functional recovery, whilst those 
segments with hyperenhancement >75% of transmural extent were unlikely 
to benefit from revascularization - importantly this finding was consistent 
whether the affected segments were hypokinetic, akinetic or dyskinetic. 
These findings have subsequently been reproduced and a recent meta-
analysis of eleven studies enrolling 331 patients using a 50% transmurality 
cut off on LGE reported a sensitivity of 95% (95%CI: 93-97%) and specificity 
of 51% (40-62%) for predicting functional recovery[74]. In the acute phase 
after MI, interpretation of viability is more difficult as some of the 
hyperenhancement on LGE imaging may relate to myocardial oedema (due 
to increased extracellular volume) rather than non-viable ‘scar’. Nonetheless, 
the transmural extent of hyperenhancement on LGE imaging has still been 
shown to accurately predict contractile recovery after MI and 
revascularisation even when imaging is performed acutely within the first 7 
days[75]. 
 
1.6.2.1 Transmurality of LGE  
Transmurality of LGE is a stronger predictor of both regional and global 
functional recovery after revascularization than myocardial wall thickness. 
Shah et al studied 201 consecutive patients with wall thinning undergoing 
revascularization observing increased myocardial wall thickness after 
revascularization in those segments where the LGE was limited to <25% 
(4.4mm increasing to 7.5mm after revascularization, p<0.001)[76]. 
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Furthermore in patients with chronic LV systolic dysfunction due to CHD, the 
transmural extent of LGE has been shown to be the most sensitive 
technique for the assessment of viability compared to end diastolic wall 
thickness and wall thickening during low dose dobutamine stress[77]. 
Nevertheless myocardial viability can be assessed with low dose 
dobutamine (5-10 mcg/kg/min) with any segment considered viable if there 
is a 2mm or more demonstrable increase in systolic wall thickening.[78] 
Inotropic reserve assessed by low dose dobutamine has significantly higher 
specificity (91%)[74] suggesting a combination of the two techniques might 
improve diagnostic performance. 
 
1.7 Prognostic Value of CMR in Coronary Heart Disease 
Currently SPECT remains the most widely performed non-invasive test for 
myocardial ischemia internationally and provides a wealth of prognostic 
information gained in over 30 years of experience with the technology. 
Emerging evidence suggests CMR will be as good, at prognostication, which 
is unsurprising since the technology assesses the same stage of the 
ischemic cascade but with higher spatial resolution allowing detection of 
more subendocardial ischemia and infarction. One recent large meta-
analysis of 19 studies and over 11,000 patients showed a negative CMR 
was associated with only 0.8% annual event rate at 32 months follow-up (vs. 
4.9% event rate in those with a positive test; p<0.0001)[79] which is 
consistent with the reported annual event rate for a negative SPECT[80]. 
This benefit was observed equally whether undergoing vasodilatory stress or 
dobutamine stress. More recent data from a large prospective cohort of 
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consecutive patients undergoing adenosine stress perfusion have 
corroborated this prognostic value at an intermediate term follow-up period 
(4.2±2.1 years) showing that the presence of a reversible perfusion defects 
was associated with a threefold increase in cardiac death (p<0.0001) and 
nonfatal myocardial infarctions (p=0.001)[81]. 
 
The presence of LGE has been demonstrated to be associated with an 
increased mortality risk in both symptomatic[82] and asymptomatic 
patients[77] without known previous myocardial infarction. In patients with 
chronic ischemic cardiomyopathy, LGE scar size independently predicts 
both death and sustained ventricular arrhythmia in those with preserved[83] 
and severely impaired LV function[84, 85]. One meta-analysis demonstrated 
the presence of LGE in CHD to be associated with a fourfold increase in the 
hazard ratio of both mortality and major adverse cardiovascular events 
(MACE), with each incremental gram of scar associated with a 4% increase 
in mortality and a 5% increase in MACE[86]. 
 
Infarct size by CMR similarly predicts sudden cardiac death (SCD) and 
arrhythmia after ST segment elevation MI independent of LVEF.[87] The 
authors of that study demonstrated that those with an LVEF of more than 
30% with significant scarring (>5% of LV mass) had a similar risk of SCD 
and appropriate implantable cardiac defibrillator (ICD) discharge than a 
cohort with LVEF<30%, whilst those with LVEF>30% and minimal or no 
scarring had a more favourable prognosis, suggesting scar could be 
potentially used in risk stratification models for ICD implantation in the future. 
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Furthermore, after ST elevation myocardial infarction the presence of MO is 
recognised as an independent marker of subsequent adverse LV 
remodelling and a strong predictor of MACE[88]. Whilst recent studies have 
shown the presence of IMH identified by CMR is associated with other 
markers of adverse outcome such as larger infarct size, greater MO and 
lower LVEF, it may also be a strong independent marker of adverse 
remodelling and 6 month MACE.[70, 89, 90].  
 
1.8 Conclusion  
CMR is a well-established non-invasive imaging technique with major 
applications in the evaluation of patients with coronary heart disease. In a 
single imaging session, CMR can assess cardiac anatomy, function, 
myocardial perfusion and tissue viability, without exposure to ionising 
radiation. Its use in both stable CHD and acute coronary syndromes is 
supported by a strong and rapidly expanding evidence-base. However the 
real challenge for any cardiovascular imaging modality is how it can change 
patient management and impact upon clinical outcomes. In this regard major 
on-going clinical trials are likely to raise the prominence of CMR in 
international guidelines and routine cardiological practice. 
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Chapter 2  
Individual Component Analysis of the Multi-Parametric 
Cardiovascular Magnetic Resonance Imaging Protocol in the 
CE-MARC Trial 
 
2. 1 Abstract 
2.1.1 Background  
The CE-MARC study assessed the diagnostic performance and investigated 
the use of cardiovascular magnetic resonance (CMR) in patients with 
suspected coronary artery disease (CAD). The study used a multi-
parametric CMR protocol assessing 4 components: i) left ventricular 
function; ii) myocardial perfusion; iii) viability (late gadolinium enhancement 
(LGE)) and iv) coronary magnetic resonance angiography (MRA). In this pre-
specified CE-MARC sub-study we assessed the diagnostic accuracy of the 
individual CMR components and their combinations. 
2.1.2 Methods  
All patients from the CE-MARC population (n=752) were included using data 
from the original blinded-read. The four individual core components of the 
CMR protocol were determined separately and then in paired and triplet 
combinations. Results were then compared to the full multi-parametric 
protocol. 
2.1.3 Results  
CMR and X-ray angiography results were available in 676 patients. The 
maximum sensitivity for the detection of significant CAD by CMR was 
achieved when all four components were used (86.5%). Specificity of 
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perfusion (91.8%), function (93.7%) and LGE (95.8%) on its own was 
significantly better than specificity of the multi-parametric protocol 
(83.4%)(all P<0.0001) but with the penalty of decreased sensitivity (86.5% 
vs. 76.9%, 47.4% and 40.8% respectively). The full multi-parametric protocol 
was the optimum to rule-out significant CAD (Likelihood Ratio negative (LR-) 
0.16) and the LGE component alone was the best to rue-in CAD (LR+ 9.81). 
Overall diagnostic accuracy was similar with the full multi-parametric 
protocol (85.9%) compared to paired and triplet combinations. The use of 
coronary MRA within the full multi-parametric protocol had no additional 
diagnostic benefit compared to the perfusion/function/LGE combination 
(overall accuracy 84.6% vs. 84.2% (P=0.5316); LR- 0.16 vs. 0.21; LR+ 5.21 
vs. 5.77). 
2.1.4 Conclusions  
From this pre-specified sub-analysis of the CE-MARC study, the full multi-
parametric protocol had the highest sensitivity and was the optimal approach 
to rule-out significant CAD. The LGE component alone was the optimal rule-
in strategy. Finally the inclusion of coronary MRA provided no additional 
benefit when compared to the combination of perfusion/function/LGE. 
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2.2 Background 
Coronary artery disease (CAD) is a leading cause of death and disability 
worldwide. Cardiovascular magnetic resonance (CMR) is recognised in 
international guidelines as a non-invasive imaging option for the 
investigation of suspected CAD[1-3]. The CE-MARC study was the largest 
prospective evaluation of the diagnostic accuracy of CMR in stable CAD to 
date[4, 5]. The trial adopted a multi-parametric CMR protocol assessing left 
ventricular (LV) function, myocardial perfusion, viability and coronary artery 
anatomy in a single study. A rigorous study design avoided referral bias by 
mandating that all patients underwent X-ray coronary angiography (XRA) as 
the reference test independent of the result of the CMR or single-photon 
emission computed tomography (SPECT) scans. The results from CE-
MARC and its sub-analyses have shown that CMR had high diagnostic 
accuracy for suspected CAD in males and females, in single and multi-
vessel disease, had higher overall diagnostic accuracy and was also cost 
effective compared to SPECT[6, 7]. 
 
Previous studies designed to determine the diagnostic accuracy of the 
individual components of the CMR examination have been small and 
revealed contrasting results. Some have shown the full multi-parametric 
approach had higher diagnostic accuracy over the individual components of 
the combined examination, although these were performed in selected 
populations[8-11]. Furthermore the clinical utility of imaging coronary artery 
anatomy for the detection of stenosis by magnetic resonance angiography 
(MRA) within already lengthy protocols remains to be established. Klein et al 
demonstrated that MRA at 1.5 Telsa (T) did not add to the diagnostic 
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accuracy over perfusion and late gadolinium enhancement (LGE).[11] Other 
investigators have evaluated the effect of adding coronary MRA to stress 
perfusion and LGE on diagnostic performance in the intermediate to high 
risk group; when compared to invasive pressure-wire derived fractional flow 
reserve (FFR) at 1.5T there was no significant improvement in diagnostic 
accuracy[12]. 
 
This predefined sub-study of CE-MARC compared the diagnostic accuracy 
of the full multi-parametric CMR protocol with the individual components, 
and their paired and triplet combinations. The aim was to determine the 
diagnostic accuracy of the individual components and their combinations in a 
large, prospective, real-world population of patients with suspected CAD 
requiring further investigation. 
 
2.3 Methods 
2.3.1 Study Design 
CE-MARC was a prospective study of 752 consecutive patients with a 
diagnosis of atypical or typical angina. They had at least one cardiovascular 
risk factor. Screening and recruitment occurred between March 2006 and 
August 2009.[5, 4] All patients were scheduled to undergo both SPECT and 
CMR (in randomized order). The protocol mandated all received XRA within 
4 weeks irrespective of the CMR and SPECT result. Inclusion and exclusion 
criteria have been previously been described.[5, 4] Patients provided 
informed written consent and the study was approved by the local Research 
Ethics Committee and complied with the Declaration of Helsinki (2000).  
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All patients from the CE-MARC population were included in this pre-
specified sub-analysis. CMR results were from the original, blinded visual 
read. The diagnostic accuracy of each individual core component of the 
multi-parametric CMR protocol (perfusion, LV function, MRA and LGE) was 
determined separately and then in paired or triplet combinations. The results 
were compared with the full multi-parametric protocol.  
 
 
2.3.2 CMR imaging and analysis 
The multi-parametric CMR (1.5-Tesla Intera CV, Philips, Best, The 
Netherlands) protocol and pulse sequence parameters have previously been 
described.[5, 4] The primary analysis used all four components of the multi-
parametric CMR study. Criteria for a positive CMR result was any of the 
following: a) regional wall motion abnormality (RWMA) on cine imaging; b) 
hypoperfusion on stress/rest perfusion imaging; c) significant stenosis on 
MRA; d) infarct on LGE images (Table 2.1) following a ‘believe the positive 
rule’. Individual component image quality scores for CMR (cines, perfusion, 
LGE, MRA) were graded 1 (unusable) to 4 (excellent). 
 
2.3.3 X-Ray Angiography 
XRA images were analysed by two experienced cardiologists blinded to the 
CMR and SPECT results. Significant CAD was defined as ≥70% stenosis of 
a first order coronary artery measuring ≥2 mm in diameter, or left main stem 
stenosis ≥50% by quantitative coronary angiography (QCA) (QCAPlus, 
Sanders Data Systems, Palo Alto, California, USA). 
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Table 2.1  Criteria for a Positive CMR result in the CE-MARC study[91, 92]. 
Parameter Method Positive Criteria 
RWMA  Wall motion in each segment (17-segment model) was visually 
graded on post-stress cine imaging [0=normal, 1=mild-moderate 
hypokinesis, 2=severe hypokinesis, 3=akinesis, 4=dyskinesis] 
Wall motion Score ≥1 in two or more 
adjacent segments, or ≥2 in one or 
more segments 
Ischemia  Perfusion in each segment (17-segment model)
*
 was visually graded 
at rest and then stress [0=normal, 1=equivocal, 2=subendocardial 
defect, 3=transmural defect, 4=transmural defect and wall thinned] 
Decrease in perfusion score ≥2 
between rest and stress in any 
segment, or ≥1 in each of two adjacent 
segments
†
 
 
Stenosis Percentage of coronary artery luminal narrowing visually assessed 
on MRA 
≥70% stenosis or ≥50% left main stem 
stenosis 
Infarction  LGE images were visually assessed for hyper-enhancement in each 
segment (17-segment model) [0=none, 1=1–25%, 2=26–50%, 3=51–
75%, 4=>75%] 
Any score ≥1 in a pattern consistent 
with myocardial infarction 
 
* 17-segment model excluding apical cap. 
†
 With the exception of change between ‘normal’ and ‘equivocal’, which was coded as ‘normal’. 
RWMA = regional wall motion abnormality; MRA = magnetic resonance coronary angiography; LGE = late-gadolinium enhancement 
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2.3.4 Statistical Analysis 
Statistical analyses were performed by the Clinical Trials Research Unit, 
University of Leeds. Confidence intervals for the sensitivity, specificity, 
overall accuracy and positive (PPV) and negative predictive values (NPV) 
were calculated with the Wilson score method. Sensitivities and specificities 
were compared by the McNemar’s test, and predictive values were 
compared using the generalised score statistic. The positive (LR+) and 
negative likelihood ratios (LR-) were calculated using standard methods[13]. 
Assessment of the value of each component as “add on tests” were made 
with relative likelihood ratios.[13] Statistical analysis performed using with 
SAS software, version 9.2 at a two-sided 5% significance level. 
 
2.4 Results 
2.4.1 Study Population 
Both CMR and XRA were available in 676 patients (mean 60±9.5 years, 
62% male). For the individual components LGE was available in 674 
(99.7%), perfusion in 661 (97.8%), ventricular function in 676 (100%) and 
MRA in 597 (88.3%). The prevalence of XRA defined significant CAD was 
39% and further demographic details are shown in Table 2.2.  
 
2.4.2 Diagnostic Accuracy 
The sensitivity of the combined CMR protocol was 86.5% (95%CI: 81.9-
90.1), specificity 83.4% (79.5-86.7), PPV 77.2% (72.1-81.6%), NPV 90.5% 
(87.1-93.0) and overall diagnostic accuracy 84.6% (81.7-87.1). The 
diagnostic accuracy of the individual components, paired and triplet 
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combinations compared to the full multi-parametric protocol are presented in 
Table 2.3 and Figure 2.1.   
We have shown that of the individual components, perfusion had numerically 
the highest sensitivity (76.9%), NPV (86.0%) and overall diagnostic accuracy 
(85.9%), whilst LGE had the highest specificity (95.8%) and PPV (86.4%) for 
the detection of significant CAD.  
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Figure 2.1.  Diagnostic accuracy of the individual components and their 
combinations compared to the full multi-parametric CMR 
examination. 
 
Cine – Cine imaging; LGE – late gadolinium enhancement; Perf –perfusion imaging; MRA – magnetic 
resonance coronary angiography [92]  
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2.4.2.1 Sensitivity 
The maximum sensitivity (86.5%) and NPV (90.5%) for the detection of 
significant CAD by CMR was achieved when the full multi-parametric 
protocol was used, no individual component, paired or triplet combination 
outperformed the full multi-parametric protocol. However its lower specificity 
and PPV, meant that its overall diagnostic accuracy (84.6%) was broadly 
similar to the majority of paired and triplet combinations (Table 2.3). 
 
2.4.2.2 Specificity 
In terms of specificity, the individual components of perfusion (91.8%), 
ventricular function (93.7%) and LGE (95.8%) all performed significantly 
better than the multi-parametric protocol (83.4%)(P<0.0001 for all). In 
addition, combining LGE with either ventricular function (91.7%) or MRA 
(90.0%) significantly improved the test specificity compared to the multi-
parametric protocol (P<0.0001 for each).  
 
2.4.2.3 Overall Diagnostic Performance 
For overall diagnostic performance, no individual component or combination 
was better statistically than the full multi-parametric protocol (Table 2.3). The 
use of coronary MRA had no additional diagnostic benefit in terms of overall 
diagnostic accuracy when performed within a multi-parametric protocol 
(84.6% Vs. 84.2%)(X2=0.3913,1df, P=0.5316). 
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Table 2.2  Summary of demographic and angiographic characteristics. 
  
 
n=676 
Age (years)   60.3 ± 9.5 
Male gender  421 (62%) 
Body Mass Index (kg/m
2
)  29.0 ± 4.3 
Ethnicity White 643 (95%) 
Black 5 (1%) 
Asian 24 (4%) 
Other 4 (1%) 
Smoking Status Never smoked 236 (35%) 
Ex-smoker 315 (47%) 
Current smoker 125 (18%) 
Systolic Blood Pressure (mmHg)  138.1 ± 20.9 
Diastolic Blood Pressure (mmHg)  79.0 ± 11.3 
Previous admission for AMI or ACS  54 (8.0%) 
Previous PCI  37 (5%) 
Hypertension  347 (51%) 
Diabetes mellitus  85 (13%) 
 Type I 4 (5%) 
Type II 81 (95%) 
Family history of premature CAD Yes 392 (58%) 
No 237 (35%) 
Unknown 47 (7%) 
Total cholesterol (mmol/L)  5.2 (1.2) 
   
Medication    
Aspirin and/or Clopidogrel  404 (60%) 
Statin  301 (45%) 
ACEi / A2 Receptor Blockers  229 (37.2%) 
Beta-blocker  203 (33.0%) 
   
Patients undergoing X-ray angiography   
    Any significant stenosis  266 (39%) 
    Triple Vessel Disease  40 (6%) 
    Double Vessel Disease  83 (12%) 
    Single Vessel Disease  143 (21%) 
    LMS Disease  22 (3%) 
    LAD Disease  169 (25%) 
    LCx Disease  126 (19%) 
    RCA Disease  105 (16%) 
Mean±standard deviation. Number (percentage).   
AMI = acute myocardial infarction; ACS – acute coronary syndrome; PCI – percutaneous coronary 
intervention; CAD – coronary artery disease; ACEi – angiotensin converting enzyme inhibitor; A2 – 
angiotensin 2; LMS – left main stem; LAD – left anterior descending; LCx – left circumflex; RCA – right 
coronary artery 
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Table 2.3  Diagnostic accuracy of a multi-parametric CMR exam and its 
individual components, paired and triplet combinations compared to the 
reference test X-ray angiography. 
 
CMR – cardiovascular magnetic resonance; LGE – late gadolinium enhancement; LR- – Likelihood 
Ratio Negative; LR+ – Likelihood Ratio Positive; MRA – magnetic resonance coronary angiography. 
 
  
 
Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
PPV  
(95%CI) 
NPV  
(95%CI) 
Overall 
Accuracy 
(95% CI) 
Overall multi-parametric CMR study  
(all components)  (n= 676) 
86.5  
(81.8, 90.1) 
83.4 
 (79.5, 86.7) 
77.2 
 (72.1, 81.6) 
90.5 
 (87.1, 93.0) 
84.6  
(81.7, 87.1) 
Individual CMR components      
LGE (n= 674)  40.8 
 (35.0, 46.8) 
95.8 
 (93.4, 97.4) 
86.4 
 (79.3, 91.3) 
71.4 
 (67.5, 75.0) 
74.2  
(70.7, 77.3) 
Perfusion (n= 661) 76.9 
 (71.4, 81.6) 
91.8 
 (88.7, 94.1) 
85.8 
 (80.8, 89.7) 
86.0 
 (82.4, 89.0) 
85.9  
(83.1, 88.4) 
Ventricular function (n= 676) 47.4 
 (41.4, 53.4) 
93.7 
 (90.9, 95.6) 
82.9 
 (76.1, 88.1) 
73.3 
 (69.3, 76.9) 
75.4  
(72.1, 78.5) 
MRA (n= 597)  71.2 
 (65.1, 76.7) 
89.8 
 (86.3, 92.5) 
81.8 
 (75.9, 86.5) 
83.0 
 (79.0, 86.4) 
82.6  
(79.3, 85.4) 
Paired combinations      
Perfusion/LGE  
(n= 676) 
78.6 
 (73.3, 83.1) 
89.3 
 (85.9, 91.9) 
82.6 
 (77.5, 86.8) 
86.5 
 (82.9, 89.5) 
85.1  
(82.2, 87.5) 
Perfusion/function  
(n= 676) 
80.1 
 (74.9, 84.4) 
87.3 
 (83.7, 90.2) 
80.4 
 (75.2, 84.7) 
87.1 
 (83.5, 90.0) 
84.5  
(81.5, 87.0) 
Perfusion/MRA  
(n= 676) 
82.3 
 (77.3, 86.4) 
89.0 
 (85.6, 91.7) 
83.0 
 (78.0, 87.0) 
88.6 
 (85.2, 91.3) 
86.4  
(83.6, 88.8) 
Function/LGE 
(n= 676) 
52.6 
 (46.6, 58.6) 
91.7 
 (88.6, 94.0) 
80.5 
 (73.9, 85.7) 
74.9 
 (70.9, 78.5) 
76.3  
(73.0, 79.4) 
Function/MRA  
(n= 676) 
72.9 
 (67.3, 77.9) 
87.8 
 (84.3, 90.6) 
79.5 
 (74.0, 84.1) 
83.3 
 (79.5, 86.6) 
82.0  
(78.9, 84.7) 
LGE/MRA  
(n= 676) 
69.2 
 (63.4, 74.4) 
90.0 
 (86.7, 92.5) 
81.8 
 (76.2, 86.3) 
81.8 
 (78.0, 85.1) 
81.8  
(78.7, 84.5) 
Triplet combinations      
Perfusion/LGE/function (n= 676) 81.6 
 (76.5, 85.8) 
85.9 
 (82.1, 88.9) 
78.9 
 (73.7, 83.3) 
87.8 
 (84.2, 90.6) 
84.2  
(81.2, 86.7) 
Perfusion/LGE/MRA 
(n= 676) 
84.6 
 (79.8, 88.4) 
86.6 
 (82.9, 89.5) 
80.4 
 (75.3, 84.6) 
89.6 
 (86.3, 92.3) 
85.8  
(83.0, 88.2) 
Perfusion/function/MRA  
(n= 676) 
85.3 
 (80.6, 89.1) 
84.9 
 (81.1, 88.0) 
78.5 
 (73.5, 82.9) 
89.9 
 (86.5, 92.5) 
85.1  
(82.2, 87.5) 
LGE/function/MRA 
(n= 676) 
75.2 
 (69.7, 80.0) 
86.1 
 (82.4, 89.1) 
77.8 
 (72.4, 82.5) 
84.2 
 (80.5, 87.4) 
81.8  
(78.7, 84.5) 
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2.4.3 The Value of Components as Individual and Add On Tests: 
Likelihood Ratios 
The highest likelihood ratio positive (LR+) was achieved when using LGE 
imaging alone (LR+ 9.81) signifying this individual component as the best 
approach for ruling in a diagnosis. All individual, paired and triplet 
combinations had higher LR+ than the full multi-parametric protocol (Table 
2.4). However the full multi-parametric protocol had the lowest LR- (0.16) 
than all of the individual components and their combinations, signifying this 
as the best approach to rule out significant CAD. The absolute likelihood 
ratios for all of the components and their combinations are displayed in 
Table 2.4. Table 2.5 illustrates relative likelihood ratios using selected 
components as “add-on” tests to stress perfusion imaging alone, and the 
absolute number of new true and false positives cases produced with each 
combination.  
 
2.5 Discussion 
This pre-specified sub-study of the CE-MARC study has demonstrated the 
diagnostic accuracy of the individual components and the paired and triplet 
combinations from the multi-parametric CMR examination. The three main 
findings were that i) no individual component or combination of components 
outperformed the full multi-parametric protocol to rule out significant 
coronary artery disease; ii) the LGE component has the best performance to 
rule-in significant CAD; and iii) the addition of MRA to 
function/perfusion/LGE does not offer any incremental benefit.  
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Table 2.4  Likelihood ratios positive and negative for the multi-parametric 
CMR exam and its individual components, paired and triplet 
combinations compared to the reference test X-ray angiography. 
 
LGE – late gadolinium enhancement; LR – likelihood ratio; MRA – magnetic resonance coronary 
angiography. 
  
 
Likelihood Ratio +ve 
(95% CI) 
Likelihood Ratio –ve 
(95% CI) 
Overall multi-parametric CMR study  
(all components)  (n= 676) 
5.21 (4.17, 6.51) 0.16 (0.12, 0.22) 
Individual CMR components   
LGE (n= 674)  9.81 (6.02, 15.97) 0.62 (0.56, 0.68) 
Perfusion (n= 661) 9.35 (6.70, 13.05) 0.25 (0.20, 0.31) 
Ventricular function (n= 676) 7.47 (5.04, 11.07) 0.56 (0.50, 0.63) 
MRA (n= 597)  7.01 (5.11, 9.61) 0.32 (0.26, 0.39) 
Paired combinations   
Perfusion/LGE (n= 676) 7.32 (5.50, 9.75) 0.24 (0.19, 0.30) 
Perfusion/function (n= 676) 6.31 (4.86, 8.20) 0.23 (0.18, 0.29) 
Perfusion/MRA (n= 676) 7.50 (5.66, 9.94) 0.20 (0.15, 0.26) 
Function/LGE (n= 676) 6.35 (4.51, 8.93) 0.52 (0.45, 0.59) 
Function/MRA (n= 676) 5.98 (4.57, 7.83) 0.31 (0.25, 0.38) 
LGE/MRA (n= 676) 6.92 (5.12, 9.35) 0.34 (0.29, 0.41) 
Triplet combinations   
Perfusion/LGE/function (n= 676) 5.77 (4.51, 7.37) 0.21 (0.17, 0.28) 
Perfusion/LGE/MRA (n= 676) 6.31 (4.90, 8.11) 0.18 (0.13, 0.24) 
Perfusion/function/MRA  (n= 676) 5.64 (4.46, 7.14) 0.17 (0.13, 0.23) 
LGE/function/MRA (n= 676) 5.41 (4.21, 6.95) 0.29 (0.23, 0.36) 
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2.5.1 Likelihood Ratios 
We have shown the absolute likelihood ratio (LR) for each component and 
their combinations (Table 2.4) and demonstrated how many more (or less) 
times a particular component or combination result is likely in patients with 
CAD compared to those without the disease. LR is defined as the ratio of the 
expected test results in subjects with a certain disease to the subjects 
without disease, and they directly link the pre-test and post-test probability of 
the disease. A likelihood ratio of greater than 1 is associated with the 
presence of disease, whereas a ratio of less than 1 would indicate the test 
result is associated with the absence of disease.  Importantly, as likelihood 
ratios are based on the ratio of sensitivity and specificity of an individual test, 
they are independent of disease prevalence, and can therefore be applied to 
different populations. The presented LRs can therefore be applied directly at 
the individual level and used to calculate how the probability of having CAD 
changes after the result of an individual component or combination of 
components of the CMR examination. Positive and negative likelihood ratios 
are therefore useful to understand the role of a test result in changing a 
clinician’s estimate of the probability of disease in a patient.  
 
The LR for positive tests (LR+) is the likelihood that a given test result would 
be expected in a patient with the disease (i.e. how much more likely the 
positive test result is to occur in subjects with the disease compared to those 
without the disease). LR+ is the best indicator for a rule-in diagnosis and the 
higher the LR+ the more indicative of disease. LR+ is calculated as follows: 
LR+ = sensitivity / (1 – specificity). Therefore high sensitivity and specificity 
result in high LR+. The individual components of LGE (LR+ 9.81) and 
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perfusion (9.35) had the highest LR+ amongst all the individual components 
and combinations with LGE benefitting from very high specificity to 
overcome poor sensitivity, and perfusion benefitting from both high 
sensitivity and specificity. For both components tested in isolation, a positive 
test finding increased the odds of the patient having CAD more than 9 fold. 
Therefore a positive LGE or perfusion test is a good test for ruling in the 
diagnosis of CAD. 
 
 
Table 2.5  Relative likelihood ratios and the numbers of new true positive 
and false positive cases produced by adding on further components 
sequentially to stress perfusion imaging in isolation. 
 
Relative 
LR+ 
Relative 
LR- 
New True Positive 
Cases Produced 
New False 
Positives Cases 
Produced 
Perfusion (+LGE)  0.78 0.91 7 11 
Perfusion (+function) 0.68 0.89 9 18 
Perfusion (+MRA) 0.79 0.76 16 12 
Perfusion +LGE (+function) 0.79 0.89 8 14 
Perfusion +LGE (+MRA) 0.86 0.74 16 11 
Perfusion +function (+MRA) 0.89 0.76 14 10 
Perfusion +function (+LGE) 0.91 0.94 4 6 
LGE – late gadolinium enhancement; LR – likelihood ratio; MRA – magnetic resonance coronary 
angiography. 
 
 
 
 
  
- 46 - 
  
Likelihood ratios for negative tests (LR-) demonstrate how much less likely 
the negative result will occur in subjects with the disease to the probability 
that the same result will occur without the disease. LR- is calculated as 
follows: LR- = (1 – specificity) / sensitivity and is a good indicator for ruling-
out the diagnosis. For a single component, perfusion imaging produced the 
smallest likelihood ratio of disease for a negative finding (LR- 0.25): i.e. the 
odds of a patient having CAD were reduced by 75% to one quarter of the 
pre-test odds with a normal perfusion result. By comparison, the odds of 
having CAD were only reduced by around 40% with a negative LGE finding 
(LR- 0.62). Therefore for a single component, perfusion resulted in the 
greatest change in post-test odds of having coronary disease, and an overall 
diagnostic accuracy of 85.9%. In terms of both positive and negative 
likelihood ratios, no paired or triplet combination offered a significant benefit 
over the best performing component of perfusion alone.  
 
When combining the information from the four components in the full multi-
parametric protocol using the “believe the positive” rule, the consequent 
reductions in specificity were not met by similar increases in sensitivity, 
which resulted in a comparatively low LR+ of 5.21. The full multi-parametric 
CMR examination, however, with all 4 components combined had the lowest 
LR- (0.16) indicating that the combination of all 4 components was best for 
ruling out CAD. 
 
The high LR+, low LR- and high overall diagnostic accuracy of the single 
perfusion component demonstrates that perfusion imaging ought to have 
most influence on a physician's risk stratification of the patients’ likelihood of 
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having significant underlying CAD. We have therefore shown the relative 
likelihood ratios of the perfusion component as the starting point, and 
building on this using selected combinations as “add on” tests, highlighting 
the number of new true and false positive cases produced by each 
combination (Table2.5). This analysis showed that no add on test to 
perfusion imaging is preferable for ruling in the diagnosis (since all add on 
tests reduce the relative LR+), but adding on components can improve the 
rule-out value of the CMR examination (all add on tests reduce the LR-). 
 
2.5.2 Comparative Literature  
There have been a number of other studies analysing the diagnostic 
performance of the components of the CMR examination, although none of 
this magnitude and many of which being performed in highly selected 
populations.   
 
One study analysed the diagnostic accuracy of CMR components in 100 
patients preselected for X-ray coronary angiography (≥70% stenosis as the 
reference standard).[8] The CMR protocol included wall motion, stress and 
rest perfusion and LGE. The analysis algorithm considered LGE images first 
with presence of severe CAD diagnosed if LGE was positive in an ischaemic 
pattern. If LGE was negative the perfusion images were analysed and a 
reversible defect used to diagnose CAD. This analysis algorithm had a 
sensitivity (89%) and specificity (87%) - which was similar to the CE-MARC 
study. In terms of individual components compared to CE-MARC, the 
perfusion component in this previous study had the highest sensitivity (84% 
vs. 77% in our population) although with a significantly lower specificity (58% 
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vs. 92%). Wall motion scoring was not considered in their analysis algorithm; 
cine images were acquired and had a similar sensitivity (49% vs. 47%) but 
lower specificity (73% vs. 94%) than in our study. 
 
In patients with non ST-segment elevation myocardial infarction our group 
has previously evaluated the diagnostic accuracy of all 4 components of the 
CMR examination, performed within 72 hours of presentation, with an overall 
sensitivity of 96%, specificity 83%, PPV 96% and NPV 83%.[9] Once again 
the perfusion component of the examination yielded the highest sensitivity 
(88%), although in this study it was higher than when compared to our stable 
elective population (77%). 
 
Cury et al studied a mixed cohort of 47 patients (14 with previous MI) and 
also demonstrated that stress perfusion imaging had the highest sensitivity 
(81%) and LGE the highest specificity (94%).[10] The maximum diagnostic 
accuracy was achieved with the combination of stress perfusion and LGE, 
and unsurprisingly this was again higher in the sub-group of patients with 
previous myocardial infarction than those with suspected CAD and no prior 
infarction (93% vs. 86%). 
 
The clinical utility of imaging coronary artery anatomy with dedicated 
coronary MRA protocols in expert centres has been demonstrated to have 
good diagnostic accuracy for the detection of proximal CAD.[14] Technical 
advances at 3.0 Tesla and using a 32 channel coil have been shown to 
further improve signal to noise ratio and overall accuracy compared with 
initial reports, yielding sensitivities of 92-96%.[15, 16] However, the efficacy 
- 49 - 
  
of coronary imaging within a combined CMR protocol remains to be 
established. Klein et al performed coronary MRA, stress and rest perfusion 
and LGE imaging on 54 patients with suspected CAD, again showing the 
perfusion component was the most accurate alone (sensitivity 87%, 
specificity 88%). They showed that the addition of LGE to stress perfusion 
imaging did not improve the overall diagnostic accuracy (sensitivity 88%, 
specificity 88%). In terms of coronary imaging, 15% of overall MRA had non-
diagnostic image quality;  whole heart MRA had significantly inferior 
diagnostic accuracy due to poor specificity (sensitivity 92%, specificity 56%) 
unless only those with excellent MRA image quality (n=18, 33%) were 
analysed, whereupon it remained similar to the perfusion component alone 
(sensitivity 86%, specificity 91%).[11] Other investigators have evaluated the 
effect of adding coronary MRA to stress perfusion CMR on diagnostic 
performance; when compared to invasive pressure-wire derived fractional 
flow reserve (FFR) at 1.5T there was no significant improvement in 
diagnostic accuracy.[12]  
 
Coronary MRA remains a time consuming acquisition, which often is non-
diagnostic when performed within an already long multi-parametric protocol. 
In our study 79 patients (11.7%) had non-diagnostic coronary MRA images. 
Furthermore, in those with adequate or excellent image quality (n=597), the 
addition of the coronary MRA made no difference statistically on the overall 
diagnostic accuracy of the CMR examination. Equally, whilst some triplet 
combinations with MRA offer similar diagnostic accuracy, the components of 
cine, LGE and perfusion imaging offer clinical information above and beyond 
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detection of coronary disease (i.e. left ventricular volumes/ejection fraction, 
myocardial viability and ischaemic burden) which may have additional 
prognostic importance.  
 
2.6 Conclusions 
From this pre-specified sub-analysis of the CE-MARC study, using the 
original blinded visual-read, we have demonstrated the diagnostic accuracy 
of the individual components and their combinations from the full multi-
parametric CMR exam. In patients presenting with stable chest pain, the 
stress perfusion component of the multi-parametric CMR exam was the 
single most important component for overall diagnostic accuracy. However, 
the full combined multi-parametric protocol was the optimal approach for 
disease rule-out, and the LGE component best for rule-in. The inclusion of 
coronary MRA had no additional overall diagnostic benefit within a multi-
parametric protocol.  
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Chapter 3  
Ischaemia and Scar Burden Measured by Cardiac Magnetic 
Resonance Imaging in Patients with Coronary Heart Disease 
- a CE-MARC Sub-study 
3.1 Abstract         
3.1.1 Background  
The prognostic importance of the ischaemia and scar burden is well 
established from single photon emission computed tomography (SPECT) 
studies. In the CE-MARC study, cardiovascular magnetic resonance (CMR), 
SPECT, and coronary angiography were performed in a large suspected 
coronary heart disease (CHD) population. The aim of this sub-study was to 
directly compare ischaemia and scar burden as quantified by CMR and 
SPECT. 
3.1.2 Methods  
From the 752 patients recruited to the CE-MARC study 241 with significant 
angiographic stenosis were identified. For each modality, the summed stress 
score (SSS), summed rest score (SRS) and summed difference score (SDS) 
were assessed on a 5-point scale for perfusion defects and/or scar in 16-
segments.  
3.1.3 Results 
The overall SSS was slightly higher for CMR compared to SPECT (median 
(interquartile range): 11(3–16) vs. 9(3–20),p=0.0447). The SRS was 
significantly lower (0(0–0) vs. 4(1–10);p<0.0001) and the SDS greater by 
CMR than SPECT (10(3–15) vs. 3(0–10),p<0.0001). Overall, there was 
moderate positive correlation and agreement (SSS: r=0.36, Bland-Altman 
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limits (BA)=-22.0–21.7; SRS: r=0.42, BA=-7.9–15.1; SDS: r=0.30, BA=-21.1–
15.4). Regression analysis fitting the CMR to SPECT SDS demonstrated a 
CMR SDS ischaemia burden of 15% would be the equivalent of an SPECT 
SDS of 10%. 
3.1.4 Conclusions  
Measurements of overall CHD burden (SSS) moderately agree between 
both modalities. However, there are differences in the proportions of scar 
and ischaemia detected, likely due to the different approach to scar imaging 
(LGE vs. matched defect), attenuation with SPECT and differences in 
cardiac coverage for perfusion assessment.  
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3.2 Introduction  
Coronary heart disease (CHD) is a leading cause of death and disability and 
its optimal diagnostic and treatment strategy is an on-going challenge. It is 
an accepted paradigm that the haemodynamic relevance of a stenosis rather 
than the degree of obstruction alone should inform the decision between 
revascularization and optimal medical therapy (OMT)[93, 94]. Patients with 
significant ischaemia and without extensive scar are more likely to benefit 
from early revascularization, whereas patients with minimal or no ischaemia 
may be treated with OMT alone [95, 96]. In addition, scar in CHD patients 
confers unfavourable clinical and functional outcomes [82, 97]. Most 
prognostic data for ischaemia and scar burden, as well as their impact on 
treatment strategy, have been derived from single photon emission 
computed tomography (SPECT) myocardial perfusion imaging, one of the 
most frequently used tests for the assessment of CHD [98]. However, 
radiation exposure from SPECT perfusion tracers is of concern [99] and the 
technique can be limited by low spatial resolution and soft tissue attenuation 
artefacts.  
 
Cardiovascular magnetic resonance (CMR) is an alternative non-invasive 
technique for the detection of ischaemia and scar. CE-MARC was the 
largest, prospective, real-world evaluation of CMR and showed that CMR 
had a higher sensitivity and negative predictive value compared to SPECT 
for the detection of CHD[29]. The rigorous design of the study minimised 
referral bias by mandating that all patients underwent coronary angiography 
as the reference test, independent of the preceding CMR or SPECT result 
- 54 - 
  
[30]. Furthermore CE-MARC five year follow-up has subsequently 
demonstrated the stronger prognostic value of CMR for the prediction of 
major adverse cardiovascular events over SPECT [100]. 
 
To date, measurements of ischaemia and scar burden by CMR and SPECT 
have not been directly compared. The CE-MARC study provides a unique 
patient population to undertake such a cross-modality comparison, such that 
our aims were to compare ischaemia and scar burden in 1) all patients with 
significant angiographic stenosis, and 2) all patients with angiographic 
stenosis and evidence of ischaemia on both CMR and SPECT (i.e. all three 
tests positive).  
 
3.3 Methods 
3.3.1 Patients 
CE-MARC was a prospective evaluation of 752 consecutive patients with 
suspected angina [29]. Between March 2006 and August 2009, patients 
were screened and enrolled if they had at least one major cardiovascular 
risk factor and a cardiologist considered them to have stable angina 
requiring further investigation. All patients were scheduled to undergo 
SPECT and CMR (in randomized order), followed by X-ray coronary 
angiography (XRA) within 4 weeks regardless of the treating physician’s 
chosen clinical pathway. Exclusion criteria were as previously published [29, 
30]. The study was conducted in accordance with the Declaration of Helsinki 
(2000) and approved by the local research ethics committee. Patients 
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provided informed written consent. For this pre-defined substudy, all patients 
recruited to CE-MARC who had diagnostic image quality and significant 
coronary artery stenosis (≥50% left main stem (LMS) or ≥70% in a first order 
coronary artery ≥2mm) on quantitative invasive coronary angiography (QCA) 
were selected.  
 
Investigational procedures and their analysis 
In the main CE-MARC analysis, SPECT, CMR and XRA were analysed 
blinded, by paired readers with at least 10 years’ experience in their 
modalities.  
 
3.3.2 CMR imaging and analysis 
The multi-parametric CMR (1.5-Tesla Philips Intera; Best, The Netherlands) 
protocol comprised cine imaging, adenosine stress perfusion (140μg/kg/min 
for 4 minutes), rest perfusion, coronary MR angiography and late gadolinium 
enhancement (LGE). Specific imaging parameters have been previously 
described[30]. Image quality was visually graded on a scale form 0-3 as 
(0=non-diagnostic, 1=poor, 2=adequate and 3=high). For calculation of 
ischaemic burden perfusion images were scored according to a 5-point 
scoring scale: 0=normal (0% reduction in transmurality of myocardial 
perfusion), 1=mild (0-49%), 2=moderate (50-74%), 3=severe (75-100%), 
4=absent (thinned with persistent absence of contrast delivery)[101] and 
LGE images were graded by transmural extent of hyperenhancement 
(0=normal, 1=1-25%, 2=26-50%, 3=51-75%, 4=76-100%) for each segment 
in a 16-segment model according to the AHA/ACC classification, (excluding 
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the apical cap). The summed stress score (SSS) was calculated by adding 
the highest scores from either stress perfusion or LGE for each segment (i.e. 
an objective score of the area of hypoperfusion). The summed rest score 
(SRS) was considered as the sum of the LGE scores for each segment 
(area of myocardial infarction). The ischaemic burden was calculated as the 
summed difference score (SDS) by adding the differences between the 
stress and LGE scores for each segment (total area of hypoperfusion minus 
the area of infarction). The semiquantitative scores were graded according 
to their severity as previously described: SSS<4, 4 to 8, 9 to 13, and >13; 
SRS<2, 2 to 7, and >7 and SDS:<2, 2 to 7 and >7, respectively [102]. LV 
volumes were calculated by manually tracing endocardial and epicardial 
borders at end-diastole on short-axis cines (QMass 6.2.1, Medis, Leiden, 
The Netherlands)[103].  
 
3.3.3 SPECT imaging and analysis 
SPECT used a dedicated cardiac gamma camera (MEDISO Cardio-C, 
Budapest, Hungary) and ECG-gating. Patients underwent a two-day protocol 
using a weight adjusted dose of 99mTc-tetrofosmin to a maximum 600MBq 
per examination. Rest and adenosine-stress images using an identical 
intravenous adenosine protocol to that in CMR were acquired. Full details 
have previously been described[30]. Image quality was visually graded in the 
same way as for CMR images, as non-diagnostic, poor, adequate and high. 
Evidence of ischaemia and scar were recorded by visual comparison of 
rest/stress SPECT scans, with reference to wall motion analysis. To allow for 
comparative analysis, this used the same 16-segment scoring system as for 
the CMR analysis. The SSS and SRS were calculated by adding the highest 
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scores for each segment from the stress and rest perfusion scans, 
respectively. The ischaemic burden was calculated as the SDS by adding 
the differences between the stress and rest scores for each segment. QGS 
software (Cedars-Sinai Medical Center, USA) was used to calculate end-
diastolic and end-systolic volumes and wall-motion scores.  
 
3.3.4 X-ray angiography 
X-ray angiograms were reported by two experienced cardiologists blinded to 
the other studies. Significant CAD was defined as LMS stenosis ≥50% or 
70% stenosis of a first-order coronary artery measuring ≥2mm in diameter 
by quantitative invasive coronary angiography (QCAPlus, Sanders Data 
Systems, Palo Alto, California, USA). 
 
3.3.5 Statistical Analysis 
Baseline characteristics were summarised using descriptive statistics. The 
summed scores by CMR and by SPECT and image quality scores were 
compared using the Wilcoxon signed-rank test. In addition, the Pearson’s 
correlation coefficient plots of difference between measures versus average 
of the two measures and the Bland–Altman limits of agreement were 
produced [104]. Image quality was compared between 2 measures using a 
chi-squared test. All statistical analysis undertaken used a 2-sided 5% 
significance level (SAS 9.2, SAS Institute, Cary, NC, USA). 
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3.4 Results 
3.4.1 Study Population  
Of the 752 CE-MARC patients, 241 patients had significant coronary artery 
stenosis on XRA, whilst 106 patients had significant coronary artery stenosis 
on XRA and evidence of ischaemia on both CMR and SPECT studies. Table 
3.1 shows the clinical characteristics of these two sub-study populations.  
 
3.4.2 Image Quality 
The image quality scores from the sub-population with both CMR and 
SPECT positive results are summarized in Table 3.2, showing a significant 
higher overall image quality for CMR than for SPECT studies. 
 
3.4.3 Summed Scores 
3.4.3.1  Primary Analysis: All Angiographic Positive Population 
The overall CHD burden, represented by the median SSS, was slightly 
higher for CMR compared to SPECT,  (median (interquartile range) 11 (3–
16) vs. 9 (3–20), p=0.0447). In contrast, the median SRS was significantly 
lower by CMR than by SPECT (0 (0–0) vs. 4 (1–10); p<0.0001) with SPECT 
showing more extensive rest perfusion defects than LGE CMR. Conversely, 
the ischaemic burden, represented by the median SDS was significantly 
greater by CMR than by SPECT (10 (3–15) vs. 3 (0–10), p<0.0001) with 
more extensive ischemia measured by CMR.  
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Table 3.1  Baseline characteristics 
 
  
 All Tests +ve (n=106) All XRA +ve patients (n=241) 
Age (Years) 62 (8.8) 62 (8.4) 
Men 88 (83%) 197 (82%) 
Body Mass Index (kg/m
2
) 28.8 (3.7) 29.0 (3.9) 
Smoking Status   
    Never smoked 37 (35%) 70 (29%) 
    Ex-smoker 51 (48%) 128 (53%) 
    Current smoker 18 (17%) 43 (18%) 
Systolic blood pressure (mmHg) 140 (20.0) 140 (20.0) 
Diastolic blood pressure 
(mmHg)  
78 (11.9) 78 (11.9) 
Hypertension 48 (45%) 126 (52%) 
Diabetes mellitus 14 (13%) 34 (14%) 
Family history heart disease   
    Yes 60 (57%) 135 (56%) 
    No 38 (36%) 86 (36%) 
    Unknown 8 (8%) 20 (8%) 
Total Cholesterol (mmol/L) 5.4 (1.2) 5.2 (1.2) 
Ejection Fraction (CMR) 54.1 (6.4) 54.1 (6.4) 
Ejection Fraction (SPECT) 54.7 (7.5) 54.7 (7.5) 
Pattern of Coronary Disease   
    LMS 10 (9%) 22 (9%) 
    LAD 72 (68%) 159 (66%) 
    RCA 48 (45%) 91 (38%) 
    LCX 56 (53%) 118 (49%) 
All Tests +ve = Positive Coronary Angiography (XRA), CMR and SPECT. 
All XRA +ve = All positive coronary angiography patients.  
Data are mean (SD) or n (%) unless otherwise stated. CMR= Cardiovascular Magnetic 
Resonance;  SPECT –  single photon emission computed tomography; LMS – left main stem; 
LAD – left anterior descending; RCA – right coronary artery; LCX – left circumflex. 
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Table 3.2  Image Quality for CMR and SPECT  
Image Quality Poor (1) Adequate (2) High (3) Overall p 
Stress Perfusion CMR 1 (1%) 29 (27%) 76 (72%) 2 (2,3) 
p<0.01 
Stress Perfusion SPECT 2 (2%) 69 (65%) 35 (33%) 2 (2,3) 
LGE Imaging 7 (7%) 33 (31%) 66 (62%) 3 (2,3) 
p<0.01 
Rest Perfusion SPECT 1 (1%) 65 (61%) 40 (38%) 3 (2,3) 
Data are presented as n (%) and median (first, third quartile). 
 
 
3.4.3.2  Secondary Analysis: All 3-Tests Positive Population 
In this subgroup, the median (IQR) SSS was significantly lower with CMR 
than SPECT (14 (10–20) vs. 18 (10–27), P=0.0005; Figure 3.1A). Again, 
SPECT demonstrated more extensive rest perfusion defects (SRS: 0 (0–0) 
vs. 5 (2–11), P<0.0001; Figure 3.2A) whilst the ischaemic burden was 
significantly greater by CMR (SDS 13.5 (10–19) vs. 9 (5–18), P=0.0113; 
Figure 3.3A).  
Figure 3.4 shows 2 case examples with similar overall SSS values by CMR 
and SPECT. In the first case scar and ischaemic burden are similar, while in 
the second case, SRS and SDS values are different between CMR and 
SPECT. 
3.4.4 Correlation and Agreement of Summed Scores 
Overall in the secondary analysis population (n=106), there was only 
moderate correlation and agreement of all summed scores between CMR 
and SPECT (SSS: r=0.36, BA= -22.0 to 21.7, bias=-0.1; SRS: r=0.42, BA= -
7.9 to 15.1, bias=3.6; SDS: r=0.30, BA= -21.1 to 15.4, bias=-2.9; Figure 3.5).  
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Figure 3.1  Median Summed Stress Score and Distribution  
  
Figure 3.2  Median Summed Rest Score and Distribution  
  
Figure 3.3  Median Summed Difference Score and Distribution  
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Case1: 
 
Case 2: 
 
Figure 3.4  Case examples of patients undergoing CMR and SPECT 
Case example 1: A 70-year-old male patient with a BMI of 25.5 kg/m2 
presented with typical chest pain and was found to have a significant 
stenosis (95%; arrow) in the proximal left anterior descending artery (LAD) 
on invasive coronary angiography (A). The cardiovascular magnetic 
resonance (CMR) stress perfusion images were of high image quality and 
showed a large anterior and septal perfusion defect consistent with the LAD 
disease (B). The CMR late gadolinium enhancement images were of 
average image quality and did not demonstrate any evidence of myocardial 
scarring (C). Similar to CMR, the single photon emission computed 
tomography (SPECT) myocardial perfusion images were of high image 
quality and showed a large reversible defect in the LAD territory (D). The 
summed stress scores (SSS), the summed rest scores (SRS) and the 
summed difference scores (SDS) were similar between CMR and SPECT in 
this patient (SSS: 24 vs. 22; SRS: 0 vs. 0; SDS: 24 vs. 22).  
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Case example 2: A 48-year-old male patient with a BMI of 39.0 kg/m2 
presented with typical chest pain and was found to have a significant 
stenosis (>90%; arrow) in the large intermediate coronary branch (IM) on 
invasive coronary angiography (A). The CMR stress perfusion images were 
of high image quality and showed an extensive perfusion defect in the infero-
lateral and antero-lateral wall (B). The CMR late gadolinium enhancement 
images were also of high image quality and did not demonstrate any 
evidence of myocardial scarring (C). In contrast to CMR, the SPECT 
myocardial perfusion images showed only average image quality and a large 
fixed inferior and infero-lateral defect as well as a small reversible antero-
lateral defect (D). The summed stress scores (SSS) were similar between 
both modalities (CMR vs. SPECT: 18 vs. 21). However, there were 
significant discrepancies between the summed rest scores (SRS) and the 
summed difference scores (SDS) between CMR and SPECT in this patient 
(SRS: 0 vs. 19, SDS: 16 vs. 2), most likely due to attenuation artefacts on 
the SPECT images. 
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Figure 3.5  Bland-Altman limits of agreement for summed stress score, 
summed rest score and summed difference scores. 
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Regression analysis on the primary population (all XRA positive cases) 
fitting the CMR to the SPECT SDS, demonstrated a SPECT ischaemia 
burden of 10% would be equivalent to a CMR ischaemia burden of ~15%, 
whilst a 12.5% ischaemia burden by SPECT would be the equivalent of 
~20% by CMR (Figure 3.6). 
 
 
 
 
 
Figure 3.6  Regression analysis fitting of cardiovascular magnetic 
resonance (CMR) ischaemic burden (%)to single photon emission 
computed tomography (SPECT) ischaemic burden (%) 
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3.5 Discussion  
CMR and SPECT are non-invasive imaging modalities that are both capable 
of assessing myocardial ischaemia and scar in patients with CHD; the 
severity and extent of which can have an important impact on risk 
stratification and patient outcome[39, 43, 105, 106]. However, it remains 
unknown how ischaemia and scar burden compare between the two 
modalities and whether thresholds defined by one technique can be applied 
to the other. Given that the two modalities use different techniques to 
visualize disease, in particular myocardial scar, and because the thresholds 
for the extent of clinically significant ischaemia have mostly been derived 
from SPECT studies, a comparison between the methods has considerable 
clinical relevance. 
 
This is the first study that has directly compared measurements of overall 
CHD burden as well as ischaemia and scar burden by CMR and by SPECT. 
The study made use of the large prospective, well-defined CE-MARC 
population to identify a unique study population of patients with proven CHD 
confirmed by consensus of an invasive and two non-invasive assessments; 
this specifically minimised the impact of the different diagnostic 
performances of SPECT and CMR. For this sub-study, the overall extent of 
CHD burden and the proportions of scar and ischaemia for both modalities 
were measured using a consistent semi-quantitative scoring system. 
 
The main findings of this study are that 1) the overall disease burden, 
represented by the SSS, and the number of patients with similar overall 
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disease severity are broadly comparable between CMR and SPECT. The 
SSS is the most powerful diagnostic and prognostic marker as shown in 
numerous SPECT studies [102, 105, 107] with superior prognostic impact 
compared with the SDS or SRS [108, 109]. As with SPECT, acquisition and 
analysis of perfusion and scar data are usually combined in CMR protocols, 
with improved detection of CHD [110]. The SSS can therefore be considered 
the most relevant marker of disease. 2) In terms of ischaemia and scar 
burden, there was only modest agreement between the two modalities, such 
that a 15% ischaemia burden by CMR was equivalent to the 10% threshold 
by SPECT, which is widely reported as the prognostic threshold [111].  
 
However, despite the good agreement for overall disease burden, there was 
a statistically significant discrepancy between the scar and ischaemic burden 
measured by CMR and SPECT. The median SRS (scar) was significantly 
lower by CMR than by SPECT with SPECT tending to detect more patients 
with extensive defects. In contrast, the median SDS (ischaemia) was 
significantly greater by CMR than by SPECT with more patients with 
extensive ischaemia measured by CMR. This difference in proportions of 
ischaemia and scar burden between modalities may in part explain the 
stronger prediction for major adverse cardiovascular events with CMR vs 
SPECT [100]. 
 
There are several reasons which might in part explain the differences in 
ischaemia and scar burden: First, the two modalities use fundamentally 
different techniques to identify scar, while the detection of ischaemia is more 
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closely related, but not identical. CMR assessment of scar is based on LGE 
imaging and ischaemia is detected by dynamic first-pass stress perfusion. 
SPECT with 99mTc uses the relative differences of tracer uptake in rest and 
stress studies to differentiate between fixed and reversible perfusion defects. 
Whilst a reversible perfusion defect represents ischaemia, a fixed perfusion 
defect may or may not be viable and does not necessarily represent 
myocardial scar as shown with LGE-CMR. Moreover, the lower spatial 
resolution of SPECT may lead to an underestimation of sub-endocardial scar 
in comparison to LGE-CMR [112]. 
 
Second, CMR LGE and SPECT cover the whole heart, whereas most CMR 
perfusion methods cover only three representative short axis slices. In CMR 
these slices are typically 10mm in thickness and thus around 60% of the 
myocardial mass is not evaluated. These differences in the cardiac coverage 
may lead to over- or underestimation of the severity and extent of ischaemia. 
In order to minimize these differences and to optimize the comparison 
between modalities, we chose a standard semi-quantitative scoring system, 
dividing the whole heart into segments and excluding the apical cap. 
 
Third, although non-diagnostic scans had been excluded prior to final 
analysis, artefacts may impair image quality and at worst lead to false-
positive or false-negative findings. These artefacts include mainly wrapping, 
motion, dark rim and metallic artefacts for CMR [113] and motion artefacts 
as well as soft-tissue attenuation for SPECT [98]. In particular, attenuation 
artefacts have remained an important issue in nuclear myocardial perfusion 
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imaging. Although the true prevalence of these artefacts is unknown, 
estimates have ranged from 20% to 50%[114]. 
 
As outlined above, CMR and SPECT have different strengths and 
limitations. Although this study provides new insights into the relative 
performance of both modalities, in the absence of a true reference test, it 
cannot determine which modality is more accurate in assessing the scar and 
ischaemic burden. It is widely accepted that LGE-CMR is superior to SPECT 
for the detection of myocardial scar [112] and that SPECT studies can be 
affected by attenuation artefacts mimicking fixed perfusion defects. This may 
lead to an overestimation of scar burden by SPECT and is the most likely 
cause for the observed discrepancies in the current study. The reasons for 
the differences in ischaemic burden between the two modalities in this study 
are less evident, but are most likely caused by the different imaging 
technique (dynamic vs. relative perfusion) and the different cardiac 
coverage. Recent developments in myocardial perfusion CMR that allow 3D 
whole heart coverage may overcome this limitation and should be compared 
with SPECT [50, 115, 116].  
3.6 Study Limitations 
The limitations of CE-MARC have been previously discussed, and include its 
single-centre design and an anatomical reference standard i.e. QCA as 
opposed to invasive functional assessment (FFR). The latter is a limitation 
common to the majority of imaging studies prior to the FAME study, which 
was published after CE-MARC had recruited [93]. Whilst we acknowledge 
our single-centre design as a potential limitation it also had the advantage of 
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unifying pharmacological stress protocols and ensured consistency in both 
imaging modality protocols. Furthermore, we did not use attenuation 
correction for SPECT as this was not the technical standard in most nuclear 
institutions worldwide including ours at time of recruitment [117]. The semi-
quantitative scores have been acquired using a modified 17-segment model 
without the apical cap for both modalities, as the apical cap is not visualized 
with CMR perfusion. This is a distinct advantage of SPECT over CMR, and 
we acknowledge that this might lead to an underestimation of disease 
burden, but in return it allows a more accurate comparison of the two 
modalities. Finally, this is a selected subpopulation from CE-MARC, which 
was analysed for the specific purpose of directly comparing scar and 
ischaemia burden between CMR and SPECT; no inference can be drawn as 
to the reasons for false positive and false negative studies.  
3.7 Conclusion 
Measurements of overall CHD burden (SSS) show reasonable agreement 
between CMR and SPECT. Given that SSS is the most powerful prognostic 
marker this suggests that CMR may be comparable to SPECT in terms of 
risk prediction. However, there are differences in the estimates of scar and 
ischaemia burden between the two modalities, which are most likely related 
to the different approach to scar imaging (LGE vs. matched defect), soft-
tissue attenuation with SPECT and different cardiac coverage for perfusion 
assessment. Further studies will have to evaluate the prognostic impact of 
these findings.  
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Chapter 4  
Patient Adaptive Maximal Resolution Magnetic Resonance 
Myocardial Stress Perfusion Imaging 
 
4.1 Abstract 
4.1.1 Background 
Magnetic resonance perfusion pulse sequences often leave potential 
acquisition time unused in patients with lower heart-rates (HR), and smaller 
body size. The aim of this study was to demonstrate the feasibility of an 
automatic adaptive acquisition sequence.  
4.1.2 Methods 
A perfusion technique was developed which automatically adapts to HR and 
field-of-view, by maximising in-plane spatial resolution whilst maintaining 
temporal resolution every cardiac cycle. Patients (n=10) and volunteers 
(n=10) were scanned with both a standard resolution and adaptive method. 
Image quality was scored, signal-to-noise ratio (SNR) calculated, and width 
of dark-rim artifact (DRA) measured. 
4.1.3 Results 
The acquired spatial resolution of the adaptive sequence 
(1.92x1.92mm2±0.34) was higher than the standard resolution 
(2.42x2.42mm2)(P<0.0001). Mean DRA width was reduced using the 
adaptive pulse sequence (1.94±0.60mm vs. 2.82±0.65mm, P<0.0001). SNR 
was higher with the standard pulse sequence (6.7±2.2 vs. 
3.8±1.8,P<0.0001). There was no difference in image quality score between 
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sequences in either volunteers (1.1±0.31 vs. 1.0±0.0,P=0.34), or patients 
(1.3±0.48 vs. 1.3±0.48,P=1.0) . 
4.1.4 Conclusion 
Optimising the use of available imaging time during first pass perfusion with 
a MR pulse sequence which adapts image acquisition duration to HR and 
patient size is feasible. Acquired in-plane spatial resolution is improved, the 
DRA is reduced, and whilst SNR is reduced with the adaptive sequence 
consistent with the lower voxel size used, image quality is maintained. 
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4.2 Introduction 
Myocardial perfusion magnetic resonance imaging with vasodilator stress 
has high diagnostic accuracy for the detection of coronary artery disease 
(CAD). A recent meta-analysis of 37 studies demonstrated a combined 
sensitivity of 89% (95%CI: 88%-91%) and specificity of 76% (95%CI: 73%-
78%)[28].  
 
Notable recent developments in acquisition techniques include highly 
accelerated pulse sequences based on spatio-temporal undersampling (for 
example k-t sensitivity encoding (k-t SENSE) and highly constrained back 
projection (HYPR))[118, 119], higher field strengths[120] and improved 
cardiac phase-array coils for higher signal-to-noise[47]. These advances 
allow improved acquired resolution and, in line with higher spatial resolution, 
a reduction of the width of dark rim artifact (DRA) enhancing visualization of 
sub-endocardial perfusion deficits. In small studies both spatio-temporal 
undersampling and perfusion at 3.0 Tesla (T) have led to even higher 
diagnostic accuracy for the detection of significant underlying CAD[47, 48].  
 
Current MR perfusion pulse sequences are usually set to acquire at least 
three slices every heartbeat, optimised to accommodate heart rates that 
typically occur during pharmacological stress and large patient size. 
Therefore, the resolution of standard perfusion sequences is optimal only for 
subjects who are at the extremes of the patient characteristic ranges: the 
largest patient, with the highest heart rate that typically occurs during 
pharmacological stress. In patients with lower heart rates and/or of smaller 
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body habitus there can be a significant amount of unused potential imaging 
time with consequent unnecessary compromises in imaging parameters 
(Figure 4.1). Lower heart rates allow for more imaging time in each heart 
beat. Smaller body habitus necessitates smaller field-of-field (FOV) and thus 
a shorter image-readout duration for the same voxel size in the phase 
encoding direction. Both circumstances allow a potential image resolution 
increase. Whilst it is possible to manually adjust the sequence parameters 
and thus maximise the acquired resolution of an MRI scan, this is time 
consuming and could introduce uncertainty in potential image quality prior to 
the scan. Furthermore, in those with heart rates which are significantly 
higher during pharmacological stress than anticipated, acquisition with the 
fixed parameters of standard perfusion sequences is not possible at every 
heartbeat. This results in image acquisition every second R-R interval which 
may impact upon adequate characterisation of the signal changes effected 
during the first passage of gadolinium-based contrast agent through the 
heart[121].  
 
A more flexible acquisition scheme could automatically optimise parameters 
specifically for each patient’s size and heart rate. This would allow potential 
improvements in image quality (with artifact reduction, improved visualisation 
of the subendocardium), or maintenance of temporal resolution at very high 
heart rates (ensuring that time-intensity changes during the first-pass of 
contrast agent are always depicted) with the best available image resolution. 
An automated method would also reduce operator dependence of  
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Figure 4.1  Schematic representing standard and adaptaive resolution 
pulse sequences.  
A: Standard spatial resolution pulse sequence and B: Adaptive resolution 
pulse sequence with acquisition duration maximised for heart rate. A longer 
acquisition duration in the adaptive sequence makes better use of available 
imaging time within each heartbeat. Blue: Pre-pulse; PD - Preparation pulse 
Delay time; k0: true centre of K space.[122]   
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acquisition parameters in those centers which manually adapt acquisition 
parameters to individual patients. 
 
The aim of this study was to assess the feasibility of a patient-adaptive 
perfusion pulse sequence which automatically adapts to the heart rate, 
maximising imaging time and acquired in-plane spatial resolution, whilst 
maintaining single-beat temporal resolution. We hypothesised that 
maximising imaging time would improve the acquisition spatial resolution 
and reduce dark rim artifact whilst preserving image quality. 
 
4.3 Methods 
4.3.1 Patient Selection 
Patients with stable angina (n=10) referred for clinically indicated myocardial 
ischaemia testing were prospectively recruited from a single tertiary centre 
from January 2013 until April 2014. Stable angina pectoris was defined as 
symptoms defined in current national and international standard[6, 123]. 
Exclusion criteria were contraindications to MR imaging (ferrous implants, 
claustrophobia or large abdominal girth), adenosine (atrioventricular nodal 
block II or III, asthma or severe hypertension) and presence of atrial 
fibrillation. Healthy volunteers (n=10) were recruited from staff and students 
of the University of Leeds. All volunteers and patients were requested to 
refrain from caffeine for 24 hours before the study. The study protocol was 
approved by the institutional research ethics committee and complied with 
the Declaration of Helsinki; all participants gave written informed consent. 
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4.3.2 Magnetic Resonance Imaging 
All patients and volunteers underwent adenosine stress and rest myocardial 
perfusion MR imaging tests on two separate visits. On the first occasion a 
conventional, fixed-parameter perfusion sequence was used and on the 
second the adaptive method was used. Scans were separate by at least 7 
days (mean of 11 days). 
 
Patients were examined using a clinical 3.0T whole-body scanner (Philips 
Achieva TX, Philips Healthcare, Best, The Netherlands) equipped with 80 
mT/m maximum field gradients, 200 T/m/sec slew rate with a dedicated 32-
channel cardiac phased array receiver coil with dual-source radiofrequency-
field shimming. Imaging was performed with the subjects in the supine 
position and cardiac synchronisation was performed using a four-electrode 
vectorcardiogram and image acquisition triggered on the R wave.  
 
Survey, receiver-coil sensitivity reference scans, and radiofrequency-field 
calibrations (B1 maps) were performed. A volume shim of both B0 and B1 
was performed on all patients, with the shim volume encompassing the 
heart, and as much as possible also excluding lung. Short axis, vertical long 
axis and horizontal long axis cine images were then acquired with balanced 
steady-state free precession (bSSFP) pulse sequence (echo time (TE) 1.3 
ms; repetition time (TR) 2.6 ms; flip angle 40°, spatial resolution 1.6×2.0×10 
mm, 40 phases per cardiac cycle, FOV 300–420mm, sensitivity encoding 
factor 1.7). Stress perfusion imaging was performed with adenosine, 
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administered at 140µg/kg/min under continuous vectorcardiogram 
monitoring for at least 4 min.  
 
Perfusion imaging was undertaken during the last minute of adenosine 
infusion with an intravenous bolus of 0.075mmol/kg of gadobutrol 
(Gadovist®, Bayer Schering Pharma, Berlin, Germany) administered at a 
rate of 4.0ml/s followed by a 20ml saline flush (Medrad Spectris Solaris 
power injector, Pittsburgh, Pennsylvania). Heart rate and blood pressure 
were recorded at rest and peak stress. Rest perfusion imaging was 
undertaken a minimum of 15 minutes after stress perfusion with a further 
injection of 0.075mmol/kg of gadobutrol in an identical geometry to the 
stress images. Rest images were acquired with the same FOV and 
acquisition duration as the stress scan for comparative purposes. The 
acquisition heart rate of the resting scan is lower than the stress heart rate, 
therefore a stress-then-rest order ensures that comparable scan geometry 
may be used without requiring further adjustment. Subjects received breath 
hold training and were instructed to hold their breath as long as possible 
during acquisition. 
 
Standard resolution, fixed parameter perfusion image acquisition used a 
spoiled turbo gradient-echo sequence (TR 1.28 ms; TE 2.8 ms; flip angle 
15°, acquired spatial resolution 2.42x2.42mm2) in three 10mm thick short 
axis slices with a FOV 300–420mm, variable matrix between 124x124 – 
172x172 (dependent on FOV), sensitivity encoding factor 2.4, 0.65 partial 
Fourier acquisition and a saturation pre-pulse delay of 80ms. The “3-of-5” 
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technique was adopted to plan the sequences in a reproducible and 
consistent manner by acquiring the central 3 slices of 5 parallel short-axis 
slices spaced equally from mitral valve annulus to LV apical cap[23].  
 
Adaptive perfusion used a new acquisition method, which automatically 
adapts the acquisition duration to maximize spatial resolution whilst 
maintaining 3 slice acquisition during every heart beat. In-plane voxel size 
was automatically minimised in order to fill the time available for data 
acquisition, according to the user’s preference of (i) maximum image 
acquisition duration, and (ii) maximum acceptable acquired voxel size. Both 
these preferences are entered into the system as scan parameters. The 
system reduces the voxel size by a small amount and checks whether the 
protocol remains valid and ready to scan, if it does, a further voxel size 
reduction is made and the check repeated. Thus the minimum allowed voxel 
size allowed is found in an iterative manner, within the user-defined 
boundary conditions. Acquisition duration was limited to 150ms  to minimise 
the blurring effect of cardiac motion[124], and acquired voxels were square 
(maximum allowed 3.0x3.0mm2). All other protocol parameters are taken into 
account as normal by the system and were the same as for the standard 
method. Acquired resolution (mm2), mean shot acquisition time (ms) and 
image acquisition time (ms) were recorded for both sequences. 
 
4.3.3 Image Analysis 
Images were evaluated independently by two readers, both with over 3 
years MR experience, who were blinded to the acquisition sequence used. 
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Overall image quality was recorded as follows: 1=high, 2=adequate, 3=poor, 
4=unusable. The occurrence of dark rim artifact was scored as 
1=none/minor, 2=mild, 3=moderate and 4=severe; when present the 
maximum width of dark rim artifact was measured with electronic callipers at 
window settings as recommended in international guidelines [125], and 
assessed in the dynamic which it appeared most prominent. In plane 
acquired spatial resolution of perfusion images was recorded.  
 
4.3.3.1 Quantitative measurements of SNR 
Quantitative measurements of SNR were taken from the interventricular 
septum at the mid-systolic slice. SNR was determined by measuring the 
mean signal from two identical regions of interest of consecutive time frame 
images and calculated using the difference method [126, 127]. A subtraction 
image from the two time frames was used for the noise estimate. Whilst the 
use of parallel imaging produces variable noise across the field of view, 
reproducible coil and scan geometry, and a consistent acceleration factor, 
allows a comparison of the SNR difference between different scans at the 
same geometry and position in the heart. The use of images from 
consecutive time frames assumes an absence of gross patient motion 
between the time frames, and minimal contrast change in the myocardium; 
this was verified by visual assessment of the noise (subtraction) image. 
 
4.3.4 Statistical Analysis 
Continuous variables were confirmed to be normally distributed and 
expressed as a mean ± standard deviation, whereas categorical variables 
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are expressed as proportions. Normal distribution of continuous variables 
was confirmed with a Shapiro-Wilk test of normality. Within group variables 
were compared with a two sided paired t-test. All statistical tests were 2-
tailed; p values <0.05 were considered significant. Statistical analysis was 
performed using IBM SPSS® Statistics 21.0. 
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4.4 Results 
Healthy volunteers (n=10, 8 male, mean age 22 years, range 21-23) and 
patients (n=10, all male, mean age 58, range 48-72) were scanned on two 
separate occasions, between 7 and 28 days apart (mean 11 days). 
Demographics and haemodynamic data are displayed in Table 4.1. No 
differences in stress haemodynamic data between the two different 
perfusion pulse sequences were observed (P>0.1 for all)(Table 4.2). 
 
4.4.1 Scan Parameters and Image Attributes 
The acquired resolution of the standard perfusion pulse sequence was 
2.42x2.42mm2 in-plane. The mean acquired resolution of the adaptive pulse 
sequence was higher in the whole population (1.92x1.92mm2±0.34, range 
1.53-2.89, P<0.0001); in volunteers (1.88x1.88mm2±0.44, range 1.53-2.89, 
P=0.004) and in patients (1.96x1.96mm2±0.21, range 1.73-2.37, P<0.0001). 
Mean shot acquisition was longer with the adaptive sequence (106ms±9vs. 
129ms±23, P=0.019) (Table 4.3). 
 
No significant differences in mean perfusion image quality scores between 
the standard and adaptive perfusion pulse sequences were detected in 
either the volunteer or patient group by either reader or in consensus read. 
Mean perfusion image scores in volunteers were as follows: Reader 1, 
standard resolution 1.2±0.42, adaptive resolution 1.1±0.32, P=0.59; Reader 
2 1.1±0.32 Vs. 1.0±0.0, P=0.34; Consensus read 1.1±0.31 Vs. 1.1±0.0, 
P=0.34. Whilst in the patient group image score was: Reader 1, standard 
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1.2±0.42, adaptive 1.2±0.42, P=1.0; Reader 2 1.4±0.51 Vs.1.3±0.48, 
P=0.34; Consensus read 1.3±0.48, Vs.  1.3±0.48, P=1.0.  
 
There was no difference in artifact scoring in volunteers. Mean artifact score 
was as follow: Reader 1, standard resolution 1.6±0.52, adaptive resolution 
1.7±0.95, P=0.76; Reader 2 2.0±0.67 Vs. 2.1±0.88, P=0.73; Consensus 
Read 1.9±0.74 Vs. 2.1±0.88, P0.34. In patients, however, the mean artifact 
score was higher with the standard pulse sequence by both readers and in 
consensus (1.8 Vs. 1.2, P=0.05; 2.2 Vs. 1.7, P=0.015 ; 2.1 Vs. 1.6, P=0.05).  
 
The mean DRA width using the standard acquisition sequence was 
2.82±0.65mm and adaptive resolution 1.94±0.60mm (P<0.0001), which was 
lower in both the volunteers and patient groups (Table 4.3). 
 
In two volunteers, the heart rate at stress exceeded the maximum heart rate 
for which the standard resolution pulse sequence can maintain every-
heartbeat temporal resolution (116 and 120 bpm) and data were acquired at 
two-heartbeat temporal resolution. This did not occur in the HR adaptive 
acquisition since the spatial resolution was adapted (to 2.84x2.84mm2 and 
2.89x2.89mm2 respectively), and every-heartbeat temporal resolution was 
maintained.  
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Table 4.1  Demographic and Haemodynamic Data 
 
Parameters Volunteers (n=10) Patients (n=10) 
Clinical Factors   
Gender, male, n (%) 8 (80%) 10 (100%) 
Age, y  22 ± 1.3 58 ± 8.8 
      Range 19 – 23  48 – 72  
Body mass index, kg/m2 21.8 ± 2.5 28.1 ± 4.5 
Body surface area, m2 1.88 ± 0.11  2.06 ± 0.11  
Current Smoker 0 2 (20%) 
Hypertension 0 5 (50%) 
Diabetes Mellitus 0 2 (20%) 
Hypercholesterolaemia 0 3 (30%) 
Previous Revascularisation 0 1 (10%) 
Baseline Haemodynamics   
Mean SBP, mmHg 112±12 127±14 
Mean DBP, mmHg 59±6 70±4 
Mean HR, 1.min-1 67±9  62±7 
Mean HR-SBP product, 
mmHg.min-1 7495±1332 7794±1134 
Stress Haemodynamics – Standard Resolution Sequence  
Mean SBP, mmHg 111±11 120±15 
Mean DBP, mmHg 57±10 67±4 
Mean HR, 1.min-1 90±12 80±10 
Mean HR-SBP product, 
mmHg.min-1 10026±1954 9565±1672 
Stress Haemodynamics – Adaptive Resolution Sequence 
Mean SBP, mmHg 106±8 115±13 
Mean DBP, mmHg 56±6 69±6 
Mean HR, 1.min-1 90 ± 20 81 ± 6 
Mean HR-SBP product, 
mmHg.min-1 9549 ± 2118 9549 ± 2118 
Data are mean ± SD.HR, heart rate; BP, blood pressure. 
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Table 4.2  Comparison of Stress Haemodynamic Data 
 
 
Parameters 
Standard 
Resolution 
Pulse Sequence 
Adaptive 
Resolution 
Pulse Sequence 
P 
Volunteers (n=10) 
Mean SBP, mmHg 111±11 106±8 0.13 
Mean DBP, mmHg 57±10 56±6 0.63 
Mean HR, 1.min-1 90±12 90 ± 20 0.93 
Mean HR-SBP product, 
mmHg.min-1 10026±1954 9549 ± 2118 0.53 
Patients (n=10) 
Mean SBP, mmHg 120±15 115±13 0.24 
Mean DBP, mmHg 67±4 69±6 0.66 
Mean HR, 1.min-1 80±10 81 ± 6 0.55 
Mean HR-SBP product, 
mmHg.min-1 9565±1672 9549 ± 2118 0.73 
Data are mean ± SD.HR, heart rate; BP, blood pressure. 
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Table 4.3  Comparison of Scan Parameters and Image Scores 
Parameters 
Standard 
Resolution 
Pulse 
Sequence 
Adaptive 
Resolution 
Pulse 
Sequence 
P 
Volunteers (n=10) 
Acquired Resolution (mm2) 2.42x2.42 1.88x1.88±0.44 0.004 
      Range (mm) – 1.53 – 2.89 – 
Shot Duration (ms) 171±7 189±17 0.016 
Image Acquisition (ms) 106±9 129±23 0.019 
Image Quality Score 1.1 1.0 0.34 
Artifact Score 2.1 1.9 0.34 
Width of Dark Rim Artifact (mm) 3.0±0.7 2.1±0.6 <0.0001 
Relative Signal-to-Noise Ratio 7.3±2.2 4.2±2.1 0.002 
Patients (n=10) 
Acquired Resolution (mm2) 2.42x2.42 1.96x1.96±0.21 <0.0001 
    Range (mm) – 1.73 – 2.37 – 
Shot Duration (ms) 184±4 210±12 <0.0001 
Image Acquisition (ms) 110±4 142±12 <0.0001 
Image Quality Score 1.3 1.3 1.0 
Artifact Score 2.1 1.6 0.05 
Width of Dark Rim Artifact (mm) 2.6±0.6 1.8±.5 0.005 
Mean Signal-to-Noise Ratio 6.1±2.1 3.4±1.4 <0.0001 
Data are mean ± SD. 
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4.4.2 Signal-to-Noise Ratio 
The mean baseline (before arrival of contrast agent) SNR of the standard 
acquisition was higher than the adaptive acquisition in the whole population 
(6.7±2.2 vs. 3.8±1.8, P<0.0001); in volunteers (7.3±2.2 vs. 4.2±2.1, P<0.002) 
and in patients (6.1±2.1 vs. 3.4±1.4, P<0.0001). This difference was 
consistent with the smaller voxel size in the adaptive perfusion group.  
 
4.5 Discussion 
This study has shown that optimising the use of available imaging time 
during MR myocardial first pass perfusion by adapting the acquisition 
duration to the heart rate and patient size is feasible, improves the acquired 
in-plane spatial resolution and reduces dark rim artifact. Whilst the SNR was 
reduced with the adaptive pulse sequence, in line with the improved spatial 
resolution, overall image quality is maintained. 
 
MR stress perfusion imaging is an established technique with high 
diagnostic accuracy for the detection of underlying coronary artery disease 
which outperforms SPECT [29, 128], partly due to the improved spatial 
resolution of the test. The Society for Cardiovascular Magnetic Resonance 
(SCMR) 2013 standardization guidelines recommends a minimum in-plane 
resolution of 3x3mm2 for first pass perfusion[129]. Recent improvements in 
both acquisition techniques and hardware, which may be utilised to improve 
the acquired spatial resolution, have been demonstrated to enhance the 
diagnostic accuracy of stress perfusion MR. In one single centre study of 
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100 patients high resolution myocardial perfusion MR using k-space and 
time sensitivity encoding (k-t SENSE) acceleration to achieve an in-plane 
spatial resolution of 1.6mm2 had greater overall diagnostic accuracy than 
standard resolution acquisition (2.5mm2) for identifying angiographically 
defined CAD, with an area under the curve (AUC) of 0.93 vs. 0.83; 
p<0.001[47]. Equally imaging at higher field strength produces greater tissue 
magnetization and therefore higher SNR and increased contrast 
enhancement which may be utilized to improve spatial/temporal resolution 
whilst preserving image quality. However, many data acceleration 
techniques currently are more susceptible to motion artifact, require post 
acquisition reconstruction, and are not routinely available in all centres[49]. 
Here, we have demonstrated a conceptually straightforward and effective 
method of obtaining spatial resolution increases in most MR perfusion 
patients, allowing access to the benefits of improved resolution[130] in many 
patients, applicable to any perfusion pulse sequence, on any MR system. 
 
SCMR standardization guidelines [129] also recommend at least three short 
axis slices to be imaged every heartbeat. The standard (fixed) resolution first 
pass perfusion pulse sequence used in this study is designed to allow 3 slice 
imaging every heart beat at heart rates typically achieved during 
pharmacological stress. In those with even higher heart rates, acquisition 
with fixed parameters may not be possible at every heartbeat, leading on 
most commercial scanners to acquire data every second R-R interval. We 
demonstrated this in two volunteers in whom the heart rate was too high for 
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every heart beat imaging (116 and 120 bpm) with the standard resolution 
pulse sequence and therefore data were acquired in alternate R-R intervals.  
 
 
Figure 4.2  Stress perfusion imaging in a health volunteer: standard 
imaging vs. adaptive resolution pulse sequence.  
Adenosine stress perfusion in a healthy volunteer. The top row shows an 
acquisition with a standard (fixed) resolution pulse sequence (2.42x2.42mm2 
in-plane resolution) and the bottom row with a pulse sequence which adapts 
the acquisition duration to the heart rate (1.97x1.97mm2) demonstrating a 
significant reduction in dark rim artefact thickness and extent (arrows) with 
the adaptive resolution scan.   
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Figure 4.3  Stress perfusion imaging in a patient: standard imaging vs. 
adaptive resolution pulse sequence. 
Adenosine stress perfusion in a 60 year-old gentleman with typical anginal 
symptoms. The top row shows an acquisition with a standard (fixed) spatial 
resolution pulse sequence (2.42x2.42mm2 in-plane) and the bottom row with 
a pulse sequence which adapts the acquisition duration to the heart rate 
(1.94x1.94mm2) demonstrating a large perfusion defect in the mid to apical 
septum and apical segment of the anterior wall.  
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This did not occur with the adaptive pulse sequence as the spatial resolution 
was automatically adapted prior to imaging (to 2.84x2.84mm2 and 
2.89x2.89mm2 respectively) to maintain the temporal resolution. The effect 
of missing dynamic images during first pass perfusion can affect the 
diagnostic accuracy of quantitative perfusion analysis[121]. Whilst in such 
cases, an expert user would appreciate that the perfusion sequence requires 
adjustment before contrast-agent injection, because they note the 
particularly high heart rate, the method described here automatically 
performs this action up to the maximum allowed voxel size saved in the 
protocol. This reduces the potential for operator-dependent error or operator-
dependent variability in scan setup. 
 
The signal-to-noise ratio may be used as a measurement to assess the 
performance of the magnetic resonance images and potential clinical 
usefulness of the images. Too much noise may render the images clinically 
uninterpretable. SNR is proportional to the voxel volume and therefore the 
adaptive acquisition, with improved spatial resolution and lower voxel size, is 
expected to have a lower SNR. We demonstrated that the reduction in SNR 
is proportional to the spatial resolution with this pulse sequence. 
 
The adaptive perfusion method used a longer acquisition duration of up to 
150ms per slice. This is longer than recommended by current guidelines, 
which propose a maximum of 125ms. Motion artifact is however related to 
heart rate and is much more likely at higher heart rates. In this study, the 
longer acquisition duration at lower heart rates had no adverse effect on 
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image quality scoring. Furthermore, given the SNR is proportional to the 
change in spatial resolution, this would suggest that cardiac motion due to 
increased imaging time has little effect on SNR measurement.  
 
Adapting pulse sequence parameters between stress and rest perfusion can 
make comparisons in the same individual challenging. Therefore in this 
study, when acquiring rest perfusion data with the adaptive method, we 
matched the acquisition parameters of the stress perfusion scan. The MR 
system acquires each slice consecutively immediately following the R-wave 
of the vectorcardiogram. This results in images acquired at earlier cardiac 
phases for the rest perfusion sequence (due to the slower heart rate) and 
makes clinical comparison between rest and stress sequences more 
challenging. Although not used here, this may be mitigated by a method of 
trigger delay matching, in which the trigger delays of the rest scan may be 
adjusted to match the timing within the cardiac cycle of the stress scan. 
 
4.5.1 Limitations 
This is a small proof of concept study with a limited number of subjects 
designed to assess the feasibility of an adaptive pulse sequence. Dark rim 
artefact was measured in a method consistent with international guidelines 
for clinical reporting perfusion MRI. Whilst this is open to the application of 
different window settings, this reflects what occurs in clinical practice for the 
reading of perfusion imaging. Furthermore whilst every attempt was made to 
blind the image interpretation to the reader, the higher resolution would have 
been apparent in visualisation which may result in reader bias. Finally further 
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research is required to assess the diagnostic accuracy of an adaptive 
perfusion sequence for the detection of underlying coronary artery disease.  
 
4.5.2 Conclusions 
This study demonstrated the feasibility of patient-adaptive perfusion imaging 
in order maximize the potential spatial resolution. We show that using a 
standard SENSE accelerated pulse sequence without spatiotemporal 
undersampling, which adapts image acquisition duration up to 150ms to 
maximise available imaging time, improves the resolution and reduces DRA, 
and therefore has potential to improve the diagnostic accuracy for the 
detection of underlying CAD. This flexible, automated method may also 
reduce operator dependence in those centers which manually adapt 
acquisition parameters to individual patients. 
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Chapter 5 
Rationale and design of the Clinical Evaluation of MAgnetic 
Resonance imaging in Coronary heart disease 2 trial (CE-
MARC 2): A prospective, multi-centre, randomized controlled 
trial of diagnostic strategies for suspected coronary heart 
disease 
 
5.1 Abstract 
5.1.1 Background 
A number of investigative strategies exist for the diagnosis of coronary heart 
disease (CHD). Despite the widespread availability of non-invasive imaging, 
invasive angiography is commonly used early in the diagnostic pathway. 
Consequently, approximately 60% of angiograms reveal no evidence of 
obstructive coronary disease. Reducing unnecessary angiography has 
potential financial savings and avoids exposing the patient to unnecessary 
risk. There were no large scale comparative effectiveness trials of the 
different diagnostic strategies recommended in international guidelines and 
none that have evaluated the safety and efficacy of cardiovascular magnetic 
resonance (CMR). 
5.1.2 Trial Design 
CE-MARC 2 was a prospective, multi-centre, 3-arm parallel group, 
randomized controlled trial of patients with suspected CHD (pre-test 
likelihood 10-90%) requiring further investigation. 1200 patients were 
randomized on a 2:2:1 basis to receive 3.0 Tesla CMR-guided care, single 
photon emission computed tomography (SPECT) guided care (according to 
ACC/AHA appropriate-use criteria) or National Institute for Health and Care 
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Excellence guidelines-based management. The primary (efficacy) endpoint 
was the occurrence of unnecessary angiography as defined by a normal 
(>0.8) invasive fractional flow reserve. Safety of each strategy was assessed 
by 3-year major adverse cardiovascular event rates.  
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5.2 Background 
Coronary heart disease (CHD) is a leading cause of death and disability 
worldwide.  In a typical hospital setting a variety of investigations may be 
used to diagnose CHD, risk-stratify and determine the need for coronary 
revascularization. Myocardial perfusion scintigraphy by single-photon 
emission computed tomography (SPECT) is the most commonly used test 
world-wide for the assessment of myocardial ischaemia and there is a large 
body of evidence to support its prognostic value. Whilst cardiovascular 
magnetic resonance (CMR) has high diagnostic accuracy for the detection of 
CHD and the CE-MARC study demonstrated CMR’s superiority over 
SPECT[29]. Despite the widespread availability and recommendation of 
these non-invasive imaging investigations in national and international 
guidelines[4-6], invasive coronary angiography is commonly used early in 
the diagnostic pathway. Evidence from large populations of patients 
presenting with chest pain have confirmed that the majority will not have 
significant obstructive coronary disease[131, 132]. In the US, the American 
College of Cardiology National Cardiovascular Data Registry identified 
almost 400,000 patients without known CHD that underwent elective 
catheterisation from January 2004 through April 2008, and only 38% had 
obstructive CHD[132].  
  
Avoiding unnecessary angiography has potential financial savings and 
avoids exposing the patient to unnecessary risk. Invasive coronary 
angiography has a risk of major complications of 1.7%. Furthermore the 
dose and stochastic effects of X-ray radiation are frequently misjudged[133] 
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with the risk of developing a solid tumour estimated at 1:2500 diagnostic 
coronary angiographic procedures[134]. Paradoxically, the implementation 
of UK national guidelines for the assessment and diagnosis of recent onset 
chest pain has been demonstrated to increase invasive coronary 
angiography rates between 20-28%[135]. 
 
A previous single centre trial (CECaT) indicated that invasive angiography 
could be avoided in 20-25% of patients using functional testing as an initial 
gate-keeper[136]. To date, there are no large scale comparative 
effectiveness trials of the different diagnostic strategies recommended in 
international guidelines and none that have evaluated the safety and efficacy 
of CMR. 
 
5.3 Study Objectives 
The primary objectives were to determine if 3.0Tesla (T) CMR-guided 
management was superior to a) National Institute for Health and Care 
Excellence (NICE) guidelines-based management (CG95)[6], and b) 
SPECT-guided management[137], in terms of reducing the rates of 
unnecessary invasive angiography occurring within 12 months in patients 
with a pre-test likelihood (PTL) of CHD of 10-90%.  
 
Secondary objectives were to determine a) if in patients with a high PTL of 
CHD (61-90%), non-invasive imaging (CMR or SPECT) was superior to 
NICE guidelines-based management, in terms of reducing the occurrence of 
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unnecessary invasive angiography; b) safety in terms of major adverse 
cardiovascular events (MACE) at 3 years between the CMR-guided care 
group and those receiving NICE guidelines-based management; c) safety in 
terms of MACE at 3 years between the CMR-guided care group and those 
receiving SPECT-guided management and d) cost-effectiveness and impact 
on health-related quality-of-life measures (HRQoL) of a CMR-guided care 
strategy compared to NICE guidelines-based management and to SPECT-
guided management. 
 
5.4 Methods 
5.4.1 Study Design 
CE-MARC 2 (clinicaltrials.gov: NCT01664858) was a prospective, multi-
centre, multi-vendor, 3-arm parallel group, randomized controlled trial of 
patients who were referred to cardiology care for further evaluation of 
symptoms thought to be angina pectoris. A total of 1200 patients with 
suspected CHD were be randomized on a 2:2:1 basis to receive CMR-
guided care, SPECT-guided care or NICE guidelines based management 
[Figure 5.1 & 5.2]. 
Statistical analysis was carried out by the Clinical Trials Research Unit 
(CTRU), University of Leeds and the Centre for Health Economics, 
University of York. The study population was followed-up prospectively for a 
minimum of 3 years to establish long-term MACE in each investigation arm. 
The study was conducted in accordance with the Declaration of Helsinki and 
has been approved by the National Research Ethics Service. 
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5.4.2 Patient Population, Recruitment & Randomisation 
Subjects were considered for inclusion if they were age ≥30yrs and 
presented to participating hospitals (Appendix 1) with suspected cardiac 
chest pain (angina) with a defined CHD PTL of 10-90%[6]. Full inclusion and 
exclusion criteria are listed in Table 5.1. An anonymized log of all patients 
screened for eligibility who are not recruited either because they are 
ineligible or because they declined to participate was kept. 
  
The treating clinician made a clinical diagnosis of typical angina if the patient 
had all three salient features of angina (constricting discomfort in the front of 
the chest, or in the neck, shoulders, jaw or arms; precipitated by physical 
exertion; and relieved by rest or GTN within ~5min) or atypical angina if they 
had two out of three[6, 123]. Those with one or none of the features were 
defined as non-anginal chest pain[6, 123] and were ineligible for the study. 
The patients’ risk factors (age, gender, ethnicity, abdominal & hip 
circumference, lipid profile, blood pressure, smoking and diabetic status), 
past medical history (including rheumatoid arthritis, hypertension, 
hyperlipidemia, peripheral vascular disease, cerebrovascular disease) and 
family history of premature CHD were recorded. 
 
Patients underwent risk stratification with their PTL of having CHD calculated 
[6, 138] and categorised as low (10-29%), intermediate (30-60%) or high 
(61-90%). Randomisation was achieved using minimisation, incorporating a 
random element through a computer-generated program accessed via a 24h 
telephone service. This allocated patients in a 2:2:1 ratio between 
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CMR:SPECT:NICE and took account of the following stratification factors: 
randomising site; age (30-64,≥65); PTL (10-29%,30-60%,61-90%) and 
gender. Those with low PTL of underlying CHD (10-29%) randomized to 
NICE guidelines will undergo cardiac CT (CCT); intermediate PTL (30-60%) 
SPECT and high PTL (61-90%) coronary angiography. 
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Figure 5.1  CE MARC 2 study flow diagram illustrating the recruitment process.  
* Pre-test likelihood as defined by NICE (CG95) guidelines(3).   
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Figure 5.2  CE-MARC 2 study flow diagram illustrating randomization, investigative strategy and study end-points[139]. 
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Table 5.1  Inclusion and Exclusion Criteria into the CE-MARC2 Study 
Inclusion Criteria  Exclusion Criteria 
Age ≥30yrs 
 
Non-anginal chest pain 
Suspected stable angina (CHD) 
that requires further investigation 
 Normal SPECT/CCT within the last 2-
years 
A defined pre-test likelihood of 
10-90% 
 
Clinically unstable  
Suitable for revascularization if 
required 
 Previous MI or biomarker positive 
ACS 
 
 Previous revascularization with 
coronary artery bypass surgery or 
PCI 
 
 
Contraindication to CMR imaging  
 
 Known adverse reaction to 
Adenosine or Gadolinium/iodinated 
contrast agents 
 
 Obesity (where body girth exceeds 
scanner diameter) 
 
 
Pregnancy and/or breast feeding 
 
 Known chronic renal failure (eGFR 
<30mL/min/1.73m2) 
 
 
Inability to give informed consent 
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5.4.3 Funding 
The trial was funded by the British Heart Foundation (SP/12/1/29062). 
Additional support was received from the Leeds Teaching Hospital 
Charitable Foundation and the National Institute for Health Research, 
through the Local Clinical Research Networks. 
 
5.4.4 Investigation Details 
5.4.4.1 CMR 
CMR was carried out on a clinical 3.0T scanner using protocols that 
conformed to international standards[140]. A cardiac imaging receiver coil 
configuration was used and ECG gating was performed. The scan 
comprised of: 
1. Survey and reference scans prior to defining the short, vertical long 
and horizontal long axes acquired with a balanced steady state free 
precession (bSSFP), single slice breathhold sequence. bSSFP pulse 
sequence parameters dependent on scanner manufacturer and site. 
Typical parameters: echo time (TE) 1.3ms, repetition time (TR) 
2.6ms, flip angle (FA) 400, field of view 320–420mm according to 
patient size, SENSE or GRAPPA acceleration, slice thickness 10mm 
and 30 phases per cardiac cycle. 
 
2. Stress perfusion imaging performed with adenosine administered 
initially at 140µg/kg/min. Adequate hemodynamic response was 
assessed by either ≥10% HR increase, ≥10mmHg decrease in 
systolic blood pressure. If there was inadequate hemodynamic 
response then the dose was increased incrementally to 170µg/kg/min 
- 105 - 
  
and then 210µg/kg/min for a further 2 minutes until hemodynamic 
response was achieved. 
 
Perfusion image acquisition used a two dimensional, T1-weighted 
saturation-recovery-prepared gradient echo pulse sequence in 3 short 
axis slices, planned using the 3/5 technique[23], using either parallel 
imaging acceleration (SENSE or GRAPPA), or spatio-temporal 
undersampling (5x kt-BLAST). First-pass contrast-enhanced study 
was performed using a dual-bolus technique(0.075mmol/kg of 
gadobutrol (Gadovist®, Bayer Schering Pharma, Berlin, Germany)) 
for the main bolus preceded by the same volume of a 10% dilute 
contrast agent dose for the pre-bolus, both administered at a rate of 
4.0ml/s followed by a 20ml saline flush. 
 
3. Resting wall motion and LV function was assessed with a contiguous 
stack of multiphase ventricular short axis bSSFP cines (10-12 slices; 
30 phases; 10mm slice thickness, 0mm gap, same cine pulse 
sequence as above).  
 
4. The rest myocardial perfusion study used identical pulse sequence, 
slice positioning and injection characteristics to the stress perfusion 
scan. If the stress perfusion scan was not of adequate quality (e.g. 
ectopics, failure to trigger) a repeat stress was performed as 
alternative to the rest study. 
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5. Late gadolinium enhancement (LGE) was performed in 10-12 short 
axis slices 10-15mins after step 4 with an inversion recovery-prepared 
T1-weighted gradient echo pulse sequence. Typical parameters: TE 
2.0ms, TR 3.7ms, FA 250, acquired spatial resolution 
0.70x0.70x10mm3, Inversion time (TI) individually adjusted according 
to TI scout. LGE was acquired with alternate heart beat acquisition 
(with single shot or navigated LGE an option for poor breath holders) 
and long axis and modified views acquired if clinically indicated. 
 
 
5.4.4.2 SPECT 
Radionuclide imaging was performed according to local standard 
departmental practice conforming to both national and international 
guidelines[141-143]. Patients underwent either a one or two-day scanning 
protocol with a radioisotope tracer 99mTc-tetrofosmin or 99mTc-sestamibi 
(MYOVIEW™; CARDIOLITE™). A weight-adjusted dose up to a maximum 
of 1000MBq per examination was used for stress and rest imaging, carried 
out within 5 days of each other. 
Stress examination was performed with either treadmill or bicycle exercise, 
pharmacological vasodilator stress (with adenosine or regadenoson), or a 
combination. Treadmill involved exercise using the BRUCE or modified 
BRUCE protocol or bicycle ergometer typically commencing at 25 watts 
increasing workload by 25 watts every two minutes. Radioisotope tracer was 
injected at peak stress. 
If pharmacological stress with adenosine was used the administration 
regime was comparable to the CMR protocol. If Regadenoson was used, 
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0.4mg was delivered by rapid intravenous injection. Radioisotope tracer was 
injected after at least 4min of adequate hemodynamic/symptom response. 
Vasodilator stress could be combined with sub-maximal exercise. 
Images were acquired on either a dual headed gamma camera or solid state 
cadmium zinc telluride camera. Stress and rest images were gated to the 
ECG and attenuation correction was used where routinely available. 
 
5.4.4.3 Cardiac CT  
Cardiac CT (CCT) was performed on a minimum 64-slice multi-detector CT 
and follow international guidelines[144]. Coronary artery calcium (CAC) 
scoring scan protocol involved: 
1. Scout Scans 
2. Unenhanced scan with prospective gating and inspiratory breathhold. 
A minimum scan length (z-axis distance) from tracheal bifurcation to 
the inferior border of the heart. 
3. Agatson CAC score was calculated and NICE-guidance followed[6]. If 
CAC was 0 no further imaging was performed; if CAC score was 1-
400 proceeded to CT coronary angiography (CTCA) ; and if CAC 
score was >400 referred for invasive coronary angiography. 
 
For CTCA heart rate control was achieved with beta-blockade (intravenous 
or oral) and short acting sublingual nitrates were routinely given. CTCA was 
performed where possible with a prospective gating technique using the 
minimum scan range planned from the unenhanced scan. Typical scan 
parameters: 0.625mm collimation, pitch 0.2-0.4, 100-120kVp and 400-
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830mAs (adjusted according to body mass index). If retrospective gating 
was required ECG dose modulation was used to minimize radiation dose. 
The acquisition window was typically centred at end-diastole (however end-
systole could be used at the discretion of the attending physician). In those 
with variable heart rates time interval padding was used to allow 
reconstruction of both the systolic and diastolic phase datasets. The exact 
scan parameters and radiation reduction algorithms used were dependent 
on the hardware vendor. 60–120ml of iodinated contrast agent was 
administered at a flow rate of 4.5-6.5 ml/s followed by a bolus of normal 
saline (e.g.50ml, 5ml/s) during an acquisition with inspiratory breath-hold. 
Either a test bolus or a bolus tracking technique was used. 
 
5.4.4.4 X-ray angiography and FFR 
Angiography was performed using a standard technique (radial or femoral 
approach). FFR (PressureWireTM, St Jude Medical, Minneapolis, USA) was 
performed in all vessels ≥2.5mm with stenosis ≥40% and ≤90%, following 
intra-coronary nitrates with adenosine at 140-210mcg/kg/min to achieve 
maximal hyperemia and hemodynamic steady state; pull back assessment 
of diffuse disease or serial stenoses may have been performed. Adenosine 
was administered as per CMR protocol. Totally occluded coronary arteries 
were recorded to have a default FFR value of 0.50; for lesions >90% FFR 
was also considered to be positive (0.50) and lesions <40% FFR were 
considered normal (0.90)[145]. All sites had an FFR quality assurance core 
laboratory assessment of the FFR recordings using vendor software 
(RADIVIEW 2.2, St Jude Medical Corp.). 
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5.4.5 Investigation Reporting 
All test results were reported by independent cardiology/radiology 
consultants with a minimum 5yr experience in the imaging modality. 
 
5.4.5.1 CMR 
CMR analysis was by both visual and quantitative following international 
recommendations[146]. Local on-site reporting included regional wall motion 
abnormalities (by visual analysis using the 17-segment American Heart 
Association (AHA)/American College of Cardiology (ACC) model). Each 
segment was scored as 0:normal, 1:mild hypokinesia, 2:severe hypokinesia, 
3:akinesia, or 4:dyskinesia. Quantitative analysis included: end diastolic 
volume (ml), end systolic volume (ml), stroke volume (ml) and ejection 
fraction (%). 
 
Detection of hypoperfusion (ischemia), by visual comparison of stress, rest 
and LGE scans, was scored as 0:normal, 1:equivocal, 2:non-transmural 
ischemia <50%, 3:non-transmural ischemia ≥50%, 4:transmural ischemia in 
16 segments of the 17 segment AHA/ACC model (excluding the apical cap). 
 
Any infarct (scar) was reported based on the LGE images (17 segment 
model) with scores of 0: no hyperenhancement, 1: 1–25% mural thickness, 
2: 26–50%, 3: 51–75%, or 4: >75% allocated to each segment. 
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A positive result (≥2 adjacent segments (or 60 degree arc-equivalent if the 
defect crosses segmental boundaries) with ≥50% transmural extent of 
ischemia, scar, or ischemia-scar combination) by protocol necessitated 
referral for invasive angiography +/- FFR 
 
5.4.5.2 SPECT 
SPECT analysis was both visual and quantitative. Local on-site reporting 
included any regional wall motion abnormality (by visual analysis using the 
17-segment model). Each segment was scored as 0 (normal), 1 (mild 
hypokinesia), 2 (severe hypokinesia), 3 (akinesia), or 4 (dyskinesia). 
 
Evidence of ischemia, by visual comparison of rest and stress scans, was 
scored as 0 (normal), 1 (mild 51-70%), 2 (moderate 31-50%), 3 (severe 10-
30%), 4 (absent <10%) in each segment. Quantitative analysis included 
summed rest score (SRS) and summed stress scores (SSS); quantitative 
perfusion SPECT (QPS) defect extent (%); QPS total perfusion deficit (%); 
end systolic volume (ml); end diastolic volume (ml); stroke volume (ml) and 
ejection fraction (%). 
 
The presence of artefacts including sub-diaphragmatic activity affecting the 
inferior wall, significant patient movement anterior attenuation, inferior 
attenuation and LBBB artefact were recorded.  
 
- 111 - 
  
A positive result (SSS≥4), unless believed by the reporting clinician to 
represent attenuation artefact, by protocol necessitated referral for invasive 
angiography +/- FFR.  
 
5.4.5.3 Cardiac CT  
The total Agatson CAC score from the unenhanced scan was determined. If the 
CAC score was >0 and <400 a contrast enhanced scan was performed.  
Coronary stenosis were graded as 0: normal, 1: minimal <25% stenosis, 2: 
mild 25-49%, 3: moderate 50-69%, 4: severe 70-99%, 5: occluded 100%. A 
positive result (either CAC>400 or any luminal stenosis ≥50% in an 
epicardial coronary artery ≥2.5mm diameter) by protocol necessitated 
invasive angiography ± FFR.  
 
5.4.5.4 X-ray angiography and FFR 
Invasive X-ray angiography was interpreted visually by the performing 
clinician recording the coronary artery dominance, location and visual 
degree (%) of all coronary stenoses in all major epicardial coronary arteries 
(with luminal diameter ≥2.5mm). FFR measurement was recorded in all 
arteries ≥2.5mm with a visually recorded diameter stenosis ≥40% and ≤90%. 
Where FFR could not be performed due to clinical/safety reasons 
quantitative coronary angiography (QCA) was performed using validated 
commercial vendor software. In this instance QCA measurements were 
made during off-line analysis by a single independent blinded observer at 
the Glasgow Angiographic core-lab. Lesions were considered significant if a 
coronary artery segment (luminal diameter ≥2.5mm) analysed by QCA had a 
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percentage diameter stenosis of ≥70% in one view or ≥50% in two 
orthogonal views. 
 
In accordance with usual clinical practice all clinical data from all imaging 
modalities was made available for the reporting physician to make an overall 
clinical judgement. 
 
5.4.6 Protocol deviations 
On occasion where the attending cardiologist over-ruled the protocol 
requirement to proceed to invasive coronary angiography, this was recorded 
as a protocol violation.  
 
5.4.7 Annual Follow-up 
Annual follow-up over the subsequent 3 years was undertaken to record 
death (including cause), other MACE and withdrawal. For alive patients, 
medical history since randomization, including details and dates of: acute 
coronary syndrome (ACS), emergency or elective revascularization 
procedure, any admission for cardiovascular cause was obtained and 
verified from hospital or family practitioner records. Details of any recent 
cardiovascular investigations was be taken. In addition, Office for National 
Statistics monitoring was sought for deceased patients to determine the 
certified causes of death.  
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5.4.8 Primary Endpoint 
5.4.8.1  Unnecessary invasive coronary angiography occurring within 
12 months in each arm. 
This was defined at the time of coronary angiography by a FFR 
measurement of >0.80  in all vessels ≥2.5mm in a patient-based analysis 
(i.e. at least one vessel with a FFR measurement of <0.8 was required to 
define a patient with disease). 
 
An “Unnecessary angiogram” was defined as one of the following:  
 A negative FFR and positive non-invasive test (i.e. a False Positive test 
result) 
 A negative FFR in a high PTL (61-90%) patient that proceeds directly to 
invasive angiography in the NICE guidelines-based strategy arm (i.e. a 
False Positive for the strategy). 
 A negative FFR and a negative non-invasive test (i.e. a True Negative 
strategy result in which the imaging result was ‘not believed’ by the 
treating cardiologist – based on intention-to-treat (ITT) principles).  
 A negative FFR and an inconclusive non-invasive test result (CMR, 
SPECT, or CCT) in which angiography had to be performed to make the 
diagnosis (i.e. failure of the strategy to produce a diagnosis).  
 
 
- 114 - 
  
5.4.9 Secondary Endpoints 
5.4.9.1 Major adverse cardiovascular events  
For all patients MACE at 12 months and a minimum of 3 years was reported. 
MACE was defined as death due to cardiovascular cause, MI (defined by the 
Third universal definition[147]), unplanned coronary revascularization and 
hospital admission for cardiovascular cause. Hospitalisation for 
cardiovascular cause were defined as: troponin negative ACS, spontaneous 
MI (Type 1), MI secondary to ischemic imbalance (Type 2), MI related to 
stent thrombosis (Type 4b), arrhythmia, stroke and heart failure. 
 
5.4.9.2 Positive coronary angiogram 
The proportion of patients who underwent an invasive coronary angiogram 
yielding a positive finding by FFR within 12 months of randomisation  
 
5.4.9.3 Economic Evaluation 
To assess the long term cost-effectiveness of the alternate diagnostic testing 
strategies, information from the trial will be used to update the economic 
model developed as part of the CE-MARC trial[36]. The model will use 
information from the trial, including resource use, costs, HRQoL and other 
clinical outcomes (e.g. on unnecessary tests and MACE events), together 
with epidemiological, clinical and economic data from other sources to 
calculate costs and quality-adjusted life-years for patients. The economic 
evaluation will use methods consistent with those recommended by 
NICE[148]. Given the potential difference between diagnostic strategies in 
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terms of mortality, the modelling will adopt a lifetime time horizon to capture 
any difference. 
 
5.4.9.4 Quality of Life 
Health-related quality-of-life (HRQoL) was measured by  
- Seattle Angina Questionnaire–UK Version (SAQ-UK);  
- Medical Outcomes Survey-Short Form 12 (SF12v2)  
- EuroQol 5-Dimensions (EQ-5D).  
 
5.4.9.5 Complications  
Complications directly related to investigational or procedural aspects of the 
study resulting in prolonged hospital stay/specific treatment that would 
otherwise have not been required were reported. These were established 
and adjudicated by the Trial Steering Committee (TSC) and Trial 
Management Group (TMG) and reported to the Data Monitoring and Ethics 
Committee (DMEC). 
 
5.4.10 Statistical Considerations 
5.4.10.1 Sample Size 
Sample size calculations were performed using nQuery 7.0. For the primary 
endpoint analyses a sample size of 1200 (allowing for 20% non-completion) 
was estimate to provide 99% power to detect a difference of unnecessary 
angiography rates between CMR and NICE-guidelines based management - 
accounting for the 2:1 allocation ratio - and 94% power between CMR and 
SPECT-guided care (2-sided test 5% significance level for a continuity-
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corrected chi-squared test[149]). This was based on projected unnecessary 
angiography rates of 4.5%, 11.7% and 30% in the CMR, SPECT and NICE 
arms respectively, arrived at by estimating the PTL profile of CEMARC 
patients (we estimated the PTL distribution to be 10%:33%;57% for 
low:moderate:high PTL, for those patients with PTL 10-90%) and the false 
positive rates of CMR and SPECT in these subgroups to compute a 
weighted average false positive rate as the expected unnecessary 
angiogram rate. For the NICE arm, we noted that in patients with 61-90% 
PTL, nearly 60% of angiograms were negative, and so would drive high 
rates for this strategy, despite CT and SPECT patients (10-60% PTL) 
undergoing fewer unnecessary angiograms. 
 
5.4.10.2 Analysis Plan 
Statistical analysis were performed as agreed in the pre-specified statistical 
analysis plan. All analyses were performed on intention-to-treat basis. The 
primary endpoint was performed after the 12-month assessment has been 
completed by the last patient entered into the study and a complete and 
exhaustive data chase has been performed. Analyses of primary and 
secondary endpoints were performed separately for the CMR-guided vs. 
NICE-guided care; CMR-guided vs. SPECT-guided care and SPECT-guided 
vs. NICE-guided care comparisons. 
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5.4.10.3 Primary Endpoint Analysis 
The difference in proportions of patients randomised to each arm with a 
study-defined unnecessary angiogram and 95%CI for this difference was  
presented for summary purposes. A binary logistic regression was used to 
model the relative odds of receiving an unnecessary angiogram for CMR-
guided care vs. the group of interest (either NICE or SPECT-guided care 
pathways) when controlling for the minimisation factors. The estimated odds 
ratios, 95%CI and P-values was presented. An unadjusted analysis 
compared the difference in the proportions between the two groups using a 
chi-squared test. 
 
5.4.10.3 Secondary Endpoint Analysis 
1. Major Adverse Cardiovascular Events 
The proportions of patients in the three groups with a MACE at twelve and 
thirty-six months and absolute differences in these MACE rates is presented. 
This analysis was performed both on the ITT and per-protocol basis. Peri-
procedural MI - type 4a (related to percutaneous coronary intervention) and 
type 5 (related to coronary artery bypass grafting) and planned 
revascularization (PCI or CABG) based on the index FFR results was 
censored. 
 
2. Quality of Life 
The scores will be presented for the groups at 6, 12, 24 and 36 months. The 
scores for the dimensions of the SAQ and SF12 will be summarised by 
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randomised group at each time point.  Multi-level repeated measures 
modelling will be used to estimate differences between the groups at all 
post-baseline time points (allowing for time, trial group, trial group by time 
interaction, and adjusting for baseline QoL and minimisation factors [all fixed 
effects], and for patient and patient by time interaction [random effects]). 
Residuals and predicted values produced from the multivariate models will 
be examined to assess the assumptions of the statistical model. 
 
5.4.11 Data monitoring 
Data was monitored for completeness and quality by the CTRU. A full 
monitoring schedule including Serious Adverse Events and Adverse 
Reactions was established and agreed by the TSC and TMG. Ethical and 
Safety considerations was monitored by the DMEC. A quality assurance 
process was undertaken centrally by independent modality-specific imaging 
experts, to monitor the quality of image acquisition and interpretation of each 
imaging modality at all recruiting centres. This involved an initial review of 
the first 15 imaging studies followed by an ongoing review of a random 10% 
of each imaging modality at each participating site. Clinical interpretation of 
the individual components of each imaging modality and overall study 
recommendation was scored as 1 (agreement), 2 (minor disagreement) or 3 
(major disagreement) and reported to the DMEC for independent 
consideration/action. 
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5.4.11 Conclusion 
The CE-MARC 2 trial was a prospective, multi-centre, 3-arm parallel group, 
randomized controlled trial; it provides comparative efficacy and safety 
evidence for three different strategies of investigating patients with 
suspected CHD, with the intention of reducing unnecessary invasive 
angiography rates. Evaluation of these management strategies has the 
potential to improve patient care, HRQoL and the cost effectiveness of CHD 
investigation. 
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Chapter 6 
Results from the Clinical Evaluation of MAgnetic Resonance 
imaging in Coronary heart disease 2 trial (CE-MARC 2): A 
prospective, multi-centre, randomized controlled trial of 
diagnostic strategies for suspected coronary heart disease 
 
6.1 Results 
6.1.1 Trial Population 
Between November 2012 and March 2015, 13 957 patients were screened 
of whom 2205 were eligible (Figure 6.1 lists reasons for noneligibility and 
nonconsent). From 6 UK centers (Leeds, Glasgow, Leicester, Bristol, 
Oxford, London [St Georges]),1202 patients (55% of eligible) were recruited 
and allocated to NICE guidelines–directed care (n = 240) or management by 
CMR (n = 481) or MPS (n = 481) (Figure 6.1). 
  
6.1.2 Baseline Characteristics 
The mean age of patients was 56.3 years (SD, 9.0), 638 patients (53%) 
were men, the mean body mass index (BMI; calculated as weight in 
kilograms divided by height in meters squared) was 29.1 (SD, 5.2), and 1107 
patients (92%) were classified ethnically as white (Table 6.1). The study 
population had a substantial burden of cardiovascular risk factors: 150 
patients (12.5%) had diabetes, 458 patients (38.1%) had hypertension, 702 
patients (58.4%) were past or current tobacco users, 483 patients (40.2%) 
had dyslipidemia, and 651 patients (54.2%) had a family history of 
premature CHD. Patients had a median of 2 of these 5 risk factors. All  
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Figure 6.1  Flow of Patients Through the Study of Noninvasive Imaging 
and Angiography Rates.  
ACS indicates acute coronary syndrome; CABG, coronary artery bypass 
grafting; CHD, coronary heart disease; NICE, National Institute for Health 
and Care Excellence; PCI, percutaneous coronary intervention.[150] 
*Patients may have received more than 1 test, in addition to or as an 
alternative to their strategy.
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Table 6.1  Baseline Characteristics of Participants With Suspected Coronary Heart Disease (CHD) by Study Group 
 
 
 
 
 
 
 
 
 
 
 
 
* Family history of premature 
CHD defined as diagnosis of the 
disease in a male first-degree 
relative before 55 years of age or 
in a female first-degree relative 
before 65 years of age.  
† According to Pryor et al.[138]  
‡ According to Goff et al.[151] 
ASCVD, atherosclerotic 
cardiovascular disease; ACE, 
angiotensin converting enzyme; 
ARB, angiotensin II receptor 
blocker. 
 
 
 
Characteristic 
CMR-guided care 
(N=481) 
MPS-guided care 
(N=481) 
NICE-guided Care 
(N=240) 
Total  
(N=1,202) 
Age, Mean (SD) 56.5 (9.10) 55.9 (8.87) 56.5 (9.21) 56.3 (9.03) 
Female sex, no. (%) 227 (47.2%) 225 (46.8%) 112 (46.7%) 564 (46.9%) 
Non-white Ethnicity, no. (%) 38 (7.9%) 38 (7.9%) 19 (7.9%) 95 (7.9%) 
Cardiac risk factors 
 Body Mass Index, Mean (SD) 29.2 (5.36) 29.1 (5.12) 29.0 (5.24) 29.1 (5.23) 
 Hypertension, no. (%) 177 (36.8%) 182 (37.8%) 99 (41.3%) 458 (38.1%) 
 Diabetes, no. (%) 53 (11.0%) 73 (15.2%) 24 (10.0%) 150 (12.5%) 
 Dyslipidemia, no. (%) 186 (38.7%) 198 (41.2%) 99 (41.3%) 483 (40.2%) 
 Current or past Smoking, no. (%) 284 (59.0%) 271 (56.3%) 147 (61.3%) 702 (58.4%) 
 Family history of premature CHD* 252 (52.4%) 259 (53.8%) 140 (58.3%) 651 (54.2%) 
 Peripheral Vascular Disease, no. (%) 8 (1.7%) 9 (1.9%) 10 (4.2%) 27 (2.2%) 
 Cerebrovascular disease, no. (%) 17 (3.5%) 17 (3.5%) 8 (3.3%) 42 (3.5%) 
Nature of Angina, no. (%)     
 Atypical 318 (66.1%) 325 (67.6%) 158 (65.8%) 801 (66.6%) 
 Typical 163 (33.9%) 156 (32.4%) 82 (34.2%) 401 (33.4%) 
Risk Burden     
 PTL %, Mean (SD)† 49.9% (24.25%) 48.6% (23.57%) 50.7% (23.28%) 49.5% (23.78%) 
 No. risk factors/patient, Mean (SD) 2.0 (1.18) 2.0 (1.11) 2.1 (1.05) 2.0 (1.13) 
 10yr ASCVD risk >7.5%‡ 175/377 (46.4%) 173/367 (47.1%) 93/179 (52.0%) 441/923 (47.8%) 
Medications, no. (%)     
 Antiplatelet therapy 271 (56.3%) 268 (55.7%) 150 (62.5%) 689 (57.3%) 
 Beta Blocker 150 (31.2%) 157 (32.6%) 74 (30.8%) 381 (31.7%) 
 Statin or other lipid lowering therapy 191 (39.7%) 201 (41.8%) 108 (45.0%) 500 (41.6%) 
 ACE inhibitor or ARB 115 (23.9%) 122 (25.4%) 66 (27.5%) 303 (25.2%) 
 Other anti-anginal medication 283 (58.8%) 276 (57.4%) 142 (59.2%) 701 (58.3%) 
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patients were symptomatic, with 401 patients (33.4%) reporting typical chest 
pain and 801 patients (66.6%) reporting atypical chest pain as their primary 
symptom. The assessment of cardiac risk, calculated according to the 2013 
atherosclerotic cardiovascular disease risk score from the American College 
of Cardiology Foundation and American Heart Association guidelines, 
showed that 441 of 923 patients (47.8%) had a 10-year risk of events of 
7.5% or higher[151]. The mean pretest likelihood of obstructive CHD 
according to the Duke score was 49.5% (SD, 23.8%)[138]. 
  
6.1.3 Test Conduct 
Of 481 patients assigned to the CMR group, 435 patients (90.4%) had CMR 
as the initial test (median time from randomization, 20 days [interquartile 
range, 13-34]), 5 patients (1.0%) had MPS, 5 patients (1.0%) went directly to 
angiography, and 23 patients (4.8%) had no test. Of 481 patients assigned 
to the MPS group, 446 patients (92.7%) had MPS as the initial test (median 
time from randomization, 28 days [interquartile range, 22-39]), 4 patients 
(0.8%) had CMR, 5 patients (1.0%) went directly to angiography, and 21 
patients (4.4%) had no test. Of 240 patients assigned to the NICE guidelines 
group, 56 patients (23.3%) had CCT (median time from randomization, 34 
days [interquartile range, 14-44]), 86 patients (35.8%) had MPS, 85 patients 
(35.4%) went directly to angiography, and 11 patients (4.6%) had no test. 
The numbers of patients adherent to receiving both their initial randomized 
test and per-protocol compliance with their test result were 200 patients 
(83.3%) in the NICE guidelines group, 414 patients (86.1%) in the CMR 
group, and 368 patients (76.5%) in the MPS group. 
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Study sites reported their interpretation of the initial test as positive for CHD 
in 54 of 435 patients (12.4%) in the CMR group, in 81 of 446 patients 
(18.2%) in the MPS group, and in 19 of 142 patients (13.4%) in the NICE 
guidelines group. There was no difference in revascularization rates (Figure 
6.1) between the 3 groups (P = .47). The rate of patients with incomplete 
data required for analysis of the primary end point was low: 18 of 240 
patients (7.5%) in the NICE guidelines group, 50 of 481 patients (10.4%) in 
the CMR group, and 33 of 481 patients (6.9%) in the MPS group. Of these, 
11 of 240 patients (4.6%) in the NICE guidelines group, 23 of 481 patients 
(4.8%) in the CMR group, and 21 of 481 patients (4.4%) in the MPS group 
were related to missing test results. 
 
6.1.4 Primary End Point 
Overall, 265 patients (22.0%) underwent at least 1 coronary angiogram (10 
patients underwent 2 angiograms) within 12 months of randomization: 102 of 
240 patients (42.5%) in the NICE guidelines group, 85 of 481 patients 
(17.7%) in the CMR group, and 78 of 481 patients (16.2%) in the MPS 
group. The primary end point of unnecessary angiography occurred in 69 
patients (28.8%) in the NICE guidelines group, 36 patients (7.5%) in the 
CMR group, and 34 patients (7.1%) in the MPS group. Of these angiograms, 
98 angiograms (70.5%)  had no visual stenosis and were not assessed 
further, 40 angiograms (28.8%) reached the conclusion by FFR 
measurement and 1 angiogram (0.7%) involved QCA only. The adjusted 
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Table 6.2  Summary of the CE-MARC 2 Trial Endpoints. 
 Total 
Patients 
(N = 1202) 
Guided Care Absolute Differences, % (95% CI) 
NICE Guidelines  
(n = 240) 
CMR 
(n = 481) 
MPS 
(n = 481) 
CMR vs NICE CMR vs MPS 
Primary End Point 
Unnecessary invasive 
angiography, No. (%) 
139 (11.6) 69 (28.8) 36 (7.5) 34 (7.1) −21.3  
(-28.7 to -13.6) 
0.4  
(−6.0 to 6.8) 
Components of the primary end point 
False-positive 
noninvasive test 
35 5 18 12   
Direct to angiography 
(by strategy) 
59 59     
Negative test, not per-
protocol 
41 5 15 21   
Inconclusive 
test/result 
4 - 3 1   
Secondary End Points 
Positive angiography 
occurrence, No. (%) 
118 (9.8) 29 (12.1) 47 (9.8) 42 (8.7) −2.3  
(−10.0 to 5.4) 
1.0  
(−5.4 to 7.5) 
False-positive 
noninvasive test 
73 4 38 31   
Direct to angiography 
(by strategy) 
23 23     
Negative noninvasive 
test, not per-protocol 
9 1 2 6   
Inconclusive 
noninvasive 
test/result 
2  2    
Acute/urgent 
angiography 
indication 
9 1 4 4   
Angiography as 
alternative initial 
investigation 
2 - 1 1   
Major adverse 
cardiovascular events, 
No. (No. of patients) 
44 (36) 7 (6) 20 (15) 17 (15) 1.0  
(−6.7 to 8.8) 
0.0  
(−6.4 to 6.4) 
  Cardiovascular death 5 1 1 3   
  Myocardial infarction 9 2 5 2   
  Revascularization       
    Unplanned PCI 12 2 6 4   
    Unplanned CABG 1  1    
  Arrhythmia 9 2 4 3   
  Heart failure 4   4   
  Stroke/TIA 4  3 1   
Abbreviations: CABG, coronary artery bypass graft; CMR, cardiovascular 
magnetic resonance; MACE, major adverse cardiovascular events; MPS, 
myocardial perfusion. 
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odds ratio of unnecessary angiography for the CMR group vs the NICE 
guidelines group was 0.21 (95% CI, 0.12-0.34; P < .001) and 1.27 (95% CI, 
0.79-2.03; P = .32) for the CMR group vs the MPS group. Table 6.2 shows 
individual components of the primary end point. For both comparisons, the 
primary analysis was repeated in the per-protocol population, with no effect 
on the trial results. Sensitivity analyses using random center effects or 
adjusting for further risk factors (hypertension, ethnicity, smoking status) or 
using the per-protocol population did not change overall trial conclusions. 
Exploratory subgroup analyses showed consistent results across subgroups 
(Figure 6.2).  
 
6.1.5 Secondary End Points 
Positive angiography was observed in 29 patients (12.1% [95% CI, 8.2%-
16.9%]) in the NICE guidelines group, 47 patients (9.8% [95% CI, 7.3%-
12.8%]) in the CMR group, and 42 patients (8.7% [95% CI, 6.4%-11.6%) in 
the MPS group (P = .36). During the minimum 1-year follow-up (median, 
15.8 months [interquartile range, 12.1-24.2]), 36 patients (3.0%) had at least 
1 MACE: NICE guidelines group, 6 patients (2.5%); CMR group, 15 patients 
(3.1%); MPS group, 15 patients (3.1%) (Table 6.2). Annualized MACE rates 
were 1.6% for the NICE guidelines group, 2.0% for the CMR group, and 
2.0% for the MPS group. Adjusted hazard ratios for MACE were 1.37 (95% 
CI, 0.52-3.57; P = .52) for the CMR group vs the NICE guidelines group and 
0.95 (95% CI, 0.46-1.95; P = .88) for the CMR group vs the MPS group. 
Hard events (cardiovascular death and myocardial infarction) occurred in 3 
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Figure 6.2  Effect of Specific Patient Characteristics on Results for 
CMR-Guided Care vs NICE Guidelines-Directed Care and MPS-
Guided Care Among Patients With Suspected Coronary Heart 
Disease 
CMR indicates cardiovascular magnetic resonance; ITT, intention to 
treat; NICE, National Institute for Health and Care Excellence; MPS, 
myocardial perfusion scintigraphy.   
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 Figure 6.3  Time to First Major Adverse Cardiovascular Event After a 
Minimum of 12-Month Follow-Up From Randomization Among 
Patients With Suspected Coronary Heart Disease (Median, 16 
Months)[150] 
 
CMR indicates cardiovascular magnetic resonance; NICE, National Institute 
for Health and Care Excellence; MPS, myocardial perfusion scintigraphy.   
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patients (1.3%) in the NICE guidelines group, 5 patients (1.0%) in the CMR 
group, and 4 patients (0.8%) in the MPS group (P = .93). Figure 6.3 shows 
the Kaplan-Meier cumulative incidence estimate of first MACE. In the study, 
five test-related medical complications were reported: CMR (1 case: mild 
urticarial reaction), MPS (0 cases), cardiac CT (1 case: vasovagal episode) 
and angiography (3 cases: ventricular tachycardia; pseudo-aneurysm & 
popliteal DVT; right coronary artery spasm & transient ST elevation). 
 
6.1.6 Functional Imaging Assessment 
Using functional imaging as a first-line strategy (CMR or MPS) in patients 
with a 61% to 90% (high, n=389) CHD pretest likelihood resulted in 
substantially reduced odds of unnecessary angiography compared with the 
NICE guidelines group; 29/307 (9.4%) vs 51/82 (62.2%), odds ratio (OR) 
0.048 (95% CI, 0.02-0.10), P < .001. Among those with less than 30% (low, 
n=330) CHD pretest likelihood, the odds of unnecessary angiography were 
also numerically lower by a functional imaging approach compared with 
anatomical (CCT) assessment; 13/269 (4.8%) vs 7/61 (11.5%), odds ratio, 
0.44 (95% CI, 0.17-1.17); P = .099). 
 
6.2 Discussion 
CE-MARC 2 was a multicenter, randomized clinical trial in a large 
community-based population of symptomatic patients undergoing 
assessment for suspected CHD, in whom further investigation was 
appropriate according to international guidelines. A CMR-guided strategy 
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significantly reduced unnecessary angiography occurrence compared with 
NICE guidelines-guided care, but was not significantly different from an 
MPS-guided strategy (following US appropriate use criteria)[137]. Between 
the 3 strategies, there was no difference in short-term MACE rates or 
disease detection (positive angiography) rates. 
 
There is concern that coronary angiography is overused in the diagnostic 
pathway of suspected CHD, and that the majority of patients investigated will 
not have significant obstructive coronary disease[131, 132]. Avoiding 
unnecessary invasive angiography could have significant financial benefits, 
avoids exposing patients to unnecessary risk, and is also a strong patient 
desire[152]. For this reason, we chose this as our patient-focused primary 
end point. 
 
Current international guidelines for investigation and management of 
suspected CHD all suggest risk stratification based on pretest likelihood 
estimation[138, 153, 154]. The Duke score, used in NICE guidelines, is 
based upon the original Diamond Forrester model, but includes additional 
demographic factors to further stratify risk[138]. These models, derived more 
than 3 decades ago, tend to overestimate CHD risk because patient 
demographics, risk factors, and treatment have changed considerably over 
time[155]. In the CE-MARC 2 trial, the reduction in unnecessary angiography 
by a CMR or MPS strategy appears largely driven by the overestimation of 
disease probability from using the Duke score. Current NICE guidelines 
categorize a pretest likelihood of 60% to 90% as being at high-risk of CHD, 
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and recommend direct referral for angiography. In the CE-MARC 2 trial, this 
explained the majority of patients in the NICE-guidelines group who got 
referred for angiography (82 of 102 patients; 80.4%), and the majority of 
unnecessary angiograms (59 of 69 patients; 85.5%). This was further 
emphasized by the preplanned, subanalysis of any functional imaging (CMR 
or MPS) in the 60% to 90% (high risk) pretest likelihood population, which 
showed substantially reduced odds of unnecessary angiography in this 
combined subgroup compared with the NICE guideline group. 
 
Overall, rates of disease detection (positive angiography) were comparable 
for the 3 strategies, suggesting no penalty for using functional imaging as a 
gatekeeper for angiography, even in high-risk subgroups. Consistent with 
published studies, the CE-MARC 2 trial showed a low overall rate of MACE 
in a stable chest pain population, with no early difference between 
strategies. 
 
It remains a point of debate as to whether all of our protocol-defined 
unnecessary angiograms are truly clinically unnecessary; some would argue 
that negative tests are the “price to pay” for not missing important disease in 
others. This assumes a population perspective, and our trial primary end 
point was derived after close consultation with patient and public 
representatives: from an individual patient perspective, an angiogram that 
does not change their treatment or their clinical outcome is considered by 
patients to have been unnecessary. Certainly guidelines are clear that 
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physicians do not need to undertake angiography to either diagnose angina 
or offer primary prevention and symptom control. 
 
To our knowledge, there have been no randomized clinical trials comparing 
the performance of current management guidelines and a broad functional 
imaging approach in terms of important clinical end points. Although cross-
sectional imaging (CMR and CCT) has improved diagnostic ability, benefits 
in terms of health outcomes are harder to demonstrate, partly due to 
complexity of subsequent treatment effects. Functional vs anatomical 
assessment as a potential gatekeeper to the catheterization laboratory is a 
topic of ongoing debate[156, 157]. The Prospective Multicenter Imaging 
Study for Evaluation of Chest Pain (PROMISE) trial showed no improvement 
in clinical outcomes using CCT vs a variety of functional tests in patients 
investigated for suspected CHD; whereas the CCT strategy increased rates 
of cardiac catheterization (12.2% vs 8.1%, P = .02) and 90 day coronary 
revascularization (6.2% vs 3.2%, P < .001)[156]. This may be important 
following a recent observational study of 544 US centers showing higher 
rates of inappropriate percutaneous coronary intervention at sites performing 
the highest rates of angiography, suggesting anatomical assessment could 
predispose patients to unnecessary therapy[158]. Although numbers are 
small, in the CE-MARC 2 trial an increased rate of unnecessary angiography 
was suggested in the low-risk subgroup of the NICE guidelines group, the 
majority of whom underwent CCT. 
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6.2.1 Limitations 
The false-positive and false-negative rates are often quantities of interest in 
evaluating diagnostic methods. The CE-MARC 2 trial only angiographically 
verified a subset of patients, contingent on strategy findings, and so cannot 
provide accurate estimates. The original CE-MARC trial defined the false-
positive and false-negative rates for CMR and MPS, and showed CMR-
guided strategy as being superior to the MPS-guided strategy[30]. In the 
current study, there was no statistical difference between the CMR and MPS 
strategies for reduction in unnecessary angiography, despite the finding from 
the CE-MARC trial. However, the CE-MARC trial was able to detect small 
differences due to its paired design (all patients underwent all tests), 
whereas the current study compared independent groups, which confers 
lower power. 
 
The study population was predominantly white northern European, therefore 
findings may not translate to other populations; geographic heterogeneity of 
CHD incidence is well known[153]. At trial initiation, contemporary guidelines 
used the Duke score[4, 6], with the NICE guidelines classifying high risk for 
CHD as 60% to 90% pretest likelihood. It is now recognized that this may 
overestimate CHD risk, such that recent guidelines[5] have adopted a 
recalibrated risk model[153]. The primary end point was objective (using 
FFR measurement), although performance was not clinically possible in all 
cases; blinded core laboratory analysis of QCA data avoided subjective 
visual angiography interpretation. Overall full adherence to the protocol was 
high, with some unavoidable variation due to individual clinical practice, 
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which could have introduced bias (eg, abnormal imaging results not 
proceeding to angiography). To mitigate this, analysis was by intention-to-
treat principles and the primary end point was purposely all inclusive (ie, 
false-positives, true-negatives when not believed by clinicians, and also test 
failures). The slightly different rates of incomplete data (not statistically 
significant) between study groups was not of concern, as the data 
completeness rate was high overall. Per-protocol and sensitivity analyses  
did not alter the trial conclusions. Although clinically robust, a MACE is not a 
proxy for a missed diagnosis or treatment (eg, missed opportunity for 
revascularization by not having angiography [due to a false-negative result]). 
However, it remains debatable whether revascularization for stable angina 
has prognostic benefit over optimal medical therapy, which will be answered 
by the ongoing International Study of Comparative Health Effectiveness With 
Medical and Invasive Approaches (ISCHEMIA) trial.  Finally quality of life 
and cost-effectiveness analyses will be important for understanding the 
patient-centered perspectives and payer/policy implications of these 
findings; these data are currently being collected/analyzed. 
 
6.2.2 Conclusions 
In patients with suspected angina, investigation by CMR produced a lower 
probability of unnecessary angiography within 12 months than NICE 
guideline–directed care, with no statistically significant difference between 
CMR and MPS strategies. There were no statistically significant differences 
in MACE rates at 12 months after randomization. 
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Chapter 7 
Final Conclusions 
 
The evidence for the use of CMR in the assessment of coronary artery 
disease is growing rapidly. There have been significant technological 
advances, it is established in both national and international guidelines and 
now in main stream use in the clinical arena. The focus of this thesis was on 
the diagnostic accuracy of the components of the multi-parametric CMR 
examination, the comparison of the ischaemic burden with SPECT and 
technical advances with perfusion sequences. Finally the utility of a CMR-
guided strategy was demonstrated for the investigation of stable coronary 
artery disease in a prospective, multi-centre, randomised controlled trial.  
 
The main findings were: 
 
7.1 Diagnostic Accuracy of Cardiovascular Magnetic 
Resonance 
i) The full multi-parametric CMR protocol using : i) left ventricular 
function; ii) myocardial perfusion; iii) viability (late gadolinium 
enhancement (LGE)) and iv) coronary magnetic resonance 
angiography (MRA) had the highest sensitivity and was the 
optimal approach to rule-out significant CAD. 
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ii) The LGE component alone was the optimal rule-in strategy to 
detect significant CAD. 
iii) The inclusion of coronary MRA provided no additional benefit 
when compared to the combination of perfusion/function/LGE 
7.2 Comparison of Ischaemic Burden between CMR and 
SPECT.  
i) Measurements of overall CHD burden (SSS) show reasonable 
agreement between CMR and SPECT. 
ii) SSS is the most powerful prognostic marker. This therefore 
suggests that CMR may be comparable to SPECT in terms of 
predicting future cardiovascular events. 
iii) There are differences in the estimates of scar and ischaemia 
burden between the two modalities. This may be due to the 
different approach to scar imaging (LGE vs. matched defect), 
soft-tissue attenuation with SPECT and different cardiac 
coverage for perfusion assessment. 
7.3 Developing a new perfusion pulse technique to maximise 
spatial resolution. 
i) Using a pulse sequence which automatically adapts the 
acquisition sequence to the available scanning time spatial 
resolution improves in both patients and healthy volunteers. 
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ii) The adaptive acquisition sequence also reduces dark rim 
artefact  in both patients and healthy volunteers. 
 
iii) There was no difference in both image quality scoring in 
patients and volunteers and in artefact scoring in volunteers. 
There was a significantly better artefact score in patients with 
the adaptive pulse sequence. 
 
iv) The improvement in spatial resolution with the adaptive pulse 
sequence lead to a reduction in signal-to-noise ratio. 
 
v) This proof of concept study suggests there may be benefits 
from using an automotive adaptive resolution sequence and 
further research is required. 
7.4 The Use of CMR as a Gate keeper to Invasive Coronary 
Angiography 
i) In patients with suspected angina using CMR as an initial 
investigative strategy produced a significantly lower probability 
of unnecessary angiography compared to NICE guidance.  
ii) There was no statistically significant difference in CMR vs MPS 
guided strategy in relation to unnecessary angiography. 
iii) There was no statistically significant difference in MACE rates 
at 12 months between NICE guideline–directed care; CMR-
directed strategy of SPECT-guided strategy. 
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iv) The rates of CAD detection were comparable for the 3 
strategies, suggesting no penalty for using functional imaging 
as a gatekeeper for angiography. 
 
7.5 Future Directions 
 
Technological advances in acquisition techniques (software) and hardware 
(scanners with higher field strengths and improved cardiac phased-array 
coils) have allowed the development of advanced perfusion techniques. 
These use highly accelerated pulse sequences based on spatio-temporal 
undersampling which allow the acquisition of high resolution images (in-
plane <1.5mm2)[130] permitting the detection of sub-endocardial myocardial 
ischaemia and 3D whole heart myocardial perfusion imaging with full left 
ventricular coverage[159, 160]. Other techniques such as blood oxygen level 
dependent (BOLD) imaging[161] and arterial spin labelling (ASL)[162] are 
able to detect myocardial ischaemia without the use of contrast agents. 
BOLD uses the inherent magnetic differences between oxygenated and 
deoxygenated blood to detect differences in signal intensity in ischaemic vs. 
non-ischaemic myocardium, and is able to detect ‘ischaemic’ myocardium 
through the use of vasodilator stress techniques’[161, 163]. More work is 
required to assess the use of these new technologies in the clinical setting. 
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List of Abbreviations 
AAR    Area At Risk  
ACCF    American College of Cardiology Foundation 
AHA     American Heart Association 
ASTM    American Society for Testing Materials 
bSSFP   Balanced Steady-State Free Precession  
CAD    Coronary Artery Disease 
CHD    Coronary Heart Disease 
CMR    Cardiovascular Magnetic Resonance 
CTCA    Computed Tomography Coronary Angiography 
DRA    Dark Rim Artefact 
DSE    Dobutamine Stress Echocardiography  
EGE     Early Gadolinium Enhancement  
ESC    European Society of Cardiology  
FFR    Fractional Flow Reserve 
FOV    Field Of View 
GE    Gradient Echo 
HYPR    Highly Constrained Back Projection 
ICD    Implantable Cardiac Defibrillator 
IMH    Intramyocardial Haemorrhage 
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LGE    Late Gadolinium Enhancement 
LMS    Left Main Stem 
LR     Likelihood Ratio 
LR-    Likelihood Ratio for Negative Tests 
LR+    Likelihood Ratio for Positive Tests 
LV    Left Ventricle 
LVEF     Left Ventricular Ejection Fraction 
MACE    Major Adverse Cardiovascular Events 
MI    Myocardial Infarction 
MO     Microvascular Obstruction 
MR    Magnetic Resonance 
MRA     Magnetic Resonance Angiography 
NICE    National Institute for Health and Care Excellence  
NPV    Negative Predictive Value 
OMT    Optimal Medical Therapy 
PPV    Positive Predictive Value 
RF     Radiofrequency  
RWMA    Regional Wall Motion Abnormality 
PET    Positron Emission Tomography 
QCA    Quantitative Invasive Coronary Angiography  
SCD    Sudden Cardiac Death 
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SCMR   Society for Cardiovascular Magnetic Resonance 
SDS    Summed Difference Score 
SE    Spin Echo  
SENSE    Sensitivity Encoding 
SNR    Signal-to-Noise Ratio 
SPECT   Single Photon Emission Computed Tomography  
SRS    Summed Rest Score 
SSS    Summed Stress Score 
QALY    Quality Adjusted Life Year 
QCA    Quantitative Invasive Coronary Angiography 
T    Tesla  
TE    Echo Time  
TR    Repetition Time 
US    United States     
XRA    X-Ray Angiography  
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9.2 Appendix 2   
9.2.1 Patient Information Leaflet Study 1 & 2 
                          
 
CE-MARC STUDY 
 
Clinical Evaluation of MAgnetic Resonance imaging in 
Coronary heart disease 
 
PATIENT INFORMATION LEAFLET 
Version 2.1 December 2005 
Dear  patient, 
 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends, 
relatives and your GP if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take part. 
 
 
WHY HAVE I BEEN CHOSEN? 
This study is looking at people like you, who have been referred to a cardiology clinic 
with chest pain. We will be asking 750 people to take part in this study. 
 
 
WHAT IS THE PURPOSE OF THE STUDY? 
We currently have several tests available to help us find out if chest pain is caused by 
heart disease. These include treadmill exercise testing, coronary angiography and 
SPECT perfusion imaging. More recently we have begun to use another test, Magnetic 
Resonance Imaging (MRI) to obtain pictures of the heart. MRI produces pictures with 
much greater detail than with other types of heart scans. Importantly, MRI is also a safer 
test than most other heart scans, because it does not expose patients to any harmful 
radiation and pictures of the heart can be taken “from the outside”. Because of all of 
these qualities, MRI might become one of the most important tests in patients who 
suffer with chest pain and coronary heart disease. As for any new test, before being able 
to use MRI on a daily basis, we need to find out how accurate it really is compared with 
the currently available tests. This is why we are carrying out this research study.  
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DO I HAVE TO TAKE PART? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. This will not affect the standard of care you receive. 
 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
All patients in this study will have three or four heart tests. One of the tests is the MRI 
scan, which is done solely for research purposes. The other three tests are those that are 
currently used to detect coronary heart disease, namely an exercise treadmill test, a 
SPECT myocardial perfusion study (to obtain information on the blood flow to the heart 
muscle) and an x-ray angiogram (to detect any blockages in the heart arteries). Of these 
other three tests, your hospital consultant may want you to have some or even all 
anyway. However, because for this study all patients must have all four tests (to allow 
us to compare them with each other), if any of the other three tests are not requested by 
your hospital consultant, we will carry them out for this research study.  
 
All tests will be performed at the Leeds General Infirmary and we will try to carry out 
as many as possible on the same day to minimise the time you have to spend travelling 
to the hospital. Information leaflets that give you more details about all of the tests will 
be provided.  
 
1. The MRI scan will take approximately 60 minutes to complete. You lie in a short 
'tunnel', which holds a large magnet. Short bursts of magnetic fields and radio waves from 
the MRI scanner allow images to be created. You will hear periodical loud “banging” 
noises while we are acquiring the images of your heart. We will remain in communication 
with you throughout the scan. Twice during the scan, we will inject an MRI contrast 
medication into a vein in your arm. The needle used for this will feel like a sharp 
scratch. Usually people are not aware of the contrast dye injection. At one point we will 
also inject a medication (Adenosine) into a vein in your arm, which is a drug to increase 
the blood flow to your heart. This can cause a brief feeling of warmth, breathlessness or 
chest discomfort. However all of these feelings, if they occur, usually settle within one 
or two minutes.  
 
2. The exercise treadmill test requires you to walk on a treadmill while your heart trace 
(ECG) and blood pressure are measured. This test will of course only be carried out if 
you are physically able to walk on the treadmill. Almost all patients referred to hospital 
with chest pain have a treadmill test anyway. 
 
3. The SPECT perfusion study is carried out on two separate days and takes 
approximately 2 hours on each day. On one day pictures of the heart will be taken at rest 
and on the second day after injection of the same medication (Adenosine) that we use 
for the MRI scan to increase the blood flow to your heart. On both days you will also 
have an injection of a radioactive dye into the blood, which is taken up by the heart 
muscle. Usually people are not aware of the contrast dye injection. One hour after the 
injection, pictures of the heart are taken with a special camera that slowly moves around 
you while you lie on a bed with one arm raised above your head. Taking these pictures 
takes approximately 20 minutes.  
 
4. With the x-ray angiogram, we take x-ray pictures of the heart arteries. This test 
requires you to come into hospital for one day. You will be taken to an x-ray room and 
lie down on your back. After cleaning the groin area, local anaesthetic is given into the 
 
- 168 - 
 
  
groin or the forearm and a needle put into the artery in the groin or arm. Because of the 
local anaesthetic putting the needle in should not be painful. A fine, hollow tube called a 
‘catheter’ is then introduced into the artery and is gently advanced through the blood 
vessels to the heart. The catheter is roughly the diameter of the lead in a lead pencil. 
You will not feel the catheter being moved around inside your chest. A dye is then 
injected into the heart blood vessels and X-rays taken from several angles. Some 
injections cause a hot, flushing sensation which lasts a few seconds. When the test is 
over, the catheter is removed and simple pressure is applied to the leg or arm for about 
10 minutes. Most patients referred to hospital with chest pain will have an x-ray 
angiogram at some point. 
 
In addition to the heart scans you will have one blood sample taken and stored to 
measure a number of biochemical markers of cardiovascular risk. The sample would be 
taken by a qualified nurse or doctor and if at all possible will be taken at a time when 
you are having blood taken for another reason. 
 
After you have had the heart tests, we will monitor your progress for three years. This 
will involve a short telephone call once a year to find out how your health has been. 
 
Sometimes we collaborate with commercial companies to pursue our research. This may 
be necessary for example if we find a new blood marker and need to develop a kit to 
measure it. Although this may involve the use of samples or research results from patients, 
these would be anonymised and there would be no direct financial gain to patients taking 
part in the study.  
 
 
WHAT ARE THE RISKS AND DISCOMFORTS? 
Magnetic Resonance Imaging (MRI) is safe and no x-rays or radiation are used for this 
scan. There are no known risks from this technique. Some patients may experience 
claustrophobia. The staff will provide every possible means to reduce this sensation. 
The contrast medication which we use is very safe but, as with any injection, reactions may 
occur. These include a warm sensation at the injection site, nausea or vomiting and 
transient skin rash. These effects usually only last for a few minutes. People with a history 
of allergy are more likely to suffer a more severe reaction, but this is rare (less than 1 in 
3000). The department is equipped to cope with allergic reactions if they happen. 
Adenosine, the medication we use to increase the blood flow to the heart, can cause 
flushing, breathlessness and chest discomfort. However, all of these feelings usually 
subside within one or two minutes or even more quickly if the medication is stopped.  
The Exercise treadmill test can cause angina or heart rhythm changes in some people. 
Should you develop such side effects, the test would be stopped immediately. 
 
SPECT imaging is very safe but exposes patients to a small amount of radiation. As for 
MRI, Adenosine, the medication we use to increase the blood flow to the heart, can cause 
flushing, breathlessness and chest discomfort. However, all of these feelings usually 
subside within one or two minutes or even more quickly if the medication is stopped. 
 
The most common complication of the X-ray angiogram is for a bruise to form in the 
groin. This is not serious, but may be inconvenient for a few days. Serious complications 
are very rare, but there is a small risk of the test causing a heart attack, stroke or kidney 
damage (about 1 in 1000). The test also exposes patients to a small amount of radiation. 
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All radiation doses carry a small risk. The radiation dose that you would receive from all 
the tests in this study together would be equivalent to between two and ten years of 
exposure to natural background radiation.  
 
 
BENEFITS TO YOU 
If you take part in this study, your chest pain will be studied very thoroughly and a lot of 
information about the health of your heart will be obtained. Most, but not all of this 
information would be gathered if you did not take part in the study and some of the 
information could help to plan what is the best treatment for you. 
 
 
EXPENSES 
We will provide reasonable travel expenses should this be necessary for you to attend the 
follow-up scan. We are also happy to arrange transport to the hospital and return you home 
if needs be. 
 
 
WILL MY TAKING PART BE KEPT CONFIDENTIAL? 
All information, which is collected about you during the course of the research will be 
kept strictly confidential. This information will be securely stored at the Clinical Trials 
Research Unit (CTRU) at the University of Leeds and at the Cardiac MRI Unit at Leeds 
General Infirmary on paper and electronically, under the provisions of the 1998 Data 
Protection Act. You will not be identified in any publication that may result from this 
research.  
 
We will inform your General Practitioner (GP) of your participation in this study as well 
as in the event of an unexpected abnormality on the scan. We will also contact the 
Office of National Statistics at a later stage for information that they already hold on 
patients treated in the UK. 
 
With your permission, your data may also provide a resource for future studies. If any 
information from this study is used to develop new research, data protection regulations 
will be observed and strict confidentiality maintained. Ethical approval will be obtained 
for any future studies involving your data. You will not be identified in the results of 
any future studies.  
 
If you withdraw consent from further study follow-up, your data will remain on file and 
will be included in the final study analysis.  
 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
When the study is complete the results will be published in a medical journal, but no 
individual patients will be identified. If you would like a copy of the published results, 
please ask your doctor. 
 
 
INDEMNITY/COMPENSATION 
If you are harmed as a direct result of taking part in this study, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then you 
may have grounds to a legal action. Regardless of this, if you have any cause to complain 
about any aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms are available to you. 
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If you have a private medical insurance please ensure that participation in the study does 
not affect your cover. 
 
 
WHO IS ORGANISING AND FUNDING THE STUDY? 
This is a research project of the Cardiac MRI department at Leeds General Infirmary, 
which is funded by the British Heart Foundation. 
 
 
WHO HAS REVIEWED THE STUDY? 
The study has been reviewed and approved by an independent local NHS Research 
Ethics Committee 
 
 
 
For further information please contact:         
Dr. Neil Maredia, Research Fellow, or 
Petra Bijsterveld, Research Nurse 
British Heart Foundation Cardiac MRI Department, 
B Floor, Clarendon Wing,  
Leeds General Infirmary. 
Tel: 0113 39 2 5481  Mobile: 07922 512 887. 
http://www.cmr.leeds.ac.uk/ 
----------------------------------------------------------------------------------------------------------
--------------- 
 
When you attend for your Cardiology out-patient appointment, a Doctor or Nurse 
connected with the research programme will talk to you about the study and give you 
further information. 
 
If, after reading this information leaflet you definitely do not want to consider this 
study, please tear off this slip and give it to the receptionist with your name written 
below. 
 
Name: 
……………………………………………………………………………………………
……..  
 
Thank you for your time. 
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9.2.1 Patient Information Leaflet Study 3 
 
 
 
PATIENT INFORMATION SHEET 
Version 1.3 16 February 2017 
 
CE-MARC 2: Optimization of acquisition and analysis methods (patients). 
 
Chief Investigator: Dr John Greenwood 
 
 
Dear Patient, 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
Purpose of the study 
Magnetic Resonance Imaging (MRI) is a test which produces detailed pictures of 
your internal organs by putting you within a strong magnetic field. With Cardiac MRI 
we are able to detect a number of important abnormalities that are caused by heart 
disease. Importantly, MRI is a safe test and does not use any radiation. MRI may 
become one of the most important tests in patients who suffer with different types of 
heart disease. 
We have been doing MRI scans of the heart in Leeds since 1995. However, 
research into improving the images is a continuous process. We always work at 
developing and improving the scanning protocols, i.e. the computer programmes 
that produce the images of patients’ hearts.  
 
Why have I been chosen? 
This study is looking at up to 300 people like you, who either have heart disease, 
are currently being investigated for heart disease, or have risk factors for heart 
disease. We are also recruiting 400 healthy volunteers. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any time 
and without giving a reason. This will not affect the standard of care that you 
receive from the NHS. If there is a possibility that you might be pregnant, you 
should not take part in the study. Our research team will be happy to discuss 
any other questions that you may have concerning your suitability for the study, 
before you decide whether to take part. 
 
What will happen to me if I take part? 
Most patients will have a single MRI scan. A small group of participants in this study 
will be asked to undergo up to four MRI scans to allow comparisons between 
different ways of obtaining MRI pictures. It is entirely up to you how many scans 
you wish to volunteer for, and you will remain free to withdraw from the study at any 
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time. All scans will be performed at the Leeds General Infirmary, and will be 
performed on separate days.  
The MRI scan will take approximately 60 minutes to complete. You lie in a short 
'tunnel', which holds a large magnet. Short bursts of radio waves from the MRI 
scanner allow images to 
be created. You will hear periodical loud “banging” noises while we are acquiring the images of 
your heart, so we protect your ears with headphones through which you can listen to the radio 
or one of your own CDs. We will remain in communication with you throughout the scan. For 
most scans we will insert one or two cannulae (small plastic tubes) into veins in your arm. It 
is likely that we will inject a contrast dye during the scan. Usually people are not aware of the 
contrast dye injection. At one point we may also inject a medication (Adenosine) into a vein 
in your arm, which is a drug to increase the blood flow to your heart. This can cause a brief 
feeling of warmth, breathlessness or chest discomfort. However all of these feelings, if they 
occur, usually settle within one or two minutes. A doctor will stay in the room with you whilst 
you are having the medication. In some cases instead of using adenosine we may immerse 
your hands or feet in cold water for up to 2 minutes to achieve the same increased blood 
flow to the heart muscle, or we may ask you to use a cycle ergometer, a bicycle which can 
be used whilst lying down in the scanner. 
If we wish to obtain specific images of your heart arteries we will wrap a belt around your 
abdomen to help improve the quality of the pictures. This is not painful and is a recognized 
method of doing this type of scan. You may be given a nitrate (GTN) spray under the tongue 
which helps us to obtaining good images. If your heart beat is quite fast we would give you a 
beta blocker to reduce your heart rate. Again, these methods are widely used in other 
centres worldwide and are used in normal clinical work too. 
Some of the MRI methods used in the heart are also applicable to other body organs. In 
some patients we will, for example, take images of the blood vessels and/or muscles in the 
abdomen, or a leg or arm during the same scan. The only difference to the heart scans is 
that we will use a different receiver coil (the aerial used for reception of MRI signals) to 
obtain these images.  
As this study is about improving our scan protocols on an ongoing basis for a period of five 
years the information we give you has to describe all the different techniques we wish to use 
in the study overall, but not all the techniques described above will be used during your 
scan(s). Before you sign the consent form we will discuss with you the specific scanning 
protocol that we are going to use. 
 
We may ask you for a blood sample, which would be taken whilst we insert the cannula in 
your arm for the contrast, so there are no extra needles involved. Knowing your haematocrit 
(the volume percentage of red blood cells in the blood) helps us to create specific images 
which are applicable to clinical practice. We may also test your blood glucose and lipid 
levels. In the unlikely event of an abnormality we will, with your permission, inform your GP. 
 
We may ask you to have an ECG, this is a heart tracing to measure the electrical impulses 
within the heart. It involves having 10 stickers applied to your chest for 5 minutes.  
 
Risks and discomforts 
Magnetic Resonance Imaging (MRI) is safe and no x-rays or radiation are used for this scan. 
There are no known risks from this technique. Some people may experience claustrophobia. 
Our MRI staff will do all that they can to make you feel comfortable during the scan, and 
will be monitoring you via a video camera and an audio link. If we are unable to make 
you feel comfortable in the scanner, we will not go ahead with scanning. The contrast 
medication which we use is very safe but, as with any injection, reactions may occur. These 
include a warm sensation at the injection site, nausea or vomiting and transient skin rash. 
These effects usually only last for a few minutes. People with a history of allergy are more likely 
to suffer a more severe reaction, but this is rare (less than 1 in 3000). The department is 
equipped to cope with allergic reactions if they happen. Adenosine, the medication we use to 
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increase the blood flow to the heart, can cause flushing, breathlessness and chest discomfort. 
However, all of these feelings usually subside within one or two minutes or even more quickly if 
the medication is stopped. Immersing your hands or feet in cold water is unpleasant, but the 
effects wear off very quickly. Nitrates and a beta blocker can cause temporary light 
headedness. For this reason if these drugs are used you will be kept under observation until the 
effects have worn off. 
Benefits to you 
This study does not form part of your normal clinical care and is done solely for research 
purposes. Your participation may however benefit future patients. 
Expenses 
We will provide reasonable travel expenses should this be necessary for you to attend the 
MRI scan. We are also happy to arrange transport to the hospital and return you home if 
needs be. 
 
Will my taking part be kept confidential? 
All information, which is collected about you during the course of the research will be 
kept strictly confidential. This information will be securely stored at the Cardiac MRI Unit 
at Leeds General Infirmary on paper and electronically, under the provisions of the 1998 
Data Protection Act. You will not be identified in any publication that may result from this 
research.  
 
We will inform your General Practitioner (GP) in the event of an unexpected abnormality 
on the scan.  
 
With your permission, your data may also provide a resource for future studies. If any 
information from this study is used to develop new research, data protection regulations 
will be observed and strict confidentiality maintained. Ethical approval will be obtained 
for any future studies involving your data. You will not be identified in the results of any 
future studies.  
 
 
What will happen to the results of the research study? 
When the study is complete the results will be published in a medical journal, but no 
individual patients will be identified. If you would like a copy of the published results, 
please ask your doctor. 
 
Indemnity/Compensation 
If you are harmed as a direct result of taking part in this study, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then you may 
have grounds to a legal action. Regardless of this, if you have any cause to complain about any 
aspect of the way you have been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are available to you. 
The research organisation 
This is a research project of the Cardiac MRI department at Leeds General Infirmary. 
 
For further information please contact:     
Petra Bijsterveld 
Research Nurse 
CMR Clinical Research Group 
X47, Sunshine Corridor 
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Leeds General Infirmary 
Leeds 
LS1 3EX 
T  0113 392 5481 
F  0113 392 5225 
M  07922 512 887 
Email   p.bijsterveld@leeds.ac.uk 
     
 
 
 
 
I am interested in hearing more about this study           
 
(study code: CE-MARC 2 physics - patients) 
 
 
 
I give permission for a researcher to contact me by telephone to discuss the study 
further.  
 
My phone number is………………………………. 
 
 
Name………………………………………………. 
 
Address…………………………………………….. 
 
……………………………………………………… 
 
 
Please return this slip to Petra Bijsterveld in the stamped addressed envelope provided. 
 
Thank you. 
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9.2.2 Patient Information Leaflet Study 4 
CE-MARC 2 
Clinical Evaluation of Magnetic Resonance imaging in Coronary heart disease. 
QUICK GUIDE 
(v 4.0 June 12 2013) 
 
 You are invited to take part in a research study, comparing different ways of 
investigating patients who have chest pain. 
 
 The study is funded by the British Heart Foundation. 
 
 If you consent to take part in the study you will be randomly assigned to be 
in one of three groups: 
 
Group 1 
 
 
This group will be  investigated with an MRI scan of the heart                         
Group 2 This group will be investigated with a SPECT scan of the heart 
Group 3 This group will be investigated following national (NICE) guidelines 
and you will either have a CT scan, a SPECT scan or an X-Ray 
angiogram (depending on the likelihood of you having narrowings 
in your heart arteries). 
 
 The test you have will be reported and if it is abnormal you will have an X-
Ray coronary angiogram (unless that was your 1st test anyway) with 
measurement of the blood flow in the heart arteries.  
 
 All patients will be followed up and therefore members of the research 
team will have access to your records during and after study participation 
 
 You will not benefit directly from taking part in the study 
 
 You do not have to take part if you do not want to, in which case you would 
receive standard care instead. 
 
If you would like to read more the study is explained in detail in the 
information sheet which follows. The research team will also be happy to 
explain the study to you in person. 
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CE-MARC 2 
Clinical Evaluation of MAgnetic Resonance imaging in Coronary heart 
disease. 
 
PATIENT INFORMATION SHEET 
Version 4.0 June 12 2013 
 
Chief Investigator: Prof J Greenwood                                                   
 
Dear Patient, 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully and discuss it with friends, relatives and 
your GP if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
Purpose of the study 
We have several tests available to help us find out if chest pain is caused by narrowings of 
the heart arteries (coronary heart disease). Currently many patients in whom coronary 
artery disease is suspected, have an angiogram (=X-ray test taking pictures of the heart 
arteries). We know from other studies that some of these angiograms will show normal 
heart arteries. Before having an angiogram many patients have had another heart test, for 
instance a CT scan or a SPECT scan. Doctors are always looking to develop and improve 
tests that can reliably tell us if a patient needs an angiogram as their next test or not. 
Nowadays we can use Magnetic Resonance Imaging (MRI) to obtain pictures of the heart 
and see how well the heart is supplied with blood and oxygen. MRI is becoming an 
important test in patients who suffer with chest pain and coronary heart disease, and may 
eventually reduce the need for invasive tests such as coronary angiograms. Doctors have 
been doing research for many years to see how accurate MRI is compared to other heart 
tests. This study is part of that on-going research. In this study we will be using a magnet 
with a stronger magnetic field (called 3Tesla) than used in our previous CEMARC I study. 
This gives sharper pictures with even more detail. 
 
Why have I been chosen? 
This study is looking at people like you, who have been referred to a cardiology clinic with 
chest pain. We will be asking 1200 people, in several UK hospitals, to take part in this 
study. 
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Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a reason. 
This will not affect the standard of care that you receive from the NHS. If there is a 
possibility that you might be pregnant, you should not take part in the study. Our research 
team will be happy to discuss any other questions that you may have concerning your 
suitability for the study, before you decide whether to take part. 
 
 
What will happen to me if I take part? 
If you take part in this study you will be assigned to one of three groups. We call one group 
‘MRI guided’ , the second group SPECT-guided, and the third group ‘NICE guidelines 
based’.  The choice will be made randomly, like tossing a coin. Neither you nor your doctor 
can influence what group you will be in. The groups will not be the same size: you have 
more chance of being in either the MRI or the SPECT group than of being in the NICE 
guidelines group.  As the names suggest, your treatment in this study will be guided by the 
results of either the MRI scan, the SPECT scan, or one of the tests recommended by NICE 
(which also includes SPECT). 
 
1,200 Patients
Randomised 2:2:1
N=480
MRI-guided management
(10-90% pre-test risk)
N=240
NICE guidelines-based 
management
Angiography and abnormal FFR?
12, 24 & 36 month Follow up
61-90%
Angio
N=480
SPECT-guided management
(10-90% pre-test risk)
10-29%
CAC/CCT
30-60%
SPECT
Yes No
PCI (stent ) or bypass surgery
Angiogram required based on test result (or NICE guidelines)?
Medical treatment (tablets)
NoYes
 
 
1. MRI guided group: (480 out of the 1200 patients will be in this group). If you are 
allocated to the MRI group you will have an MRI scan next. The scan will take 
approximately 60 minutes to complete. You lie in a short 'tunnel', which holds a large 
magnet. Short bursts of magnetic fields and radio waves from the MRI scanner allow images 
to be created. You will hear periodical loud “banging” noises while we are acquiring the 
images of your heart, though we do protect your ears with headphones. You can listen to the 
radio, or to one of your own CDs.  We will remain in communication with you throughout the 
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scan. During the scan, we will inject an MRI contrast medication into a vein in your arm. At 
one point we will also inject a medication (Adenosine) into a vein in your other arm, which 
is a drug to increase the blood flow to your heart. This medication is used routinely in 
many heart tests.  What happens next: The MRI scan will be reported by a consultant who 
is an expert in this area. If the test is normal your further treatment will be decided by your 
own cardiologist. If the test shows that there may be one or more narrowings in your heart 
arteries you will be offered a further test called an X-Ray coronary angiogram (see page 4).  
 
2. SPECT guided group: (480 out of the 1200 patients will be in this group).  If you are 
allocated to the SPECT group you will have a SPECT scan next. The SPECT perfusion study is 
carried out on two separate days and each visit takes approximately 2 hours. On one day 
pictures of the heart will be taken at rest, and on a second day after injection of a 
medication (Adenosine) to increase the blood flow to your heart. On both days you will 
also have an injection of a radioactive dye into the blood, which is taken up by the heart 
muscle. One hour after the injection, pictures of the heart are taken with a special camera 
that slowly moves around you while you lie on a bed with one arm raised above your head. 
Taking these pictures takes approximately 20 minutes. What happens next: The SPECT 
scan will be reported by a consultant who is an expert in this area. If the test is normal your 
further treatment will be decided by your own cardiologist. If the test shows that there 
may be one or more narrowings in your heart arteries you will be offered a further test 
called an X-Ray coronary angiogram (see page 4). 
 
 
3. NICE guidelines group: (240 out of the 1200 patients will be in this group). If you are 
allocated to the NICE guidelines group you will have the heart test recommended by these 
guidelines, published by NICE, the National Institute for Health and Clinical Excellence, in 
2010.   This will be one of the following: a CT calcium score (followed by a CT coronary 
angiogram if required), a SPECT scan, or an X-Ray coronary angiogram. Which test you are 
offered depends on how likely it is that you have narrowings of the heart arteries. We can 
calculate this from your medical history and you will fall into either a low, intermediate, or 
high likelihood group. 
 
a. For patients with a low likelihood:  
CT calcium score: CT stands for ‘computerised tomography’ and is a sophisticated type of 
X-ray.  You will lie on a bed under a scanner and will be asked to hold your breath briefly 
for the scan to be performed. This scan will let us see how much calcium there is in your 
heart arteries. If there is very little then the scan will be stopped at that point and you will 
have no further tests. If there is a lot of calcium the scan will also be stopped and you will 
be offered an X-Ray coronary angiogram (see below). If there is a moderate amount of 
calcium we will continue to see whether there are any narrowings, this is called a CT 
coronary angiogram.  For this you will receive an injection of a contrast dye into a vein in 
your am. You may also receive an injection of a medicine (a beta-blocker) to slow your 
heart rate down a little bit. This can help reduce the time you will need to hold your breath 
for. 
 
b. For patients with an intermediate likelihood: 
SPECT scan: this is the same scan as the patients in the SPECT guided group have, and is 
described on page 3.  If the test shows that there may be one or more narrowings in your 
heart arteries you will be offered a further test called an X-Ray coronary angiogram (see 
below). 
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c. For patients with a high likelihood: 
X-Ray Coronary angiography: This test requires you to come into hospital for one day. 
With a coronary angiogram we take X-ray pictures of the heart arteries. You will be taken 
to an X-ray room and asked to lie down on a bed. After cleaning the skin, local anaesthetic 
is given and a needle put into the artery in the wrist or occasionally the groin. A fine, 
hollow tube called a “catheter” is then introduced into the artery and is gently advanced 
through the blood vessels to the heart. You will not feel the catheter being moved around 
inside your chest. A dye is then injected into the heart blood vessels and X-rays taken from 
several angles. A narrowing or a blockage may be seen which would confirm the diagnosis 
of coronary artery disease. To assess the importance of a narrowing in a heart artery a 
pressure wire will be used. This technique is increasingly used during a coronary 
angiogram to guide further treatment. This is a very small wire inserted through the 
catheter into the vessel of the heart to measure the blood flow. It also involves the 
injection of Adenosine to improve blood flow to the heart. When the test is over, the 
catheter is removed and simple pressure is applied to the wrist (or groin). 
After the angiogram the doctor carrying out the test will discuss the findings with you, and 
the options for treatment if any narrowings were found. Any treatment you receive is not 
part of the study and will be carried out following current best practice. If you do need an 
angiogram for any reason within a year of joining the study we will do the pressure wire 
test on narrowings seen in your heart arteries. 
 
Health Questionnaires  
If you agree to participate in this study, you will be asked to complete three simple health 
questionnaires when you join the study, after six months, and then once a year for three 
years. 
 
Follow–up: As part of the study we would like to see how you are getting on once a 
year for three years. We may telephone you to ask you some simple questions about 
your health. With your permission we may also look at your hospital records, request 
access to your GP records, central NHS records and/or use information from The 
Health and Social Care Information Centre.  
It is very helpful if we can continue to track your health condition over a long term 
period. The Health and Social Care Information Centre (HSCIC) allows us to access health 
information about you with your permission.  In order to this we are seeking your 
permission to provide HSCIC with some of your personal details (including your name, 
date of birth, address and NHS number) and with this information HSCIC will be able 
to provide us with simple health information about you beyond the 3 year follow up 
period of this study, for a period of up to 20 years.  It is very important to understand 
the long term health condition of patients to find out if the treatments we are giving 
are effective. Information will be provided to HSCIC in strict confidence and will be kept 
securely by them and will not be released to a third party.  
 
What are the possible disadvantages and risks of taking part? It is important to remember 
that if you were not in the study you would be having one of these tests anyway. 
 
MRI scan: Magnetic Resonance Imaging (MRI) at 3Tesla is safe and no radiation is used for 
this scan. There are no known risks from the technique. Some people may experience 
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claustrophobia. Our MRI staff will do all that they can to make you feel comfortable during 
the scan, and will be monitoring you via a video camera and an audio link. If we are unable 
to make you feel comfortable in the scanner, we will not go ahead with scanning. We will 
need to insert two small tubes (cannulae) into your arms for the contrast dye and the 
adenosine medication. The contrast medication we use during the scan is very safe but, as 
with any injection, reactions may occur. These include a warm sensation at the injection site, 
nausea or vomiting and transient skin rash. These effects usually only last for a few minutes. 
People with a history of allergy are more likely to suffer a more severe reaction, but this is rare 
(less than 1 in 3000). The department is equipped to cope with allergic reactions if they 
happen. Adenosine, the medication we use to increase the blood flow to the heart, can cause 
flushing, breathlessness and chest discomfort. However, all of these feelings usually subside 
within one or two minutes or even more quickly when the medication is stopped.  
 
SPECT scan: SPECT imaging is very safe but exposes patients to a small amount of radiation. 
The dose is equivalent to receiving approximately 3 years of natural background radiation in 
the UK. We will need to insert one small tube (cannula) into your arm for the contrast dye 
and the adenosine medication.  Adenosine, the medication we use to increase the blood flow 
to the heart, can cause flushing, breathlessness and chest discomfort. However, all of these 
feelings usually subside within one or two minutes after the medication is stopped. 
 
CT coronary angiogram: CT imaging is very safe but exposes patients to a small amount of 
radiation. The dose of a CT calcium score only scan is equivalent to receiving approximately 6 
months to 1 year of natural background radiation in the UK . The dose of a CT angiogram is 
equivalent to receiving approximately 3 years of natural background radiation in the UK. We 
will need to insert one small tube (cannula) into your arm for the contrast dye. The contrast 
medication we use during the scan is very safe but, as with any injection, reactions may occur. 
The department is equipped to cope with allergic reactions if they happen. You may also be 
given a medication (by mouth or into a vein) to slow your heart rate down a little, this is called 
a beta-blocker. If this is the case you will usually be kept under observation until the after 
effects of any possible light headedness have worn off, which is usually for about half an 
hour. 
 
X-Ray Coronary angiography and pressure wire: 
At present most patients with chest pain or other symptoms consistent with coronary 
artery disease will have an angiogram at some point. The advantage of an angiogram is 
that it can look inside the arteries. However this also means that it is invasive and bears 
some risks. The most common complication of the X-ray angiogram is for a bruise to form 
on the wrist or in the groin. This is not serious, but may be inconvenient for a few days. 
Allergic reactions to the iodine based dye are rare and the department is equipped to cope 
with reactions. Other serious complications are very rare, but the test can cause a heart 
attack, stroke or kidney damage. This is estimated at about 1 or 2 in every 1000 people. 
However the level of risk depends on your overall health and your individual heart 
condition. A pressure wire test is safe, but as a wire is passed down the coronary artery a 
small risk of damage to the blood vessel wall or heart muscle is added. 
The amount of radiation you are exposed to during a coronary angiogram is approximately 
equivalent to the radiation you are exposed over the course of 3 years from the natural 
environment.  
 
What are the alternatives? 
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If you do not wish to take part in the study you will have the heart test your cardiologist 
chooses for you. 
 
 
Benefits to you 
We cannot promise the study will directly benefit you, but the information we get from 
this study might help the treatment of future patients. If you take part in a study you will 
have more contact with us, and have more opportunities to ask questions and be informed 
about your health, which some patients find helpful. 
 
Expenses 
You will not be asked to undergo any extra tests as a result of taking part in this study, so 
you will incur no extra expenses. 
 
Will my taking part be kept confidential? 
All information collected about you during the course of the study will be kept strictly 
confidential. This information will be securely stored, electronically on Leeds Teaching 
Hospitals NHS Trust and University of Leeds secure servers, and on paper, under the 
provisions of the 1998 Data Protection Act. Images (scans) and data, after your personal 
details have been removed, may be sent to participating study centres, or to an 
independent laboratory,  for analysis. Your data, including personal data such as your 
name, address and NHS number will be sent to the Clinical Trials Research Unit at the 
University of Leeds. The data collected will be coded and your personal details will be kept 
entirely separately from details about your health and treatment. You will not be identified 
in any publication that may result from this research.  
We may contact the Health and Social Care Information Centre or other central NHS UK 
bodies at a later stage for information which they hold on your health status. This means 
some of your personal data will be shared with the Health and Social Care Information 
Centre. Any information exchanged between us Health and Social Care Information Centre 
will be subject to strict data protection regulations. 
With your permission, your data may also provide a resource for future studies. If any 
information from this study is used to develop new research, data protection regulations 
will be observed and strict confidentiality maintained. Any information about you which 
leaves the hospital will have your name and address removed so that you cannot be 
identified. Your data and or images may be sent to institutions in the UK, the European 
Economic Area or outside the EEA.  Ethical approval will be obtained for any future studies 
involving your data. With your consent we may also wish to contact you in future about 
new studies you may wish to participate in. We will never give your personal details to any 
researchers outside of our department. 
If you withdraw consent from further study follow-up, or if you were to become 
incapacitated, any data collected about you up to that point will remain on file and will be 
included in the final study analysis.  
 
What will happen to the results of the research study? 
When the study is complete the results will be published in a medical journal, but no 
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individual patients will be identified. If you would like a copy of the published results, 
please ask your doctor. 
 
 
Indemnity/Compensation 
If you are harmed as a direct result of taking part in this study, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then you may 
have grounds to a legal action. Regardless of this, if you have any cause to complain about any 
aspect of the way you have been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms are available to you. 
The research organisation 
This is a research project of the Cardiac MRI department at the University of Leeds and the 
Leeds Teaching Hospitals NHS Trust, in collaboration with the Clinical Trials Research Unit 
at the University of Leeds. It is being funded by the British Heart Foundation. 
 
Who has reviewed the study? 
The study has been reviewed and approved both by the South Yorkshire Research Ethics 
Committee and by your hospital trust’s Research and Development Office.  More details 
can be provided, on request, by your study doctor. 
 
 
 
For further information please contact:     
 
Dr David Ripley, CMR Research Fellow             or                
Cardiac MRI Department                                                           
B Floor Clarendon Wing                    
Leeds General Infirmary      
LS1 3EX                                     
d.ripley@leeds.ac.uk                                                                  
                                                                                                    
                  
 
 
 
 
 
 
 
  
Petra Bijsterveld  
Research Nurse 
Cardiovascular Research 
Sunshine Corridor  
Leeds General Infirmary 
LS1 3EX 
Tel: 0113 392 5481 / 0113 
392 6286 
Mob: 07922 512 887 
p.bijsterveld@leeds.ac.uk 
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9.3 Appendix 3  
9.3.1 Consent Form for Study 1& 2 
 
CONSENT FORM – Version 2.1 December 2005                    
 
CE-MARC Study 
Clinical Evaluation of MAgnetic Resonance imaging in 
Coronary heart disease 
 
Patient Study Number: ………………..   Date of Birth: ………………… 
 
Hospital Number: …………………….   Initials: ……………………….. 
                                                                                                                              Please initial boxes         
1. I have read the Patient Information Sheet dated December 2005          
              (Version 2.1) for the above study and I have had the  
 opportunity to ask questions and discuss the research study  
 and I am satisfied with the answers to my questions. 
            
2. I have received enough information about this study. 
 
3. I understand that my participation is voluntary and that I am  
             free to withdraw from the study at any time without  
             giving a reason and without affecting my future care.  
 
4. I understand that my medical records may be looked  
at by authorised individuals from the Clinical Trials  
Research Unit in order to check that the study is 
being carried out correctly.  
 
5. I understand that information held by the NHS and  
records maintained by the Office of National Statistics  
(ONS) may be used to follow up my health status,  
should I lose contact with my hospital doctor.  
I give permission for this information to be obtained  
from the ONS and/or NHS if necessary. 
 
6. I agree that my medical data maybe used to help develop  
future research studies and I understand that my identity will  
remain anonymous. 
 
7. I understand that my samples may be used in future research  
             projects which may involve collaborations with commercial 
companies and I understand that I will not benefit financially 
if the research leads to the development of  a new test or 
treatment. 
 
8. I agree to take part in this research study.  
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Signature.............................................................. 
 
 
Name (block capitals)........................................................... Date................ 
 
 
Signature of witness............................................. 
 
 
Name (block capitals)............................................................Date………… 
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9.3.2 Consent Form for Study 3 
 
CONSENT  FORM v 1.3 16 February 2017 
 
CE-MARC 2: Optimization of acquisition and analysis methods (healthy 
volunteers). 
Chief Investigator: Professor John Greenwood 
 
Patient Number: ………………..   Date of Birth: ………………… 
 
Name ……………………………… 
                                                                                                                                         
Please initial boxes         
1. I have read the Volunteer Information Sheet dated 16 
February 2017 (Version 1.3) for the above study and I 
have had the opportunity to ask questions and discuss 
the research study  
 and I am satisfied with the answers to my questions             
. 
            
2. I have received enough information about this study. 
 
3.  I understand that my participation is voluntary and that I 
am  
             free to withdraw from the study at any time without  
             giving a reason.  
 
4. I give my consent for my General Practitioner to be 
informed in the event of any abnormality being 
discovered. 
 
5. I understand that images collected will be stored on a 
computer system, and, after my personal details have 
been removed, may be available to researchers at other 
institutions. 
 
6.         I understand that some of the blood samples taken from me may be                                                                                                                                                   
            stored and may be analyzed in the future for markers 
related to   heart disease 
   
7. I understand that relevant sections of my medical notes 
and data collected during the study, may be looked at 
by individuals from the University of Leeds, from 
regulatory authorities, or from the Leeds Teaching 
Hospitals NHS Trust, where it is relevant to my taking 
part in this research. I give permission for these 
individuals to have access to my records. 
 
8. If I were to lose capacity, I understand that data already 
collected will be kept and used for the purposes of the 
study. 
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9. I agree to take part in this research study and that the 
general results of the study will be made available to 
the medical community most likely through publication 
in a reputable medical journal. 
 
 
 
Signature.............................................................. 
 
 
 
Name (block capitals)........................................................... Date................ 
 
 
 
Signature of researcher............................................. 
 
 
 
Name (block capitals)............................................................Date…………… 
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9.3.1 Consent Form for Study 4 
CONSENT FORM v 4.0 June 12 2013 
CE-MARC 2 
Clinical Evaluation of MAgnetic Resonance imaging in Coronary heart disease. 
CI: Prof John Greenwood 
                                    
 
Patient Study Number: ………………..          Patient Initials................... 
 
NHS number: .................................          Date of Birth: ………………… 
                                                                                                                                                                                                                  
Please initial boxes                                                                                           
1.  I have read the Patient Information Sheet dated June 12 
 2013 (version 4.0) for the above study and I have had the 
 opportunity to ask questions and discuss the research 
study and I am satisfied with the answers to my 
questions. 
 
2.  I understand that my participation is voluntary and that I 
am free to withdraw from the study at any time without 
giving a reason. 
              
3 I give my consent for my General Practitioner to be 
informed, and I understand that my cardiologist will be 
informed only if we find any abnormality over and 
above what is already known. 
 
4. I understand that data and images collected will be 
stored on a computer system, and, after my personal 
details have been removed, may be sent to participating 
study centres or to an independent laboratory, and may 
be available to researchers at other institutions in the UK, 
the EEA, and countries outside the EEA. 
 
5. I understand that relevant sections of my medical notes 
and data collected during the study (including personal 
data) may be looked at by individuals from the 
University of Leeds, the Clinical Trials Research Unit, 
from regulatory authorities, or from the Leeds Teaching 
Hospitals NHS Trust, where it is relevant to my taking 
part in this research. I give permission for these 
individuals to have access to my records. 
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6.           I understand that information held by the NHS, by my 
General Practitioner, and information held and 
managed by the Health and Social Care Information 
Centre and other central UK NHS bodies, may be used 
to contact me and provide information   about my 
health status. I give permission for this information to 
be obtained from The Health and Social Care 
Information Centre, the NHS Central Register and/or 
my GP if necessary. To do this, I understand that my 
details (including my name, address, NHS number and 
date of birth) will be shared with The Health and Social 
Care Information Centre. 
 
7. If I were to lose capacity or withdraw consent for further 
follow-up I understand that data already collected will be 
kept and used for the purposes of the study. 
 
8. I agree to take part in this research study and that the 
general results of the study will be made available to 
the medical community most likely through publication 
in a reputable medical journal. 
 
9.  I am willing to be contacted again in the future with 
regard to potentially taking part (without any obligation) 
in further related research studies. 
  
10.       I agree to a copy of this consent form being sent to the 
Clinical Trials Research Unit. 
 
 
 
Signature.............................................................. 
 
 
Name (block capitals)........................................................... Date................ 
 
 
Signature of researcher............................................. 
 
 
Name (block capitals)............................................................Date…………….. 
   
 
